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Background: During New Zealand’s first outbreak in early 2020 the Southern Region 
had the highest per capita SARS-CoV-2 infection rate. PCR testing was initially limited 
by a narrow case definition and limited laboratory capacity, so cases may have been 
missed. Serological assays that detect SARS-CoV-2 antibodies are an important tool for 
determining past infection and investigating immune responses. However, it was not 
known how long the antibodies persist. 
Objectives: Four main aims relating to SARS-CoV-2 serological testing were explored: 
1) evaluate the clinical performance and concordance of seven serological assays, 
including the surrogate virus neutralization test, which estimates the level of neutralising 
antibodies; 2) determine the frequency of SARS-CoV-2 antibodies in higher-risk 
individuals in the Southern Region, to determine whether any cases were missed during 
the first outbreak; 3) assess the likelihood of infection among those diagnosed as 
‘probable’ cases, using serological testing; and 4) assess the persistence of SARS-CoV-
2 antibodies in recovered COVID-19 patients. 
Study design: Pre-pandemic sera (n=300) were used to establish assay specificity and 
sera from PCR-confirmed SARS-CoV-2 individuals (n=78) to establish sensitivity. All 
higher-risk participant sera (n=1127) were tested on the Abbott Architect assay, and any 
samples with grey-zone or positive results were tested on five additional assays. Sera 
from the probable cases (n=9) were tested on all seven assays. Results run on multiple 
assays were used for the assessment of assay concordance. For the antibody persistence 
study, sera from PCR-confirmed COVID-19 patients (n=42) collected at multiple time 
points, up to 10-12 months post-infection were tested on four assays. 
Results: The median time from infection onset to serum collection for the first time-point 
for the PCR-confirmed cases was 14 weeks (range 11-17 weeks). The nucleocapsid-
based Abbott Architect IgG assay demonstrated suboptimal sensitivity (76.9%). The 
nucleocapsid-based Roche pan-Ig assay demonstrated highest sensitivity (100%). The 
spike-based assays demonstrated high sensitivities ranging 89.7-94.9%. Anti-RBD IgG 
antibodies had the strongest correlation with NAbs (kappa statistic = 0.914; Pearson’s r 
= 0.914). Nine previously undiagnosed seropositive individuals were identified within 
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the higher-risk individuals and all had epidemiological risk factors. Seven of the nine 
probable cases were negative on all the assays, suggesting that these individuals likely 
did not have infection. The sensitivity of the Abbott Architect assay dropped to 15.4% 
by the last time point (median of 45 weeks post-infection), while the S-based assays 
remained above 80%.  
Conclusions: The results demonstrated SARS-CoV-2 antibodies measured on different 
assays using different antigen targets and different assay formats can give varying results 
and highlights the need to choose an assay appropriate for the testing purpose and to 
consider an orthogonal testing algorithm to reduce false positive and false negative 
results. Importantly, in this study there was extremely low probability the PCR-
confirmed cases had immune boosting from re-exposure to SARS-CoV-2, thus the 
antibody responses measured can be attributed to the initial exposure. Significantly, no 
unexpected undiagnosed SARS-CoV-2 infections were found in the Southern region of 
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Chapter 1: Introduction/literature review 
1.1 General introduction 
The novel virus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
2) and COVID-19 (the disease it causes), were detected first in Wuhan, China in 
December 2019,1 and as of July 9, 2021, there have been nearly 184 million confirmed 
COVID-19 cases across the world, with over 4 million deaths2,3 (Figure 1.1). Most 
individuals with COVID-19 present with respiratory tract symptoms and fever, but in 
some individuals, infection can progress to involve other organs and can ultimately cause 
death (even if only lung involvement), especially in those with co-morbidities.3,4  
During the first outbreak of COVID-19 in New Zealand (NZ) (February 28 to 
May 22, 2020), 1154 polymerase chain reaction (PCR) confirmed cases and 350 
‘probable’ cases (symptomatic contacts of PCR-confirmed cases who had a negative 
PCR test or no PCR test) were identified, with 22 COVID-19 related deaths.3,5 In NZ, 
during the first outbreak, PCR testing for SARS-CoV-2 was initially restricted due to a 
narrow case definition and limited access to diagnostic reagents, therefore it was 
unknown if COVID-19 cases were missed due to these restrictions.3 Serology testing 
could be used to identify previously unrecognised infections in individuals by performing 
a serosurvey of individuals who were at higher risk of infection. However, since the virus 
was new, there was a limited choice of tests, limited data on the clinical performance of 
these tests, and limited knowledge of SARS-CoV-2 antibody kinetics. Therefore, 
additional research was required to provide more information on these serological assays, 
in order to validate the results of a serosurvey.  
1.1.1 SARS-CoV-2 pandemic – the worldwide situation 
In late December 2019, in the city of Wuhan (Hubei province, China), clusters of 
individuals with pneumonia of unknown aetiology were reported by several health 
facilities.1 All these cases appeared to be linked epidemiologically to a live animal market 
in Wuhan and a group of scientists were deployed to investigate and found the cause to 
be a novel coronavirus.1 The World Health Organization (WHO) declared COVID-19 a 
public health emergency of international concern on January 30, 2020 and classified it as 
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a pandemic on March 11, 2020.6 By March 11, 2020, there were already more than 
118,000 cases in 114 countries with 4291 fatalities, with greater than 90% of the cases 
coming from four countries (China, Republic of Korea, Iran, and Italy).7 Cross-border 
traffic was a significant factor in the transmission of SARS-CoV-2 between countries, 
and with the help of the long incubation period of the virus, the outbreak took the world 
by surprise; the WHO had deep concerns about the rate of spread and the severity of the 
disease, as well as the failure of some countries to act to prevent the spread of the virus.7 
China undertook quick and stringent public health measures such as lockdowns and 
quarantining infected individuals and was able to significantly decrease the number of 
infections quickly.8 As of July 9, 2021, the United States of America has the highest 
number of confirmed cases (over 33 million) and fatalities (over 600,000).9  
 
Figure 1.1: Global COVID-19 situation. As of July 9, 2021, graphed by average weekly numbers. 
Globally, there have been 184,820,132 confirmed cases of COVID-19, including 4,002,209 deaths. From 
Coronavirus Disease (COVID-19) Dashboard, by World Health Organization, 2021. 
(https://covid19.who.int/).9 Under Creative Commons licence CC BY-NC-SA 3.0 IGO.  
 
1.1.2 SARS-CoV-2 outbreak – the New Zealand situation 
New Zealand’s (NZ) response to the outbreak is summarised in Table 1.1. On 
February 3, 2020, the NZ government’s initial response to the COVID-19 outbreak 
overseas was to restrict the entry of foreign nationals coming from mainland China.10 By 
February 28, 2020, NZ had its first reported case of COVID-19, from a traveler from 
Iran, with the first case of person-to-person transmission reported on March 5, 2020.10 
Further restrictions were put in place in early March 2020 to stop foreign nationals 
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coming in from Iran, South Korea, and northern Italy, and by March 19, 2020, the borders 
were closed to all but NZ citizens and permanent residents. Initially individuals coming 
in from affected regions required a 14 day quarantine period upon arrival, which was 
eventually extended to all arrivals.10 On March 21, 2020, A four-tier alert system was 
introduced by the NZ government, starting the country off in level 2, and quickly moving 
to the highest alert level 4 restrictions on March 26, 2020.3,10 Alert level 4 involved a 
national lockdown with strict stay-at-home orders for all of the population except 
essential workers.11 NZ remained at alert level 4 for approximately five weeks before de-
escalating through to alert level 1 on June 9, 2020, where “strict controls on the border 
[remained in place], but all current rules and restrictions on businesses and services” were 
“essentially lifted”.12,3 By June 8, 2020, there were no active COVID-19 cases in NZ, 
and the first outbreak was over.3,10 
Table 1.1: Timeline of the main events relating to NZ's first SARS-CoV-2 outbreak. From “Go 
Hard, Go Early”: Preliminary Lessons From New Zealand’s Response to COVID-19, by Jamieson, 






Of the total 1503 PCR-confirmed or probable cases during the first outbreak in 
NZ, 40% were imported, 29% were ‘import-related’, 25% had an epidemiological link 
to a known case, and 6% were classified as cases acquired locally with an unknown 
source (community transmission).3,5 At the peak of the pandemic in NZ in early April 
2020, 89 new cases were recorded in one day and 929 active cases3,5 (Figure 1.2). 
 
Figure 1.2: NZ daily confirmed and probable cases by source. From COVID-19: Source of cases, by 
Ministry of Health, NZ, 2021. (https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-
novel-coronavirus/covid-19-data-and-statistics/covid-19-source-cases).14 Under Creative Commons 
Attribution 4.0 International Licence. 
As NZ is a relatively small island nation with no land borders with other nations, 
it was well placed to eradicate SARS-CoV-2, and after the success of the initial strict 
lockdown measures, the government shifted their response from ‘mitigation’ or the 
‘flatten the curve’ approach to the current ‘stamp it out’ and ‘elimination strategy.3,15 NZ 
remained without any community transmission of COVID-19 for 102 days until August 
12, 2020, when four cases of COVID-19 were detected in a family from South 
Auckland.10 Auckland went into level 3 lockdown, while the rest of the country was put 
into level 2; a total of 179 cases were related to this cluster.10 Auckland moved back to 
level 1 on October 7, 2020.5 The most recent cluster of community transmission begun 
on February 14, 2021, with a total of 15 cases; Auckland moved back into level 1 on 
March 13, 2021.16 As of July 9, 2021, NZ has reported 765 COVID-19 cases, with 76% 




The national cumulative incidence of COVID-19 during NZ’s first outbreak was 
approximately 30/100,000, with most cases located in the Auckland region, but the 
Southern District Health Board (DHB) region of NZ had the largest number of cases per 
capita (217 total cases, with a cumulative incidence of approximately 66/100,000), which 
was significantly higher than the national average cumulative incidence3,5,17 (Figure 1.3). 
Queenstown, a tourism hub, is located in the Southern DHB region of NZ, and was where 
community transmission took place (mainly due to World Hereford Conference cluster, 
resulting in at least 39 cases).3,5 Additionally, there was a large cluster initiating from a 
















Figure 1.3: Incidence of COVID-19 during NZ’s first outbreak Between February 24, 2020 and June 8, 2020. A) Relative incidence. B) Cumulative incidence. From NZ 





At the beginning of the outbreak little was known about the transmission 
dynamics of the virus, its incubation period, duration of the illness, or the symptom 
profile amongst different individuals. Furthermore, few diagnostic laboratories in NZ 
were set up to detect the virus. This made deciding which individuals to test difficult, 
particularly when swabs and PCR reagents were in short supply due to the unprecedented 
worldwide demand for these items. Initially in NZ, only individuals with acute 
respiratory symptoms (shortness of breath, sore throat or cough, with fever) who had 
recently returned from COVID-19 affected countries, or those who had contact with a 
confirmed case were able to get a SARS-CoV-2 PCR test to maintain testing capacity 
due to limited access to PCR reagents and consumables.18 A systematic review of 
COVID-19 research by Oran and Topal (2021) found that up to one-third of individuals 
with COVID-19 were asymptomatic at the time of their positive PCR test and that three-
quarters of these individuals remained asymptomatic for the period of their 
infectiousness, therefore many cases may have been missed if using symptoms alone as 
an indication for testing.19 NZ’s narrow case definition early in the outbreak may have 
resulted in some individuals who had COVID-19 not being identified.  
As more information about the virus came to light, the case definition evolved. 
On March 14, 2020, the clinical case definition in NZ was extended to include non-febrile 
acute respiratory infection symptoms (shortness of breath, sore throat or cough, with or 
without fever), as well as the testing of household contacts who were asymptomatic; 
although clinicians were able to able to test others if thought necessary.18,20 On March 
31, 2020, the case definition was further widened to remove the requirement of recent 
travel to COVID-19 affected countries or close contact with a confirmed case, and 
anosmia and coryza were added to the list of symptoms.21 The rapid public health 
response limited the community transmission and the laboratory capacity improved 
rapidly within a matter of weeks. Daily PCR test numbers in NZ at the peak of the first 
outbreak in early April were at just 5000 tests per day, whereas now the highest number 







1.2 SARS-CoV-2 epidemiology 
1.2.1 History of human coronavirus outbreaks 
There are seven known human coronaviruses (CoV); four typically only cause 
mild respiratory infections (alphacoronaviruses 229E and NL63, and betacoronaviruses 
OC43 and HKU1), while three commonly cause severe disease (Severe Acute 
Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV), and SARS-CoV-2).23 Human CoVs 229E, OC43, NL63, and 
HKU1 are the cause of 15-30% of all respiratory tract infections in humans every year.24 
SARS-CoV-2 is the first known pandemic caused by a coronavirus.7 There have been 
two other major outbreaks of severe coronavirus disease in the last two decades: SARS-
CoV (2002-2004) and MERS-CoV (2012 onwards).24 The SARS-CoV outbreak began 
in the Guangdong Province in China in 2002 and had a case fatality rate of approximately 
10% (but approximately 50% in the elderly), with over 8000 cases across more than 24 
countries, with 774 deaths.24 The MERS-CoV outbreak started in 2012 in the Middle 
East, with nearly 2500 cases and approximately 880 deaths to date, with a case fatality 
rate of approximately 34% (which is likely over-estimated due to mild unreported 
cases).24 
The basic reproductive number (R0) of an infectious disease is the average 
number of people infected by one infected person, during the early phase of an outbreak 
(when there is no countermeasures or immunity yet).25 R0 can vary geographically due to 
host population demographics (biological, socioeconomic, and sociobehavioural factors) 
and the climate.25 As an outbreak develops, public health countermeasures and immunity 
(from natural infection and/or vaccination) affects the spread of the disease and the 
reproduction number is then referred to as the effective reproduction number (Re), which 
is a calculation of the R value at a specific point of time in a population.25 An R value of 
greater than 1.0 suggests the disease will grow exponentially, whist an R value of less 
than 1.0 suggests the disease will peter out over time on its own.25 The estimates of R0 
for the three severe human CoV outbreaks vary widely between studies. One early review 
found the estimates of R0 for SARS-CoV-2 ranged from 1.9-6.5,
26 higher than SARS-
CoV (2.0-3.0), and MERS-CoV (0.5-0.9).27 Some of emerging SARS-CoV-2 variants 
appear to be even more transmissible than the ancestral variant.28 SARS-CoV-2 is similar 




due to structural differences in its viral surface proteins and/or its viral load kinetics.29 
Studies have shown SARS-CoV-2 has its peak viral load earlier in infection (within about 
five days of symptom onset) as compared to SARS-CoV and MERS-CoV, with one study 
estimating 44% of secondary cases become infected during the pre-symptomatic stage of 
the index case,30 which means SARS-CoV-2 may go undetected in the community more 
easily.29 
1.2.2 SARS-CoV-2 classification  
In December, 2019, the SARS-CoV-2 virus was isolated by a team of Chinese 
scientists from bronchoalveolar lavage fluid samples from three COVID-19 patients from 
a Wuhan hospital.1 The virus was sequenced and classified as a betacoronavirus, within 
the Sarbecovirus subgenus, and initially named 2019-nCOV.1,31 On February 11, 2020, 
the WHO named the disease the virus caused as Coronavirus Disease-2019 (COVID-19) 
and the International Committee on Taxonomy of Viruses officially named the virus 
SARS-CoV-2.32,33 CoVs are part of the virus subfamily Orthocoronavirinae, family 
Coronaviridae, and order Nidovirales34 (Figure 1.4). Genetically, SARS-CoV-2 is 
related closely to bat-derived ‘SARS-like’ coronaviruses (approximately 88% similar), 
similar to SARS-CoV (approximately 79% similar), and less closely related to the 
MERS-CoV virus (approximately 50% similar).35 
 
Figure 1.4: Classification of human coronaviruses. From Properties of coronavirus and SARS-CoV-2, 




1.2.3 SARS-CoV-2 structure 
CoVs are spherical particles, 80-160 nm in diameter, with crown-like spikes 
jutting out of their surface.23 SARS-CoV-2 has four main structural proteins: Spike (S), 
Membrane (M), Envelope (E), and Nucleocapsid (N).34 The S, M, and E proteins are 
located in the phospholipid bilayer envelope, and the N protein is bound to the 
ribonucleic acid (RNA) genome inside (Figure 1.5).36 The S protein consists of two 
subunits, S1 and S2, which facilitate the attachment of the virus to the surface receptors 
on the host cell, which results in fusion and entry of the virus into the host cell via the 
receptor-binding domain (RBD) contained in the S1 subunit.23 The M protein is the most 
abundant structural protein of the CoV virion; its function is not fully understood but it 
likely aids in the assembly during replication of the virus through its interactions with 
the other viral proteins.23 The transmembrane E protein is the smallest structural protein 
and is involved in the assembly of the virus and budding.23 The N protein, bound to the 
tightly coiled RNA genome within the envelope is also involved in viral replication and 
RNA packaging, and the is most abundantly expressed protein during infection.23  
 
Figure 1.5: Coronavirus structure. From Overview of Immune Response During SARS-CoV-2 
Infection: Lessons From the Past, Shah, Firmal, Alam, Ganguly, and Chattopadhyay, 2020. 
(https://doi.org/10.3389/fimmu.2020.01949).36 Under Creative Commons Attribution License (CC BY). 
1.2.4 SARS-CoV-2 genome 
The genome of the CoV is single-stranded, positive-sense RNA 26-32 Kb in 
length, the longest genome known for an RNA virus.34 The genome of CoVs have a 5’-




at the 5’ terminus, which comprise roughly two-thirds of the genome, encodes RNA 
polymerase and other non-structural proteins (NSPs) involved in viral replication and 
transcription.36 The remaining third of the genome comprises genes that encode the 
structural proteins (including S, M, E, and N proteins), as well as some other NSPs and 
accessory proteins,36 as shown in Figure 1.6. 
 
Figure 1.6: Coronavirus genome. From Insights into SARS-CoV-2 genome, structure, evolution, 
pathogenesis and therapies: Structural genomics approach, by Naqvi et al., 2020  
(https://doi.org/10.1016/j.bbadis.2020.165878).37 Permission obtained from Elsevier, license number 
5104710521308. 
The SARS-CoV-2 genome has undergone numerous mutations since the start of 
the pandemic, resulting in distinct variants of the virus.38 Some mutations may provide 
the virus with an advantage, such as better binding to the angiotensin-converting enzyme 
2 (ACE2) receptor and may result in these variants becoming more common, through 
natural selection.38 Certain variants appear to be more transmissible and/or able to cause 
more severe disease and such mutations may pose problems if vaccines and antibody 
therapies are no longer effective against them, and there is the question of their effect on 
diagnostic tests.38  
1.2.5 Replication cycle of SARS-CoV-2  
The entry of SARS-CoV-2 into the host cell is achieved through the recognition 
of the RBD in the S protein and its receptor ACE2, which is present on the host cell’s 
surface (Figure 1.7).34 After binding to ACE2, the S protein is cleaved by a protease 
enzyme (TMPRSS2), permitting  fusion of cell and virus membranes, releasing the viral 
genome into the host cell’s cytoplasm.39 The virus’s RNA genome is translated by the 
host cell’s ribosomes, starting with the NSPs that produce the replication/transcription 
complex, which translate the structural and accessory proteins.40 The structural proteins 
are incorporated into the endoplasmic reticulum and the N protein combines with the +ve 
ssRNA, followed by budding of the assembled virions in the endoplasmic reticulum-to-






Figure 1.7: Replication cycle of coronavirus. From Coronavirus biology and replication: implications 
for SARS-CoV-2, by V’Kovski, 2021 (https://doi.org/10.1038/s41579-020-00468-6).40 Permission 
obtained from Springer Nature Limited, license number 5083480273740. 
1.2.6 SARS-CoV-2 transmission and pathogenesis 
The zoonotic source of the SARS-CoV-2 virus is unknown, but it is believed to 
have originated in bats because SARS-CoV-2 is closely related genetically to bat CoVs.41 
SARS-CoV-2 was likely transmitted from bats to humans via an intermediary host 
species, possibly from farm or market animals, which has been postulated since humans 
do not generally have much contact with bats and because the CoVs identified in bats are 




because SARS-CoV-2 can infect other animals such as pangolins, ferrets, and cats.42 
The main mode of SARS-CoV-2 spread is person-to-person transmission via 
respiratory droplets but other means include aerosols, the faecal-oral route, and contact 
with individuals, objects, and surfaces contaminated with the virus.43 SARS-CoV-2 
attaches to the epithelial cells, via ACE2 receptors in the upper respiratory tract, where 
the initial viral replication occurs.44 Further replication can occur in the lower respiratory 
tract and the gastrointestinal tract but the virus can also extensively attack other target 
organs that express ACE2 including the lungs, heart, kidneys, and vascular tissues.44 The 
incubation period (time between virus exposure and the onset of symptoms) for SARS-
CoV-2 is relatively short, on average 5-6 days, but it can be as long as 14 days.45 Figure 
1.8 shows the pathophysiology of COVID-19.46 Tissue damage occurs via cell death by 
lysis caused by viral replication and from the over-production of immune mediators.37 
The main cause of severe COVID-19 disease and death is acute respiratory distress 
syndrome, of which the main mechanism is a ‘cytokine storm’, which is when large 
amounts of pro-inflammatory cytokines are released, triggering the death of many cells.47 






Figure 1.8: Pathophysiology of COVID-19. From COVID-19: Current understanding of its 
pathophysiology, clinical presentation and treatment, by Parasher, 2021 
(https://doi.org/10.1136/postgradmedj-2020-138577).46 Permission obtained from BMJ Publishing Group 




1.2.7 SARS-CoV-2 clinical presentation 
COVID-19 has wide-ranging symptoms (Figure 1.9), ranging from 
asymptomatic infection to a severe acute respiratory syndrome that can be fatal.48 
 
Figure 1.9: Clinical symptoms of COVID-19. From Mechanisms of SARS-CoV-2 Transmission and 
Pathogenesis, by Harrison, Lin, and Wang, 2020 (https://doi.org/10.1016/j.it.2020.10.004).48 Permission 
obtained from Elsevier, license number 5083490965866. 
A large epidemiological study reviewing the clinical data of 1099 confirmed SARS-
CoV-2 cases (from 552 hospitals, from 30 provinces) in China, in January 2020, 
identified the most common symptoms, including fever (44% on admission; 89% during 
hospitalisation), cough (68%) and shortness of breath (19%).49 At least one-third of 
individuals infected with SARS-CoV-2 are asymptomatic.19 Approximately 80% of 
individuals with COVID-19 only experience mild symptoms, but approximately 20% of 
individuals have severe disease, 5% critical, and for approximately 2% of individuals, 




Individuals with certain co-morbidities are at an increased risk of developing severe 
disease, which includes being >65 years old, having cancer, cardiovascular disease, 
diabetes, chronic lung disease, sickle cell disease, obesity, pregnancy, or being on 
immunosuppressive treatment.4 COVID-19 disease severity (in adults) is generally 
classified into the following groups, as per the USA’s National Institutes of Health (NIH) 
(and outlined in Table 1.2): asymptomatic or pre-symptomatic disease, mild illness, 
moderate illness, severe illness, and critical illness:4 
Table 1.2: COVID-19 disease severity classification. Adapted from Clinical Spectrum of SARS-CoV-2 
Infection, National Institutes of Health, 2021 




Individuals with confirmed infection by PCR but who have no symptoms 
consistent with COVID-19. 
Mild illness 
Individuals who have any of the non-specific features of mild respiratory 
disease, including fever, cough, sore throat, headache, muscle pain, malaise, 
nausea, loss of taste (ageusia), loss of smell (anosmia), vomiting, or diarrhoea; 
but no shortness of breath and normal chest imaging. 
Moderate illness 
Individuals who show signs of lower respiratory disease and have an oxygen 
saturation (SpO2) of ≥94% (when on room air at sea level). 
Severe illness 
Individuals who have SpO2 <94% (when on room air at sea level), or an 
arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) 
of <300 mm Hg, or respiratory frequency >30 breaths/min, or lung infiltrates 
>50%. 
Critical illness 
Individuals who are in respiratory failure, septic shock, and/or have multi-
organ dysfunction. 
1.3 Clinical management of COVID-19 
1.3.1 Treatment of COVID-19 
The treatment of COVID-19 is essentially supportive, helping with breathing, 
providing fluids, and reducing fever and coughing.46 Mild infections generally do not 
require medical intervention, but some patients, particularly those with co-morbidities, 
may require some basic oxygen support, paracetamol for reducing fever, fluids, and in 
some cases antiviral drugs (less common).46 Monoclonal antibodies have also been 
utilised for COVID-19 outpatients who are at higher risk of developing severe disease.52 
Patients with moderate infection may also require high-flow nasal oxygen and may be 




thromboembolisms).46 Severe infections generally require high-flow nasal oxygen, and 
patients who have deteriorated may require non-invasive ventilatory support, 
endotracheal intubation and invasive mechanical ventilation, or extracorporeal 
membrane oxygenation.46 There is a major role for immunosuppressants including 
steroids and other immunomodulatory drugs (e.g., anti-IL-6) in severe infection.46 Other 
treatments may be used in the treatment in COVID-19, including putting patients in the 
prone position to improve ventilation, antibiotics to treat secondary bacterial infections, 
and convalescent plasma via plasma exchange.53 There are other drugs, with limited 
clinical verification, such as the anti-viral remdesivir.53 
1.3.2 Prevention and prophylaxis of SARS-CoV-2 infection 
Main strategies for the prevention of SARS-CoV-2 infection involve social 
distancing, covering of the face during coughing/sneezing, the use of face coverings, and 
frequent handwashing.53 Numerous SARS-CoV-2 vaccines have been developed, 
considerably faster than any vaccine ever produced, including mRNA vaccines from 
Pfizer-BioNTech and Moderna, and the adenovirus-vectored Oxford-AstraZeneca 
vaccine.53 In December 2020, the regulatory authorities in the USA and the UK granted 
Emergency Use Authorization (EUA) for certain vaccines to be administered (to adults), 
with final approvals coming later.53,54 In New Zealand, Medsafe, gave provisional 
approval for the Pfizer-BioNTech vaccine in February 2021, with rollout beginning in 
February/March 2021, with several other vaccines still undergoing the approval process 
as of June 2021.55 
1.4 Immune response to infection 
1.4.1 Innate immune response to infection 
The immune response can be divided into the innate and the adaptive immune 
responses. The innate immune response is the first line of defence against pathogens and 
is made up of physical, chemical, and cellular defences, to immediately prevent 
pathogens from spreading throughout the body.56 Pathogen recognition receptors present 
on innate immune cells recognise pathogen-associated molecular patterns, which are 
‘microbial non-self’ molecules associated with pathogens,56 activating them so that they 
can kill the pathogen directly, produce chemicals such as cytokines and chemokines, and 




killer cells, neutrophils, mast cells, and eosinophils).57  
1.4.2 Adaptive immune response to infection 
The adaptive immune response consists of two different immune responses, 
involving different lymphocytes: cellular-mediated immunity (T cells) and humoral 
immunity (B cells), where the response is acquired and is specific to the pathogen.58 
Following initial exposure to the pathogen (immunologic priming) it takes time for these 
responses to build, but subsequent exposure to the pathogen results in a quick and robust 
immune response (immunologic memory).58 
1.4.3 Cellular-mediated immunity 
Cellular-mediated immunity involves T cells. T cells are a type of lymphocyte 
that are formed in the bone marrow and migrate to the thymus to mature, where they start 
to express T cell receptors and CD4+ or CD8+ co-receptors, then migrate to lymph 
nodes.58 Intracellular antigens are degraded within cells, transported to the endoplasmic 
reticulum, and expressed on MHC class I, which is presented to CD8+ T cells, which 
recognise peptide epitopes presented on MHC class I on infected cells and become 
cytotoxic T-cells, which proliferate and induce apoptosis of cells that display this 
epitope.58 Extracellular antigens are taken up by antigen presenting cells (dendritic cells 
and macrophages), degraded within these cells, then expressed on MHC class II, which 
is presented to CD4+ T cells, which recognise peptide epitopes presented on MHC class 
II on APCs and become helper T-cells, of which one of their functions is to support the 
activation of B cells and their differentiation into plasma cells, that produce antibodies 
specific to the antigen.58 
1.4.4 Humoral immunity 
Humoral immunity involves the production of antibodies in response to an 
antigen and is mediated by B cells. B cells are produced in the bone marrow and begin 
maturation there, with each B cell clone producing an immunoglobulin (antibody) with 
a unique antigen-binding site.57 During development these immunoglobulin molecules 
are inserted into the cell’s membrane to become B cell receptors .57 Naïve B cells travel 
to the peripheral lymphoid organs and are activated when antigen binds to the B cell 
receptor (along with co-stimulatory signals from helper T cells), proliferating and 




activated upon re-exposure).57 At first, plasma cells secrete IgM antibodies (which bind 
to identical epitopes as the original B cells), which are usually of low affinity, but because 
of their pentameric form, they can bind to multiple, identical antigens simultaneously, 
increasing the overall avidity.57 In the germinal centre reaction, which requires T cell 
help, activated B cells undergo the process of isotype switching and somatic 
hypermutation, which increases antibody binding affinity.59 Activated B cells undergo 
isotype or class switching by rearrangement of the constant domain of the heavy chain 
while retaining their specificity for antigen.59 Class switching results in B cells that 
secrete different immunoglobulin isotypes, but with unchanged specificity; different 
antibody isotypes have different functions.59 Immunoglobulins are made up of four 
polypeptide chains, two identical heavy chains and two identical light chains, with parts 
of the heavy and light chains joining to form the antigen binding sites (Figure 1.10).57 
There are five classes (isotypes) of immunoglobulins (IgG, IgA, IgM, IgD, and IgE), 
each having a distinctive heavy chain and light chains of kappa or lambda 57 (Figure 
1.10). The heavy chains form the tail of the antibody (Fc region), which governs what 
other proteins the antibody will bind to (and therefore its biological function).57  
 
Figure 1.10: General antibody structure. A) Typical antibody molecule. B) The five antibody isotypes. 
From Antibody Structure, by BioCell, 2021 (https://bxcell.com/antibody-structure/).60  
The different tail regions give the antibody different functions: IgM binding to an 
antigen can activate the complement system; IgG can also activate complement but can 
also coat pathogens via opsonisation, to mark them for phagocytosis (and IgG can pass 
through the placenta).57 IgA antibodies are usually found in secretions and move through 




epithelia.57 IgE antibodies bind to an Fc receptor on mast cells and basophils, with antigen 
binding triggering the release of chemicals, particularly histamine, causing vasodilation 
and increased permeability of blood vessels, which helps other immune system 
components to enter the sites of infection.57 
1.4.5 Immune response to SARS-CoV-2 infection 
1.4.5.1 General antibody response 
SARS-CoV-2 is a new virus, and much is still unknown about the nature and 
durability of the antibody response, but new research is continually being published. 
Antibody responses in general are notoriously variable and this is also true for the SARS-
CoV-2 antibody response.61 as it appears to vary depending on the individual’s immune 
system, medications, and disease severity.62 Figure 1.11 illustrates the estimated SARS-
CoV-2 antibody response relative to viral RNA and antigen detection and symptoms. 
 
Figure 1.11: The estimated time relationship between SARS-CoV-2 viral load, symptoms and 
positivity on diagnostic tests. From The Main Molecular and Serological Methods for Diagnosing 
COVID-19: An Overview Based on the Literature, by Machado et al., 2021. 





A systematic review on the antibody response to SARS-CoV-2, reviewing 150 
papers published between January 1, 2020, through to June 26, 2020, found IgM is the 
first detectable antibody in serum and usually appears 5-10 post-onset of symptoms, 
usually persisting for up to six weeks.64 Seroconversion, with the appearance of IgG, 
begins on average 10-14 days post-onset of symptoms, but some individuals can take 
longer, have a low IgG response, or not be detected at all.64 They found IgG peaks around 
3-7 weeks post-symptom onset, and levels plateauing and persisting for at least eight 
weeks.64 However, 72% of these studies used data from hospitalised patients, i.e., likely 
severe disease, and few studies involved participants with mild or asymptomatic 
infection.64 These studies were undertaken during the early stage of the pandemic, so 
although SARS-CoV-2 antibody kinetics were well described during the acute phase of 
infection, there was limited information over a longer period and even these studies often 
had inconsistent results, likely due to differences in the time since infection, differences 
in cohort characteristics (including disease severity) and the considerable heterogeneity 
between the assay used (different targets, different antibody isotypes, and different assay 
technologies). More recent studies show antibody levels in individuals with mild 
COVID-19 disease appear to decline faster than those with severe disease65,66 and that 3-
5 months post-infection, neutralising antibodies (NAbs) (and potentially immunity to 
SARS-CoV-2) starts to wane.67,68 
The antibody response to SARS-CoV-2 appears to be similar to that of other 
human CoVs,36 with studies showing other human CoV antibodies declining over time, 
from 12 weeks post-onset of symptoms and lasting for 1-2 years,69 but it does appear 
SARS-CoV-2 IgG antibodies may decline faster.66 However, studies on the closely 
related SARS-CoV virus indicate NAbs may persist for up to 17 years post-infection.70 
There are also reports of reinfection with seasonal human CoV 6-12 months after initial 
infection.71 and there are already reports of SARS-CoV-2 reinfection,72,73 although the 
reinfection risk to date appears low.74 A study examining memory B cells from 24 
confirmed COVID-19 patients found memory B cell levels increased up to 150 days post-
infection and were still detectable after 240 days, even though IgG levels started to 
decline after 20 days.75 This indicates that the B cells are primed to respond to reinfection 
and this, along with the T cell response, may explain why there are very few reported 




1.4.5.2 Kinetics of antibodies to different antigen targets 
The S and N protein of SARS-CoV-2 are the most immuno-dominant antigens of 
the virus,76 and since the N protein is the most abundantly expressed viral protein during 
infection, it is unsurprising that the majority of antibodies produced are anti-N 
antibodies.77 Anti-N antibodies appear to be produced first, early on in the infection, and 
anti-S antibodies a few days later.78,79 But it is clear from varying reports, that SARS-
CoV-2 antibodies with different targets have differing kinetics.80-84 Since starting my 
study there have been numerous studies published regarding the persistence of SARS-
CoV-2 antibodies,80,82,85-89 with the general consensus being that anti-S IgG antibodies 
persist longer than anti-N antibodies,86-88,90 therefore anti-N IgG antibodies may be a 
better marker of recent infection, rather than past SARS-CoV-2 infection.86   
1.4.5.3 SARS-CoV-2 Neutralising Antibodies 
SARS-CoV-2 infection produces antibodies that bind to the virus (binding 
antibodies (BAbs)), but not all antibodies are neutralising antibodies (NAbs), which are 
antibodies that inhibit infection.91 Generally, NAbs are more strongly correlated with the 
prevention of infection than BAbs.92 The presence of SARS-CoV-2 NAbs appears to be 
protective against reinfection, as evident from the lack of infection in a group of 
individuals with NAbs on a fishing vessel with a high attack outbreak, which also showed 
that those who were seropositive, but lacking NAbs, could be reinfected.93 There are also 
reports of convalescent plasma therapy potentially having a therapeutic effect when 
treating severe COVID-19 patients.94 The primary mechanism of NAbs is by blocking 
viral attachment to host cells.91 Other mechanisms include inducing the aggregation of 
viral particles (reducing viral attachment), interfering with the fusion of the virus and 
host cell, or less likely, by interfering with the replication of the virus.91 Since the N 
protein is associated with RNA packaging, they are generally thought to be non-
neutralising.95 But the RBD of the S protein binds to the ACE2 receptor on host cells for 
virus entry, and anti-RBD/anti-S antibodies can block this process (Figure 1.12) leading 






Figure 1.12: The mechanism of SARS-CoV-2 neutralising antibodies. Neutralising antibody 
competes with the cell’s ACE2 receptor for binding to the RBD of the SARS-CoV-2 spike protein. The 
protruding triangle (purple) on the RBD is ACE2 receptor-binding site and the antibody epitope. From 
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2, by 
Zhou and Zhao, 2020 (https://doi.org/10.7150/ijbs.45123).96 Under Creative Commons Attribution-Non 
Commercial 4.0 License. 
NAb antibody responses appear to peak 3-5 weeks post-infection, associated with 
the peak of the severity of the illness.97 There are conflicting reports on NAb persistence, 
with some reports of NAbs rapidly decaying during the early recovery period, with a 
half-life of approximately 55 days,98 but a slower decay later post-infection (with a half-
life of approximately 90 days up until at least eight months post infection),99 but more 
recent data shows that NAb levels may increase again as the immune response matures.100 
1.4.5.4 T cell response to SARS-CoV-2 
Less is known about the SARS-CoV-2 T cell response but memory T cell 
responses that persist for years have been reported for MERS-CoV and SARS-CoV.101 
There is one study that shows SARS-CoV-2 infection induces a strong CD4+ T cell 
response and that immunogenic epitopes on the S, M, and N proteins can activate CD4+ 
and CD8+ T cells from COVID-19 patients.102 The same study suggested there is likely 
cross-reactivity of immunity between human CoVs as the researchers repeated the 
experiment on healthy unexposed individuals and found 40-60% of these individuals 
elicited CD4+ T cell responses, which could potentially be due to infection with other 
human CoVs.102 T cells might provide longer-lasting immunity defence against SARS-
CoV-2 infection than the B cell response but immunity against SARS-CoV-2 will likely 




1.5 SARS-CoV-2 diagnostic and laboratory methods 
Although COVID-19 can be diagnosed provisionally based on the clinical history 
and the epidemiology history, the gold-standard method for diagnosis of SARS-CoV-2 
infection is detecting the presence of SARS-CoV-2 RNA from a respiratory sample by a 
nucleic acid amplification test (NAAT, referred to here as PCR).103 Chest x-rays or 
computerised tomography scans can be used to demonstrate the presence of ground-glass 
pulmonary opacities in the lungs, which are common in COVID-19,104 and depending on 
the severity of infection, certain non-specific laboratory findings can be seen, including 
leukopenia, lymphopenia, mild thrombocytopenia, increased inflammatory markers (C-
reactive protein, and ferritin), increased aspartate aminotransferase, lactate 
dehydrogenase, troponin T, and increased levels of cytokines (interleukins, tumour 
necrosis factor).103 Serological assays, used to detect the presence of antibodies, can 
provide evidence of recent or past infection, including for patients who have been 
symptomatic for some time, but are PCR negative.3,62 Serological antigen assays have 
also been developed, which can rapidly detect virus antigen in a sample.62 
1.5.1 Nucleic acid amplification test 
SARS-CoV-2 RNA is generally detectable 2-3 days before symptom onset and 
remains so up to 25-50 days post symptom onset (or longer in individuals who are 
symptomatic for longer or have severe disease).30,105 The first genome sequence of 
SARS-CoV-2 was made available publicly in January 2020,106 and several days later a 
further five genomes were uploaded onto the Global Initiative on Sharing All Influenza 
Data database.107 International scientific groups worked at record speed to design primers 
and probes, using the data from these sequences, to create PCR assays to detect the 
presence of SARS-CoV-2 RNA in diagnostic specimens, since there was no commercial 
test available during the initial phase of the outbreak.107 
A sample for PCR testing is generally an upper respiratory swab (nasopharyngeal 
and/or oropharyngeal), and once the swab has been taken, it is put into a tube containing 
a virus transport media to preserve the virus, then viral RNA is extracted from the 
sample.62 The first step of the reverse transcriptase-PCR (RT-PCR) assay is the 
conversion of the viral RNA into deoxyribonucleic acid (DNA) using reverse 
transcriptase, which requires DNA primers designed to recognise the complementary 




amplification via PCR, which is monitored in real-time, using a fluorescent marker 
(Figure 1.13).61 The amplification process is repeated, automatically, for about 40 
cycles.61 The number of cycles it takes for the cDNA to be detected is called the cycle 
threshold, with a lower cycle threshold indicating more virus is present.62 
  
Figure 1.13: Schematic showing the principle of RT-PCR. From Molecular diagnostic technologies 
for COVID-19: Limitations and challenges, by Afzal, 2021. 
(https://doi.org/10.1016/j.jare.2020.08.002).108 Under Creative Commons CC-BY-NC-ND license.  
A positive PCR test indicates viral RNA is present in the sample and usually 
means the individual is currently infected, but a PCR test can return a positive result in 
an individual who has recovered if there are remnants of dead virus present.109 False 
negative results may occur if insufficient viral RNA is present at the collection site, or 
the sample was of poor quality, or the time window of the virus replication has been 
missed.62 A PCR test cannot determine whether an individual has past infection after they 
have recovered.61 It has also been shown that individuals can have high levels of IgG but 




1.5.2 Antigen tests 
Antigen tests detect the presence of viral antigens in a sample (e.g., swab, blood, 
or saliva), usually by a lateral flow assay (LFA), a type of serological assay where SARS-
CoV-2 antibodies are bound to a substrate and as the sample passes over the antibodies, 
if any antigen is present will result in a band of immobilised viral antigen-antibody 
complex, giving a positive result, indicating the presence of viral antigen in the sample 
(Figure 1.14).61 These tests are cheap and fast to perform but they generally have lower 
sensitivity than PCR.111 Antigen tests also generally have good specificity but they can 
give false positive results, particularly if used in low disease prevalence populations or if 
the test is not performed correctly.112 Also, as with NAAT, antigen tests are only useful 
during the viral shedding phase of the infection.109  
 
 Figure 1.14: Schematic showing the basic principle of a lateral flow assay. From COVID-19 
Diagnostic Strategies Part II: Protein-Based Technologies, by Shaffaf, 2021. 
(https://doi.org/10.3390/bioengineering8050054).113 Under Creative Common CC BY license. 
1.5.3 Serological tests 
Serological tests can indirectly detect recent or past SARS-CoV-2 infection by 
measuring the antibody response to the virus. Individuals are classified as seropositive 
by an assay when their antibody level is greater than a pre-defined cut-off value. The 




anti-N antibodies.3,62 These assays are highly variable and may differ in their format, 
including the antibody being detected (total immunoglobulin, IgG, IgA, IgM), and the 
antigen target (S, N, E, or subunits of these).114 Differing degrees in the conservation of 
protein sequence between the S (including S1 and RBD) and N proteins and proteins 
from other CoV species, also with differences in the kinetics and magnitude of the 
antibody response to these proteins, may impact SARS-CoV-2 serological assay 
performances.3,115 Numerous serological assays are now commercially available, 
including LFAs, enzyme-linked immunosorbent assays (ELISA), and chemiluminescent 
immunoassays (CLIA) (including chemiluminescent microparticle immunoassays, 
CMIA, and electrochemiluminescent immunoassays, ECLIA).  
The most common serological assays for SARS-CoV-2 antibodies are ELISA and 
chemiluminescence due to their short turn-around-time, ease of use, and ability for high 
throughput testing (including automation).116 The traditional ELISA employs viral 
protein adsorbed onto plate wells, and if the antibody of interest is present, it will bind to 
the wells and the antibody-antigen complex can be detected with an enzyme-labelled 
secondary antibody that with the addition of substrate produces a colorimetric reaction 
that can be read on a plate reader; viral antigens can be detected similarly, using bound 
target antibodies.61 The CLIA is performed in a single vessel on an automated analyser, 
utilising recombinant antigens labelled with a chemiluminescent tag, which form 
complexes with the target antibody in the sample, emitting light as a result of a reaction 
in the well.113 There are variations of CLIA, with the main difference being how the 
chemiluminescence is produced (a electrochemical reaction in ECLIA, and a chemical 
reaction using microparticles in CMIA).113 Refer to Chapter 2, Methods and Materials, 
for a more detailed description of the ELISA and CLIA methods used in this study. 
1.5.4 Neutralising antibody tests 
Assays that can detect NAbs include conventional virus neutralisation assays 
(cVNTs), utilising live virus (focus-reduction neutralization test, plaque reduction 
neutralization test (PRNT), and the live virus micro-neutralization assay),117 the 
pseudovirus neutralization test (pVNT),118 and more recently fluorescence-based 
neutralisation assays,119 and the surrogate virus neutralisation test (sVNT).95 The PRNT 
is considered the reference standard method for the detection of NAbs, involving 




cell cultures, and if NAbs are present they will inhibit viral infection, and the number of 
infectious virus particles can be estimated by observing the cytopathic effects of viral 
replication, which can be quantified.120 However, the PRNT involves handling live 
SARS-CoV-2 virus in a specialised biosafety level (BSL) 3 containment facility; it is a 
laborious method, requires a high level of expertise to perform, and the results are 
somewhat subjective.114 Although the PRNT is highly sensitive, it is not efficient enough 
to be suitable for high-throughput testing.117 The pVNT uses a genetically modified viral 
vector, which expresses the SARS-CoV-2 spike protein on its surface and contains the 
luciferase gene (which is expressed only after entering a host cell).117 Its genome is also 
modified so it is unable to replicate, making it safer than the PRNT.117 The assay involves 
incubating a mix of pseudovirus and decreasing concentrations of serum, and adding it 
to cell cultures, and if NAbs are able to inhibit the pseudovirus entry into the cells, less 
luciferase is expressed and less light is emitted, which can be quantified and reported as 
percent inhibition and/or as a serum dilution titre.121 However, the pVNT still requires a 
BSL2 laboratory and is also a laborious, time-consuming method.122  
The sVNT is an ELISA-based assay that measures the presence of NAbs that can 
block the binding of the RBD with the ACE2 cell surface receptor.95 The assay involves 
plate wells coated with human ACE2 protein and a reagent containing a labelled 
recombinant SARS-CoV-2 RBD protein.122 If no NAbs are present, the RBD is able to 
bind to the ACE2, and after the addition of a substrate, a colour is emitted and measured, 
with the absorbance inversely related to the concentration of NAbs in the sample.122 The 
sVNT is a simple, quick (1-2 hours) ad safe method.122 Refer to Chapter 2, Methods and 
Materials, for a more detailed description of the sVNT and pVNT methods used in this 
study. 
The creators of the sVNT assay compared the sVNT to both a cVNT and pVNT 
and found all three had overall good correlation, with the sVNT/cVNT combination 
having a slightly better correlation than the sVNT/pVNT or cVNT/pVNT combination.95 
Anti-RBD/anti-S antibodies have been shown to correlate well with NAbs (more so than 
anti-N antibodies).95,123-126 Although it is unclear what concentration of NAbs provide 
protection against infection,127 there have been non-human primate studies that suggest 





1.5.5 Clinical performance of SARS-CoV-2 serological tests 
The specificity and sensitivity of serological assays for SARS-CoV-2 are 
generally lower than PCR, largely due to cross-reactivity of other antibodies in the 
sample, which may include antibodies to other human CoVs; over 90% of adults over the 
age of 50 years have been shown to have antibodies to human CoV strains NL63, 229E, 
OC43, or HKU1.129,130 Other cross-reacting antibodies include heterophile antibodies 
(weakly binding antibodies generated from poorly defined antigens, with multi-specific 
binding, most commonly produced after Epstein Barr Virus infection), rheumatoid factor, 
and anti-nuclear autoimmune antibodies.129 It is important serological assays undergo 
thorough validation to assess the potential for cross-reactivity. Sensitivity of SARS-CoV-
2 serological assays may depend on the timing of the sampling, the antigen target, and 
the format of the assay. A good assay needs to have the ability to detect antibodies from 
individuals from various clinical situations (early versus late post-exposure, mild versus 
severe illness, and natural versus acquired immunity).131 
The probability of a test result being the correct result does not depend on the 
specificity or sensitivity of the test alone. The positive predictive value (PPV) is the 
percentage of patients with a positive test result who are correctly diagnosed, and the 
negative predictive value (NPV) is the percentage of patients with a negative test result 
who are correctly diagnosed, both which vary with the test specificity, sensitivity, and 
disease prevalence.132 The higher the disease prevalence, the more likely a positive result 
is a true positive, and therefore the higher the PPV, and vice versa.132 Even if an assay 
has a high specificity, if it is imperfect and the prevalence of SARS-CoV-2 is low (which 
was the case in many countries early in the pandemic), then many positive antibody test 
results may be false positives. In these situations, it is necessary to confirm positive 
results with a confirmatory assay (preferably with a different antigen target), to minimise 
the false positive results.  
When setting up my study, commercially available SARS-CoV-2 serological 
assays were new and some did not have regulatory approvals (some had EUAs). These 
assays were rapidly developed and released with less rigorous validation procedures than 
usual, generally using a low number of clinical samples (due to the difficulty of obtaining 
sera from confirmed cases, and needing to release assays quickly). Most assays were 




period, which may have resulted in a biased estimate of assay performance (if disease 
severity or time since infection affects antibody levels). Therefore, the sensitivity of these 
assays appeared acceptable, however, the data concerning the sensitivity after 14 days 
post onset of symptoms was limited, simply because it had not been assessed yet. Clinical 
laboratories should do their own verification of the manufacturer’s stated assay 
performance to ensure the assay is fit for purpose for their population.  
There was also little information early in the outbreak about what target antigen 
would be best for various testing scenarios. Early in the pandemic, studies suggested anti-
N antibodies may be less specific than anti-S antibodies since the N protein sequence 
appears to be more conserved across CoVs,76 but more sensitive than anti-S antibodies 
for detecting early SARS-CoV-2 infection, since the majority of antibodies produced are 
anti-N antibodies.133 Also, anti-S antibodies appear correlate better with NAbs (due to 
the S protein’s involvement in the virus-host attachment), they may be more clinically 
useful than anti-N antibodies.77 
Assessing the sensitivity and specificity of serological tests can be difficult as 
there is not a gold-standard test. PCR testing is used as a surrogate gold-standard test but 
‘false’ negative antibody results can occur for reasons other than imperfect analytical 
assay performance, including biological reasons (failure to mount a robust antibody 
response in immunocompromised individuals, or if the infection was cleared through 
other mechanisms, such as via T cells), interferents in the sample, or the PCR test result 
could be a false positive result.134 Comparing results to PCR results should be interpreted 
with caution and discrepant results should be examined for possible explanations for a 
false serology or PCR results. 
Most serological assays are only able to detect BAbs, so if these serological 
assays are to be used to monitor potential immunity (including vaccine response), then it 
is important to assess the correlation of these assays with NAb assays. 
1.5.6 Role of serology testing 
Testing for SARS-CoV-2 antibodies can be used for seroprevalence 
investigations, part of contact tracing procedures, and to help identify subclinical 
infections or diagnostic workup in difficult cases (when patients are symptomatic but 




a correlate of protection is identified (useful for vaccine development and monitoring, 
and to identify workers and/or travellers who have been infected or vaccinated who may 
be at less risk of becoming infected).114,135 Certain countries, e.g., China, require 
travellers to present proof of a negative SARS-CoV-2 IgM within 48-72 hours before 
they may travel to the country (in addition to a negative PCR), to reduce border 
transmission,136 and others require a positive SARS-CoV-2 IgG (as proof of vaccination, 
or prior infection). 
1.6 SARS-CoV-2 seroprevalence studies 
Seroprevalence studies (or ‘serosurveys’) are an important epidemiological tool 
to determine the true extent of an infectious disease outbreak, whose results can be used 
to estimate the disease mortality and case fatality rates, and guide public health actions 
such as deciding when it is safe to remove restrictions and/or lockdowns.114,137  
SARS-CoV-2 IgG antibodies are used for seroprevalence studies because 
seroconversion has been reported to occur in up to 100% of individuals after 14 days of 
onset of symptoms.62 Blood specimens for serological methods are easy to collect and 
most of the assays are quick and easy to perform, with most methods available on 
automated analysers. However, seroprevalence studies require assays that are both very 
sensitive and specific, which is particularly important when the pre-test probability of 
having the disease is low. The presence of SARS-CoV-2 IgG does not necessarily mean 
an individual is immune to infection (or reinfection), and not all IgG antibodies are be 
protective.  
When choosing a method, it is important to detect an antibody suited to the 
purpose, e.g., anti-N IgG antibodies may be well suited to detect recent infection, while 
anti-S IgG antibodies may be better suited to detect infection when it was been some time 
since infection (depending on the vaccination status of the individual), and monitoring 
response to an S-based vaccine clearly requires measuring anti-S antibodies. Measuring 
both anti-N IgG and anti-S IgG antibodies may be able to distinguish natural immunity 
(via infection) versus acquired immunity (by vaccination), and an anti-N IgG antibody 
assay would be more useful in the surveillance of disease in the setting of widespread 





At the time of setting up this study, very few SARS-CoV-2 seroprevalence studies 
had been performed, but numerous have since been reported overseas, including among 
blood donors,138,139 healthcare workers,140-142 and the general public.143-145 However, 
these results varied greatly, owing to differences in sample size, and population tested 
(including cohort demographics and the severity of the outbreak in the location).137 One 
large systematic review and meta-analysis146 reviewed 47 seroprevalence studies 
performed prior to August 14, 2020, including 399,265 participants from 23 countries, 
which showed that the sero-prevalence of SARS-CoV-2 was wide-ranging between 
different geographic regions, as was expected, but some of these studies may have been 
affected by the use of unreliable methodology (sample biases and assays with less than 
desirable performance).146,147 
1.6.1 Issues with seroprevalence studies 
The issue with some seroprevalence studies is they used a single SARS-CoV-2 
IgG assay to determine seropositivity, but as discussed earlier, an assay with nearly 
perfect specificity in a low prevalence population will still have a low PPV and 
potentially many false positive results (potentially more false positives than true 
positives), therefore confirmatory assays should be employed in such a scenario. One 
seroprevalence study with some obvious flaws was a study out of Santa Clara, USA, led 
by researchers at Stanford University, initially published on an online preprint server in 
April 2020, which caused some uproar in the media, reporting a SARS-CoV-2 
seroprevalence of 2.5-4.2% in the county, suggesting 48,000-81,000 individuals had been 
infected, 50-85 fold more than the number of PCR-confirmed cases at that time.148 One 
issue with that study is they used a LFA assay with an estimated specificity of 99.5%, 
and this, combined with the likely low prevalence of disease in the population tested, 
means the PPV would be low, giving little value to a positive result, since they did not 
confirm these results with another method.148 Additionally, there was probable bias in 
their cohort as they recruited via Facebook, which likely resulted in a young demographic 
and potentially attracted participants wanting to confirm if they had had COVID-19; 
therefore, this was not a random sample set, but the authors still extrapolated these results 





1.7 Aims and objectives 
My thesis is set out with an initial introduction (including review of the literature), 
a Methods and Materials chapter, then five results chapters, each reporting the findings 
of each aim of my research, then finishing with concluding remarks. The main aim of 
this study was to determine whether any SARS-CoV-2 infections went undetected during 
NZ’s first outbreak, by utilising a number of serological assays. This firstly required the 
assessment of the clinical performance of these assays and provided an opportunity to 
expand the research into further aims by recruiting participants to study the longitudinal 
kinetics of SARS-CoV-2 antibodies. 
1.7.1 Aim 1 
To investigate the clinical performance (sensitivity and specificity) of the Abbott 
Architect SARS-CoV-2 IgG assay based on the N protein, together with a series of other 
SARS-CoV-2 serological assays, including a sVNT assay. This aim was achieved using 
a case-control study design, measuring the levels of SARS-CoV-2 antibodies in pre-
pandemic sera and sera from PCR-confirmed cases, using the different assays. These 
results were also used to assess the validity of the serosurvey (Aim 2). This aim is 
henceforth referred to as the clinical performance study. 
1.7.2 Aim 2 
To determine the frequency of SARS-CoV-2 IgG antibodies among higher-risk 
individuals in the Southern DHB region of NZ to determine whether cases were missed 
during the initial outbreak due to limited PCR testing and/or asymptomatic infection. 
This aim was achieved by performing an observational cross-sectional (serosurvey) 
study. Sera from higher risk individuals from the Southern DHB region of NZ were tested 
for the presence of SARS-CoV-2 IgG antibodies using a main screening assay (Abbott 
Architect) and confirmed with a series of other SARS-CoV-2 serological assays. This 
aim is henceforth referred to as the serosurvey study. 
1.7.3 Aim 3 
To utilise serological testing to assess the likelihood of infection among those 
diagnosed as ‘probable’ cases. This aim was achieved by performing an observational 
cross-sectional study, testing for the presence of SARS-CoV-2 IgG antibodies in a cohort 




1.7.4 Aim 4 
To perform a longitudinal analysis of SARS-CoV-2 antibodies in confirmed cases 
to determine how long these antibodies persist, using several different serological assays, 
including a sVNT assay. This aim was achieved by performing a prospective, 
longitudinal cohort study, measuring the levels of SARS-CoV-2 antibodies in a subset of 
the PCR-confirmed cases (and several seropositive higher-risk participants) in sequential 
serum samples collected up to approximately 10-12 months post-onset of symptoms. 
This aim is henceforth referred to as the antibody persistence study. 
1.7.5 Aim 5 
The last aim was to establish an in-house pseudovirus neutralisation test (pVNT) 
in the Ussher Laboratory at the University of Otago. The original aim was to also 
investigate the clinical performance (sensitivity and specificity) and concordance of the 
pVNT with the sVNT assay, but due to reasons stated in Chapter 2, only the setup and a 
few sample comparisons with the sVNT were described. 
1.8 Inclusion of published material 
Early on during my research, my study collaborators and I decided to publish our 
initial results on the findings of our serosurvey to assess whether any SARS-CoV-2 
infections had gone undetected in the Southern DHB region during NZ’s first outbreak, 
because this would be of interest to public health and the general public. I was the main 
author and main contributor to this article; we initially published the article on a pre-print 
server and then it was accepted in a peer-reviewed journal, with the title SARS-CoV-2 
antibodies in the Southern Region of New Zealand, 2020.3 As per the publisher, I have 
the right to include material from my article in my thesis, and I have done so in part, but 
with proper acknowledgment by citation. Results and excerpts from this article have been 
included in my thesis, mainly in Chapter 3 (clinical performance of the assays; although 
additional results were obtained after publishing), Chapter 4 (the serosurvey results) and 
Chapter 5 (testing of probable cases). I was also a co-author on another paper published 
during my research, Comprehensive analysis of SARS-CoV-2 antibody dynamics in New 
Zealand,86 which included, but was not limited to, the results of some of the samples 
from my antibody persistence research (Chapter 6). Copies of both articles can be found 




Chapter 2: Methods and materials 
2.1 Introduction 
This research was performed primarily at Southern Community Laboratories 
(SCL), Dunedin, NZ, in conjunction with the University of Otago, the Southern District 
Health Board (SDHB), WellSouth (a local primary healthcare organisation), the 
University of Auckland, the Institute of Environmental Science and Research (ESR), and 
LabPlus. I was involved in all aspects of the study, from the setting up of the study, 
logistics of blood collection, preparation of samples for analysis, sample transport to 
external laboratories, setting up a serum bank, the majority of the sample analysis, and 
results analysis. Refer to Section 2.8 for details on which analyses I performed. 
2.2 Methodology and research design 
The aims of my research were described in the Chapter 1 and were carried out 
using a case-control study design for assessing the clinical performance of the assays, an 
observational cross-sectional study design for the serosurvey, and a prospective 
longitudinal cohort study design for the antibody persistence study. The majority of these 
aims were carried out simultaneously, with the exception of the antibody persistence 
study, which was continued for approximately ten months from the first blood 
collections, and the pVNT comparison, which was performed towards the end of the 
research period. 
2.3 Procedure and timeline 
● Ethics application (early May 2020) 
● Ethics approval (late May 2020) 
● Recruitment (May-July 2020) 
● Phlebotomy (initial blood collection June-August 2020, antibody persistence 
blood collections up until March 2021) 
● Sample analysis (June 2020 – June 2021) 
● Data analysis (Sept 2020 – June 2021) 





The New Zealand Health and Disability Ethics Committee approved the 
collection of blood samples from the study participants, use of pre-pandemic antenatal 
sera, and the creation of a serum bank (Ethics reference: 20/NTB101).  
2.5 Sample cohorts 
In total, 1214 individuals (excluding the sera from the antenatal patients) gave 
informed consent and participated in the study, with bloods collected between 4th June 
and 4th August 2020 initially, and up until March 2021 for the antibody persistence study. 
Four sets of sample cohorts were used amongst the aims of this study: pre-pandemic 
antenatal sera, PCR-confirmed cases, higher-risk participants, and probable cases.  
2.5.1 Pre-pandemic antenatal sera 
2.5.1.1 Overview 
To determine assay specificity, de-identified antenatal sera collected from early-
to-mid 2019 (pre-pandemic), were used. SCL Dunedin receives approximately 50 
samples a week from pregnant women, or women planning pregnancy, as part of their 
first antenatal screen. In accordance with good laboratory practice, aliquots of 750 µL of 
these serum samples are stored at -20oC for at least 12 months. 
2.5.1.2 Sample size justification 
The sample size for the specificity samples was mainly determined by the 
availability of pre-pandemic samples. 300 antenatal/pre-pandemic samples were able to 
be saved in the period before the testing was started.  
2.5.2 PCR-confirmed cases 
2.5.2.1 Overview 
To determine sensitivity, sera from individuals with PCR-confirmed SARS-CoV-
2 infection were used. The severity of COVID-19 infection in the PCR-confirmed cohort 
were classified on the basis of their symptoms and the level of hospital care provided: 1 
– asymptomatic to mild: coryza (runny nose), and/or sore throat; 2 – moderate: fever, 
or cough, or shortness of breath; 3 – moderately severe: admitted to hospital for 
assessment; 4 – severe: admitted to hospital and given supplemental oxygen therapy; 5 




internationally recognised criteria (in order to enable comparison between studies), such 
as the USA’s National Institutes for Health’s Clinical Spectrum of SARS-CoV-2 
Infection53 because the majority of infections in the Southern DHB region were mild-to-
moderate and we were unable to obtain all the clinical information required for the NIH 
classification system (oxygen saturation, etc). The survey was also retrospective, 
performed some time after infection, and sought self-identified symptoms rather than 
assessment by a medical professional (aside from those few who received hospital 
treatment). All PCR-confirmed cases were invited to be part of the antibody persistence 
study (Chapter 6). Participants were asked to donate a blood sample approximately every 
two months, up until approximately ten months after their original blood collection.  
In addition, samples from two of the PCR-confirmed cases were tested using the 
quantitative S-based Abbott Alinity assay after each of their two doses of the Pfizer-
BioNTech SARS-CoV-2 vaccine (note: this was not part of an original aim but towards 
the end of the study the opportunity to test these individuals arose).  
2.5.2.2 Sample size justification 
The sample size was mainly determined by the availability of samples from 
participants who were willing to participate (out of the 187 PCR-confirmed cases in the 
Southern DHB region).  
2.5.3 Higher-risk participants 
2.5.3.1 Overview 
Sera from higher-risk participants were tested as part of the serosurvey (Chapter 
4). 1127 individuals gave informed consent and participated in the serosurvey. These 
individuals were considered to be of higher risk than the general population of having 
previous undiagnosed COVID-19 infection, either by contact with a PCR-confirmed case 
or because of workplace duties (frontline healthcare workers, tourism workers, police), 
or were Queenstown residents. Several participants in this cohort appeared to fit the 
definition of a probable case (as they self-reported to be symptomatic, household contacts 
of known cases), but they were not under public health management and therefore not 
categorised as probable cases (refer to section 2.5.4). A subset of the higher-risk 
participants (n=6) who tested positive on the Abbott Architect assay were invited to be 




these participants were invited to donate a blood sample, up until approximately 10 
months after their original blood collection. 
2.5.3.2 Sample size justification 
Since the suspected SARS-CoV-2 prevalence was suspected to be low in the 
Southern DHB region, a screening assay with a high specificity would be required (to 
ensure a high PPV). The SARS-CoV-2 prevalence for NZ and Southern DHB were 
estimated between 0.05-0.1%.5 We assumed a screening test would have a  specificity of 
95% and sensitivity of 90%. Table 2.1 shows the calculated samples sizes to estimate 
true prevalence using an imperfect test.149 If the true prevalence amongst higher-risk 
participants was 0.05%, a sample size of >637 would allow us to achieve a precision of 
at least 2%. 
Table 2.1: Sample size required to estimate true prevalence. Using a 95% CI and varying precision, 
assuming a test with 90% sensitivity and 95% specificity. Calculated using the online calculator: Sample 
size to estimate a true prevalence with an imperfect test, by Epitools, 2021. 
(https://epitools.ausvet.com.au/prevalencessone).149 
 Desired precision 
Assumed true 
prevalence 
1% 2% 5% 
0.01% 2530 633 102 
0.05% 2546 637 102 
0.1% 2567 642 103 
1% 2929 773 118 
5% 4464 1116 179 














   
2.5.4 Probable cases 
2.5.4.1 Overview 
Sera from nine individuals with ‘probable’ SARS-CoV-2 infection were used. 
Probable cases were PCR negative (or no PCR test performed), a close contact of a 
confirmed case, and had a clinically compatible illness with other causes excluded.18 
COVID-19 consistent symptoms (at that time) were defined by the Medical Officer of 
Health as any acute respiratory infection with at least one of the following symptoms 





2.5.4.2 Sample size justification 
The sample size was determined by the availability of samples from participants. 
The Southern DHB region had 30 probable cases in total. 
2.6 Participant recruitment 
A study email address was created for communication with participants. The 
PCR-confirmed cases, probable cases, and their known contacts (close and casual) were 
identified via Public Health South and contacted directly via email, with an invitation to 
participate in the study and provided with a link to the REDCap (Research Electronic 
Data Capture) online survey. Higher-risk participants were recruited through a variety of 
means - through workplaces, posters, social media, news articles, and television 
interviews. Participants were initially instructed to make contact via the study email 
address and if they met the criteria of being higher-risk as determined by one of the 
investigators (Dr Upton), they were provided a link to the REDCap survey. Towards the 
end of the recruitment period, participants were able to enrol directly, when the REDCap 
link was made available through social media and posters, in order to boost numbers.  
2.6.1 REDCap Overview 
REDCap (Research Electronic Data Capture) is a secure web-based application 
for building and managing online surveys and databases.151,152 The University of Otago 
hosts REDCap and all survey data is stored in their data centres. Two separate REDCap 
projects were set up, one for the PCR-confirmed and probable cases, and one for the 
higher-risk group. This was to allow for different questionnaires and registration of the 
correct tests into the laboratory’s information system (LIS). The REDCap survey 
included the participant information sheet (PIS), consents, and questionnaire. A research 
support specialist from the University of Otago set up an initial survey template and we 
modified it for the needs of the study. Refer to Appendix B for a copy of the forms.  
2.6.2 Participant information sheet 
The PIS (Appendix B) described the purpose of the study, the blood samples that 
would be taken, the health information to be collected, an outline of the study protocol, 






The REDCap survey included embedded consents, utilising electronic signatures. 
Children under 16 years were asked for assent and their parents/guardians provided the 
consent (hard copy). An additional optional consent/assent was obtained for storage of 
serum in the SRSSB for future specified SARS-CoV-2 antibody research. Participants 
were emailed a copy of their consents at the completion of the survey. A number of 
participants were provided with manual consents and questionnaires if they were unable 
to complete the online survey.  
2.6.4 Questionnaire 
The questionnaire included name, email address, phone number, date of birth, 
age, gender, NHI, doctor’s details, postcode, ethnicity, and a set of questions relevant to 
the sample cohort. PCR-confirmed and probable cases were asked if they remembered 
having any COVID-19 related symptoms during their illness. Higher-risk participants 
were asked what higher risk category they associated with, if they had contact with 
anyone diagnosed with COVID-19, and whether they remembered having any COVID-
19 related symptoms before or during the first lockdown period (during Alert level 3-4). 
Refer to Appendix B for a copy of the questionnaires. 
2.6.5 Sample registration 
Data from REDCap was extracted into a spreadsheet and emailed to the 
laboratory’s data entry department regularly. The extract contained the details required 
to pre-register the participant and the appropriate test code into the laboratory’s LIS, 
using the laboratory’s electronic ordering system (e-Order). 
2.6.6 Blood collection 
At the completion of the survey, participants were provided a link to the SCL 
online blood collection booking site, and information on how to proceed with blood 
collection. Participants were able to book for phlebotomy at two collection centres in 
Dunedin, one in Invercargill and one in Queenstown, where dedicated study clinics were 
set up. If participants were unable to attend these clinics, they were able to contact us and 
we made alternative arrangements for them. 
For adults, four 5 mL serum separator tubes (SST) were collected (up to a 




under ten years old, 1 mL per kg to a maximum of 10 mL; 10 to 14 years, 15 mL; and > 
14 years, 20 mL. At the time of blood collection, the participants were given a barcode 
which would serve as a password to access their results, which were sent automatically 
via the LIS to their email in a password protected file. For the antibody persistence study, 
at subsequent time points, only one 5 mL SST was collected.  
PCR-confirmed and probable cases also had three 10 mL 
ethylenediaminetetraacetic acid (EDTA) blood tubes collected. This was for the isolation 
of peripheral blood mononuclear cells (PBMCs) at the Department of Microbiology and 
Immunology, Ussher Laboratory, University of Otago, for T cell studies (separate from 
my study). EDTA tubes were not collected on children. After failed separation of PBMCs 
from participant’s blood that was not separated within six hours, it was later decided to 
only collect EDTA tubes on participants at the Dunedin Hospital collection centre and 
transport them immediately to the Ussher Laboratory. 
2.7 Laboratory logistics 
2.7.1 Pre-analytical processing 
Blood tubes were collected and transported to SCL Dunedin by routine SCL 
couriers. Once at the laboratory they were delivered to the Biochemistry department 
where the tubes were loaded onto the Roche MPA (Modular Pre-Analytics) instrument, 
which is an automated system for pre-analytical processing of samples, which can 
remove and insert tube caps, barcode, aliquot, and accession samples. The MPA was 
programmed to create one capped 900 µL aliquot of serum in a 5 mL polypropylene (PP) 
tube for the samples from PCR-confirmed and probable cases (manual aliquots were 
prepared later for long-term storage in cryovials). For the higher-risk group, the MPA 
was programmed to create one capped aliquot of 300 µL and four uncapped aliquots of 
900 µL in 5 mL PP tubes. The capped tubes were for used testing on the Abbott Architect 
instrument. The uncapped samples were manually capped with a push cap suitable for 
freezing and put aside for accessioning into the SRSSB serum bank. Before testing, each 
sample was manually checked against the REDCap extract spreadsheet to record the 
laboratory request number against the participant’s details in the spreadsheet, to check 
for correct registration, whether they consented to their samples being included in the 
SRSSB serum bank, whether they requested their sample to be de-identified, whether 




results, whether they wanted their results to go into the local results depository database, 
and whether they wished a Karakia to be performed before their sample was disposed of. 
2.7.2 Sample processing 
The pre-pandemic/antenatal samples were thawed, de-identified (labels removed 
and replaced with a study number) and centrifuged at 3000 RPM (revolutions per minute) 
for 10 minutes before testing. All other samples were tested on the Abbott Architect 
within several days of collection. Sample aliquots were then prepared and frozen for 
testing on other assays at a later date.  
2.7.3 Post analytical processing 
After testing on the Abbott Architect, sample aliquots requiring testing on the 
additional assays were sent frozen to the other laboratories in batches. Aliquots for the 
SRSSB serum bank were prepared and stored. Any patient identifiers were removed from 
the tube label prior to storage, leaving only the request number. If the participant 
requested their sample to be de-identified, after testing and recording of the results, the 
sample tube was given an anonymous study number, which could not be linked back to 
the participant. 
• The pre-pandemic/antenatal samples were split into three aliquots for testing at 
other laboratories. 
• For the samples from PCR-confirmed cases, probable cases and samples from the 
higher-risk cohort with grey-zone or positive results on the Abbott Architect 
assay, the primary tubes were located and 11 aliquots of 500-1000 µL were 
manually prepared in 2 mL cryovials. Eight aliquots were stored in eight sets of 
boxes for the SRSSB, archived using a spreadsheet, and stored at -80oC. The 
remaining aliquots were frozen for later testing at other laboratories. 
• For the negative higher-risk group, the four 900 µL aliquots were stored into four 
sets of boxes for the SRSSB, archived using a spreadsheet, and stored at -20oC.  
• For the antibody persistence study samples, four aliquots of approximately 250 
µL were prepared. One aliquot was sent for testing at another laboratory, and the 
remainder stored in the SRSSB.  





The Abbott Architect results were exported into a spreadsheet and the results released 
into the LIS. The requests from the PCR-confirmed and probable cases were pre-
registered for the additional testing panels and any grey-zone and positive higher-risk 
participant samples had a confirmatory panel automatically added by the LIS. Negative 
results were automatically released immediately with an interpretative comment. Once 
the additional test results from the other laboratories were ready, the results were entered 
into the LIS and an appropriate interpretative comment attached and the results released. 
2.8 Testing protocol 
Table 2.2 describes the assays performed during the study, the testing location, 
and who performed the testing. The assays will generally be described in an abbreviated 



















Table 2.2: SARS-CoV-2 assays utilised during the study 
 Referred to as Testing location 
Analysis  
performed by 
Abbott Architect SARS-CoV-2 
IgG (nucleocapsid) 
Abbott Architect SCL, Dunedin Alyson Craigie 
Roche Elecsys anti-SARS-CoV-
2 pan-Ig 
Roche LabPlus, Auckland Paul Austin 
Wantai SARS-CoV-2 pan-Ig 
ELISA (spike) 
Wantai ESR, Wellington 
David Harte,  
Michelle Sutherland 










ELISA IgG (spike) 
Euroimmun ESR, Wellington 
David Harte,  
Michelle Sutherland 
Abbott Alinity SARS-CoV-2 
IgG II (spike) 
Abbott Alinity SCL, Dunedin Alyson Craigie 

















University of Otago, 
Dunedin 
Alyson Craigie,  
Ellie Torbati 
Euroimmun Anti-SARS-CoV-2 
ELISA IgA (spike) 
Euroimmun IgA ESR, Wellington 
David Harte,  
Michelle Sutherland 
Abbott Architect SARS-CoV-2 
IgM (spike) 
Abbott Architect IgM SCL, Dunedin Alyson Craigie 
Abbreviations: ELISA: Enzyme-linked immunosorbent assay; sVNT: surrogate viral neutralisation assay; 
pVNT: pseudovirus neutralisation test. 
*I had a one-week laboratory site visit to the University of Auckland, where I performed batches of these 
assays. 
Table 2.3 below describes the testing protocol. The Abbott Architect assay 
(nucleocapsid-based) was chosen to be the screening assay for the serosurvey because 
when designing the testing protocol (early during the pandemic), assays measuring 
nucleocapsid protein antibodies appeared to the most sensitive.133 Additionally, SCL had 
an Abbott Architect analyser that was available to use. The Abbott Architect is a random-




additional SARS-CoV-2 serological assays, with a mixture of various antibody targets, 
served as confirmatory assays to minimise the risk of false positives and false negatives 
in the serosurvey and to assess the clinical performance of these assays. 
Originally, I planned to utilise five main serological assays (Abbott Architect, in-
house ELISA, Wantai, Euroimmun, and the sVNT). Later I added further assays to the 
testing protocol, including the newly released Abbott Alinity based assay, and pVNT, 
and then I had the opportunity to test a subset of our samples on the Roche assay (whose 
results I was kindly allowed to include here). The Euroimmun IgA and the Abbott 
Architect IgM assays were only used for limited analysis (refer 2.9.2). 
2.8.1 Pre-pandemic/antenatal samples 
Two sets of pre-pandemic/antenatal sera were used for assessing specificity. 
Originally, only the specificity of five serological assays were assessed (Abbott 
Architect, in-house ELISA, Wantai, Euroimmun, and sVNT). The first set of specificity 
sera were tested on these assays, as well additional testing on an ELISA using antigens 
from other human coronaviruses to assess cross-reactivity. The pVNT is a very time-
consuming and laborious method and it was not practical to test all specificity samples, 
thus only a subset of the first set of specificity samples were tested on the pVNT assay 
(to date). The Abbott Alinity assay only became available later in the study and 
unfortunately there were no more sera from the first set of specificity samples available 
for testing and therefore a second set of pre-pandemic antenatal samples were tested on 
this assay. No specificity samples were tested on the Roche assay because it was not part 
of our original testing protocol, and due to the cost.  
2.8.2 Sensitivity samples 
Sera from all PCR-confirmed cases were tested on all seven serological assays, 
and eight were tested on the pVNT assay (to date). 
2.8.3 Probable case cohort 
Sera from the probable cases were tested on seven of the assays (all other than 
the pVNT).  
2.8.4 Higher-risk participant samples 




Samples from the higher-risk group classified as positive (≥1.4 S/C), or as negative but 
≥0.5 S/C (i.e. 0.5–1.39 S/C, defined as the grey-zone on the basis of a receiver operating 
characteristic (ROC) curve, refer Chapter 3) were tested on six additional assays (all 
excluding the Roche and pVNT assays). 
2.8.5 Antibody persistence study samples 
Sera from the antibody persistence study were tested on four of the assays (Abbott 
Architect, Abbott Alinity, in-house ELISA, and sVNT). It was not feasible to test the 
samples on all the assays due to cost and labour, so I chose one N-based, one S-based, 




Table 2.3: Summary of the testing protocol 
Higher-risk participants PCR-confirmed cases Probable cases Antenatal specificity samples Antibody persistence study 
 
• Abbott Architect SARS-
CoV-2 IgG  
 
• Abbott Architect 
SARS-CoV-2 IgG  
 
• Roche Elecsys 
Anti-SARS-CoV-2 pan-Ig 
 
• Wantai SARS-CoV-2 
pan-Ig ELISA  
 
• In-house two-step 
SARS-CoV-2 IgG ELISA 
 
• Euroimmun  
Anti-SARS-CoV-2 
ELISA (IgG)  
 
• Abbott Alinity 
SARS-CoV-2 IgG II 
Quant 
 
• sVNT   
 
• pVNT (only subset of 
samples) 
 
• Abbott Architect 
SARS-CoV-2 IgG  
 
• Roche Elecsys 
Anti-SARS-CoV-2 pan-Ig 
 
• Wantai SARS-CoV-2 
pan-Ig ELISA  
 
• In-house two-step 
SARS-CoV-2 IgG ELISA 
 
• Euroimmun  
Anti-SARS-CoV-2 
ELISA (IgG)  
 
• Abbott Alinity 
SARS-CoV-2 IgG II 
Quant 
 





• Abbott Architect 
SARS-CoV-2 IgG  
 
• Wantai SARS-CoV-2 
pan-Ig ELISA  
 
• In-house two-step 
SARS-CoV-2 IgG ELISA 
 
• Euroimmun  
Anti-SARS-CoV-2 
ELISA (IgG)  
 
• sVNT   
 
• Human Cov ELISA 
 





• Abbott Alinity 




• Abbott Architect 
SARS-CoV-2 IgG  
 
• In-house two-step 
SARS-CoV-2 IgG ELISA 
 
• Abbott Alinity 
SARS-CoV-2 IgG II 
Quant 
 
• sVNT   
 
Any samples with Abbott 
Architect results of grey-zone 
(0.50 – 1.39 S/C) or positive 
(≥1.40 S/C): 
 
• Wantai SARS-CoV-2 
pan-Ig ELISA  
 
• In-house two-step 
SARS-CoV-2 IgG ELISA 
 
• Euroimmun  
Anti-SARS-CoV-2 
ELISA (IgG)  
 
• Abbott Alinity 
SARS-CoV-2 IgG II 
Quant 
 





2.9 SARS-CoV-2 assays 
Seven serological assays were employed during this study, with various assay formats, 
with different antigen targets (N, RBD, and S) and/or detection of different antibody isotypes 
(IgG or total immunoglobulin (pan Ig)). The majority of the assays detected BAbs, other than 
the sVNT and pVNT, which detect NAbs. The only truly quantitative assay is the Abbott 
Alinity assay, but the other assays do, however, give a ‘signal over cut-off’ value, which 
correlates with the level of antibody. Table 2.4 shows a summary of the serological SARS-
CoV-2 assays used in this study. Note, two additional serological assays (Euroimmun IgA and 







































SARS-CoV-2 IgG II Quant 
RBD of S protein 





≤7 days = 65.6% 
8-14 days = 97.0% 
≥15 days = 98.8% 
99.6% 
In-house SARS-CoV-2 
two-step IgG ELISA 
RBD of S protein 
S protein 
In-house 
RBD: ≥0.2 OD 
Spike: ≥300 titre 
Manual ELISA n/a n/a 
Wantai SARS-CoV-2 
pan-Ig ELISA 
RBD of S protein 
Beijing Wantai Biological 
Pharmacy, Beijing, China 
≥1 A/C.O. Manual ELISA 
94.5 % 
(dependent on time 
since disease onset) 
100% 
Euroimmun 




≥1.1 ratio Manual ELISA 
≤10 days = 60.2% 










0-6 days = 60.2% 
7-13 days = 85.3% 
≥14 days = 99.5% 
99.8% 
cPass sVNT S1 protein 
GenScript, New Jersey, 
USA 
≥20 % inhibition Manual sVNT 95.0% 100% 
In-house human CoV ELISA 
S1 antigens from 
HKU1, NL63, and 
SARS-CoV-2 
In-house ≥0.2 OD Manual ELISA n/a n/a 
Abbreviations: N: Nucleocapsid; RBD: Receptor Binding Domain; S: Spike; CMIA: Chemiluminescent microparticle immunoassay; ECLIA: Electrochemiluminescence 




2.9.1 Chemiluminescent immunoassays 
2.9.1.1 Abbott Architect SARS-CoV-2 IgG 
The Abbott Architect assay is an automated, two-step chemiluminescent 
immunoassay, utilising CMIA technology, used for the semi-quantitative detection of 
SARS-CoV-2 nucleocapsid IgG antibodies in human serum. The CMIA principle is 
outlined in Figure 2.1. The test kit utilises recombinant SARS-CoV-2 nucleocapsid 
antigen coated paramagnetic microparticles and an IgG conjugate. The amount of SARS-
CoV-2 nucleocapsid IgG antibodies in the sample is directly proportional to the relative 
light units (RLU) detected and is given as a concentration ‘signal-to-cut-off’ index (S/C). 
The sample RLU value is divided by the calibrator RLU to determine the cut-off ratio 
index (S/C); index values of 1.4 S/C and above are considered positive. Samples were 
analysed on the Abbott Architect i2000SR Immunoassay Analyzer in accordance with 
the manufacturer’s instructions.153,154 Manufacturer supplied calibrator and quality 
controls were used and results were accepted if quality control values were within the 







A        B       C  
 
D 
Legend:   
1. Photomultiplier tube  
2. CMIA reader 
3. Light pipe 
4. Trigger solution delivery nozzle 
5. Reaction vessel 
6. Magnet 
7. CMIA shutter assembly  
 
Figure 2.1: CMIA technology and reaction sequence. Caption continues on the following page. 
Legend: 
1. Anti-analyte microparticle with capture molecule 
2. Sample analyte measured 
3. Acridinium-labeled conjugate 




A) The pipettor dispenses paramagnetic microparticles coated with capture molecules, and the sample, 
into the reaction vessel, and it is mixed. The reaction mixture is incubated and the analyte present in the 
sample binds to the corresponding capture molecules on the microparticles, forming an immune complex. 
B) A magnet attracts the microparticles (bound to specific analyte) to the wall of the reaction vessel. A 
wash zone manifold washes the reaction mixture to remove unbound materials. C) The pipettor dispenses 
a chemiluminescent acridinium-labelled conjugate. The conjugate binds to the immune complex and the 
reaction mixture is incubated. A wash zone manifold washes the reaction mixture to remove unbound 
materials. Pre-trigger solution (hydrogen peroxide) is dispensed and the CMIA optical system takes a 
background read. The pre-trigger creates an acidic environment to prevent the early release of light, helps 
to prevent microparticle clumping, and splits the acridinium dye off the conjugate. Trigger solution 
(sodium hydroxide) is dispensed and the acridinium undergoes an oxidative reaction, causing a 
chemiluminescent reaction to occur and light is emitted. D) The CMIA optical system measures the 
chemiluminescent emission over a predefined period to determine the concentration of the analyte 
concentration or qualitative interpretations (for index/cut-off assays). The chemiluminescent light 
produced is directly proportional to the amount of analyte present in the sample. From Abbott 
ARCHITECT® System Operations Manual, by Abbott, 2007.154 
2.9.1.2 Abbott Alinity SARS-CoV-2 IgG II Quant 
The Abbott Alinity assay is an automated, two-step chemiluminescent 
immunoassay, utilising CMIA technology. It is used for the quantitative detection of 
SARS-CoV-2 spike IgG antibodies in human serum. The principle is identical to that of 
the Abbott Architect assay, outlined in Figure 2.1 above. The test kit incorporates 
recombinant SARS-CoV-2 spike antigen coated paramagnetic microparticles and an IgG 
conjugate. The amount of SARS-CoV-2 spike IgG antibodies in the sample is directly 
proportional to the RLU detected. The assay has six calibrators and uses a 4-parameter 
logistic curve fit data reduction method (4PLC, Y-weight) to generate a calibration curve 
and results. The result is given as a concentration in arbitrary units per mL (AU/mL), 
with values 50 AU/mL and above considered positive. Samples were analysed on the 
Abbott Alinity i Immunoassay Analyzer in accordance with the manufacturer’s package 
insert.155 Manufacturer supplied calibrators and quality controls were used. Results were 
accepted if quality control values were within the manufacturer stated ranges. I 
performed all testing myself at SCL Dunedin. 
2.9.1.3 Roche Elecsys anti-SARS-CoV-2 pan-Ig 
The Roche Elecsys anti-SARS-CoV-2 pan-Ig assay is an automated, two-step 
chemiluminescent immunoassay, utilising ECLIA assay technology for the semi-
quantitative detection of SARS-CoV-2 nucleocapsid total antibodies (IgG, IgA and IgM) 
in human serum. The CMIA principle is outlined in Figure 2.2. The amount of SARS-
CoV-2 nucleocapsid antibodies in the sample are directly proportional to the 




a cut-off index (COI) 156. The COI is calculated from the sample signal divided by the 
signal of the cut-off (which is based on the measurement of the two calibrators). COI 
values of 1.0 and above are considered positive. Samples were analysed on the Roche 
Cobas e601 analyser in accordance with the manufacturer’s package insert156 
Manufacturer supplied calibrator and quality controls were used. Results were accepted 
if quality control values were within the manufacturer stated ranges. Analyses were 
performed by staff at LabPlus, Auckland. 
 
Figure 2.2: ECLIA principle. In step one, the patient sample is incubated with a mix of biotinylated 
and ruthenylated nucleocapsid (N) antigen. Double-antigen sandwich immune complexes are formed in 
the presence of corresponding antibodies. In step 2, after the addition of streptavidin-coated 
microparticles, the complexes bind to the solid phase via interaction of biotin and streptavidin. In step 3, 
the reagent mixture is transferred to the measuring cell, where the microparticles are magnetically 
captured onto the surface of the electrode. Unbound substances are then removed. 
Electrochemiluminescence is induced by applying a voltage and measuring with a photomultiplier. The 
amount of signal produced is directly proportional to the level of antibodies in the sample. From 





















2.9.2 ELISA assays 
The ELISA assays used in this study were all indirect sandwich ELISAs, whose 
principle is outlined in Figure 2.3. 
 
Figure 2.3: Basic principle of an indirect sandwich ELISA. From COVID-19 Diagnostic Strategies 
Part II: Protein-Based Technologies, by Shaffaf, 2021. (https://doi.org/10.3390/bioengineering8050054). 
Under Creative Common CC BY license.113 
2.9.2.1 In-house two-step SARS-CoV-2 ELISA 
The in-house two-step ELISA is an indirect sandwich ELISA for the semi-
quantitative detection of SARS-CoV-2 spike or RBD IgG antibodies in human serum. 
The ELISA was adapted from published protocols,157 as previously described.123 Refer 
to Figure 2.4 for an overview. The S protein and RBD antigens used in the ELISAs were 
expressed and purified (from pCAGGS-solSpike and pCAGGS-RBD vectors 
respectively), using Freestyle293 or Expi293F human embryonic kidney (HEK) cells. 
In step one, RBD protein was coated onto immunoplates (5 μg/mL) and left at 
4oC overnight, then blocked with phosphate-buffered saline with 0.1% Tween 20 (PBST) 
and 3% skim milk powder for 1 hour at 20oC. 50 µL of serum diluted 1:101 was added 
to the RBD immunoplates, incubated at 20oC for 1 hour, washed 3 times with PBST, then 
peroxidase-labelled anti-human IgG (Abcam, 97221) diluted 1:10000 was added for 1 




and was stopped with 1M HCl. The optical density (OD) at 450-570 nm was measured 
using an EnSight absorbance reader. Samples with an OD above the cut-off (>0.2) 
proceeded onto the confirmatory S protein ELISA (step two). In step two, S protein was 
coated onto immunoplates (5 µg/mL) and left at 4oC overnight. The ELISA was carried 
out using the same protocol as step one, with the exception that three-fold dilutions of 
the sample were prepared, starting at 1:101. Samples were classified as positive if they 
had an OD above the cut-off (>0.2) in the single point RBD ELISA and in at least two 
consecutive wells in the S protein ELISA. The result was reported as the highest titre 
above the cut-off (>0.2). Positive and negative quality controls were included on each 
plate and results accepted if the positive control OD was >0.75 and the negative control 
was <0.03. Analysis was performed by the staff at the Faculty of Medical and Health 
Sciences, University of Auckland, New Zealand (Dr Nikki Moreland’s laboratory). I 
performed a batch of each of the ELISAs myself in their laboratory during a site visit in 
March 2021. 
 
Figure 2.4: Overview of the in-house 2-step SARS-CoV-2 IgG ELISA protocol. From SARS-CoV-2 
Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test 






2.9.2.2 Wantai SARS-CoV-2 total antibody ELISA 
The Wantai assay is an indirect sandwich ELISA for the semi-quantitative 
detection of SARS-CoV-2 spike-RBD total antibodies (IgG, IgA and IgM) in human 
serum. The ELISA was performed manually in accordance with the manufacturer’s 
package insert, using reagents supplied with the kit.158 The plates are coated with 
recombinant SARS-CoV-2 spike-RBD antigen. 50 µL of serum was added to the wells 
and incubated at 37oC for 30 minutes. The plate was washed with the wash buffer five 
times, then 100 µL of the HRP-conjugated recombinant SARS-CoV-2 antigen was added 
and incubated at 37oC for 30 minutes. After another wash, 50 µL of the Chromogen 
Solution was added to the plate and incubated at 37oC for 15 minutes in the dark. In the 
wells with the antigen-antibody-antigen (HRP) sandwich complex, the colourless 
chromogens are hydrolysed by the conjugate to produce a blue colour. 50 µL of Stop 
Solution (sulphuric acid) was added and the colour reaction was stopped, and the blue 
colour turns yellow. The intensity (absorbance) of the colour was measured by a plate 
reader (450 nm) and was proportional to the amount of antibody in the sample. The 
signal-to-cut-off ratio (S/CO) was calculated by adding 0.160 to the calculated negative 
control value. The results are given as A/CO (Absorbance related to cut-off). Values <1.0 
are considered negative, whilst values ≥1.0 are considered positive. Each plate run had 
manufacturer supplied positive and negative controls that were required to be within the 
stated range before accepting the results. Analysis was performed by staff at ESR, 
Wellington. 
2.9.2.3 Euroimmun Anti-SARS-CoV-2 IgG ELISA 
The Euroimmun assay is an indirect sandwich ELISA for the semi-quantitative 
detection of SARS-CoV-2 IgG antibodies against the spike S1 subunit, in human 
serum.159 The ELISA was performed manually in accordance with the manufacturer’s 
package insert, using reagents supplied with the kit.159 
100 µL of serum diluted 1:101 were added to wells coated with recombinant 
SARS-CoV-2 spike S1 protein and incubated for 1 hour at 37oC. The plate was washed 
three times with the wash buffer, then 100 µL of HRP-conjugated anti-human IgG was 
added and incubated for 30 minutes at 37oC. The plate was washed three time and 100 
µL of chromogen (TMB/hydrogen peroxide) was added. After 30 minutes incubation, 




(absorbance) of the colour was measured by a plate reader (450-620 nm) which was 
proportional to the amount of antibody in the sample. A result was determined by 
calculating a ratio of the OD of the sample over the OD of the calibrator. A ratio <0.8 is 
considered negative, 0.8-1.0 equivocal and ≥1.0 considered positive. Each plate run had 
manufacturer supplied positive and negative controls that were required to be within the 
stated range before accepting the results. Analysis was performed by staff at ESR, 
Wellington. 
2.9.2.4 Genscript cPass Surrogate Viral Neutralization Test (sVNT) 
The sVNT assay measures the presence of neutralising antibodies that are capable 
of blocking the interaction between the RBD with the ACE2 cell surface receptor.95 It is 
a blocking ELISA detection tool, mimicking the virus neutralisation process, and 
therefore detects neutralising antibodies rather than just binding antibodies.95 The ELISA 
was performed manually in accordance with the manufacturer’s package insert, using 
reagents supplied with the kit.122 The kit includes two key reagents: an HRP-conjugated 
recombinant SARS-CoV-2 RBD fragment (HRP-RBD) and a recombinant human ACE2 
receptor protein. The interaction between these two components can be blocked by 
neutralising antibodies against SARS-CoV-2 RBD (Figure 2.5). 
In the first step, samples and controls were diluted 1 in 10, then mixed with the 
HRP-RBD reagent at a 1:1 ratio and incubated for 30 minutes at 37oC; this is to allow 
any neutralising antibodies in the sample to bind to the HRP-RBD. 100 µL of the mixture 
was then added to the plate, which is coated with hACE2 protein. Unbound HRP-RBD 
and HRP-RBD bound to non-neutralising antibodies will be bound to the hACE2 protein 
on the plate, while the HRP-RBD bound to neutralising antibodies will remain in the 
supernatant and will be removed during washing. After washing, 100 µL TMB substrate 
is added, producing a blue colour. 50 µL stop solution was added to stop the reaction and 
the colour turns yellow if HRP was present. The plate was read at 450 nm; the absorbance 
of the sample is inversely proportional to the concentration of SARS-CoV-2 neutralising 
antibodies in the sample. The result of a sample was calculated by comparing the OD of 
the sample to the OD of the negative control and was reported as a percentage inhibition. 
Inhibition values of 20% and above are considered to be positive (neutralising antibodies 
present). Each plate run had manufacturer supplied positive and negative controls that 




primarily performed by the staff at the Faculty of Medical and Health Sciences, 
University of Auckland, New Zealand (Dr Nikki Moreland’s laboratory). I performed a 
plate of the ELISA myself in their laboratory during a site visit in March 2021. 
 
Figure 2.5: Principle of the sVNT. From SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, 
by Genscript, 2020. (https://www.genscript.com/covid-19-detection-svnt.html).122 
2.9.2.5 Human CoV ELISA 
To assess cross-reactivity of the antenatal sera (n=300) with other human CoVs, 
an ELISA was performed (as described by the in-house ELISA methods above and as 
described by McGregor et al., 2020)123 using S1 antigens from the HKU1, NL63, and 
SARS-CoV-2 strains (Sino Biological, Beijing, China) coated at 5 µg/mL and a 1 in 300 
serum dilution. 
2.9.2.6 Euroimmun Anti-SARS-CoV-2 IgA ELISA 
The Euroimmun SARS-CoV-2 IgA ELISA was only investigated in a limited 
capacity as initial results found it unsuitable for further analysis. The principle of the 
Euroimmun SARS-CoV-2 IgA ELISA is identical to that of the Euroimmun SARS-CoV-
2 IgG ELISA performed, except it utilises an IgA conjugate instead of IgG. The ELISA 
was performed manually in accordance with the manufacturer’s package insert by staff 
at ESR, Wellington. 
2.9.2.7 Abbott Architect SARS-CoV-2 IgM 




Architect SARS-CoV-2 IgM (spike based) assay (PCR-confirmed cases that were 
negative on the Abbott Architect SARS-CoV-2 IgG assay). Reagent was provided by 
Abbott. Testing was performed at the request of Abbott to try determine whether false 
negative results on the Abbott Architect SARS-CoV-2 IgG assay were because these 
individuals had yet to sero-convert. 
The principle of the Abbott Architect SARS-CoV-2 IgM assay (Abbott 
Diagnostics, Chicago, Illinois, USA) is identical to that of the Abbott Architect SARS-
CoV-2 IgG assay we performed, except it has a spike antigen target and utilises an IgM 
conjugate. Samples were analysed on the Abbott Architect i2000SR Immunoassay 
Analyzer in accordance with the manufacturer’s package insert. I performed all testing 
myself at SCL Dunedin. 
2.9.3 Pseudovirus neutralisation test (pVNT) 
The pVNT assay also detects the presence of neutralising antibodies in sera. The 
pVNT assay requires a BSL2 facility and ‘Replication Deficient Viral Vector’ (RDVV) 
training by the University of Otago. I was trained to work with and handle RDVVs and 
observed the production of the pseudovirus, and performed the titration and 
neutralisation assays (alongside Ellie Torbati, a research assistant). The pVNT assay uses 
a genetically modified HIV viral vector (the backbone of the virus consisting of a non-
replicating lentivirus), which poses little to no infection risk to the operator. The spike 
protein from SARS-CoV-2 was ‘pseudotyped’ onto a safer, non-replicative lentivirus, 
replacing its endogenous entry protein, making the virus’ entry into cells dependent on 
the spike protein instead.118 
The pVNT protocol was designed and optimised using methods modified from 
previously described SARS-CoV-2 pVNT methods.118,121,160 Similar methods have been 
used for other viruses, such as SARS-CoV,161 MERS-CoV,162 and influenza.163 In brief, 
pseudovirus was produced by co-transfecting HEK-293T cells with five plasmid vectors: 
a reporter vector, encoding a lentiviral backbone/genome, containing the gene for the 
reporter protein (firefly luciferase reporter gene, Fluc); a vector encoding the gene for the 
SARS-CoV-2 spike protein; a vector encoding a fluorescent marker (green fluorescent 
protein, GFP); a packaging vector, encoding the genes for HIV non-envelope proteins; 
and a vector encoding Rev protein. The transfected HEK-293T cells produced 





HEK-293T cells were also transfected with a plasmid encoding human ACE2 (a 
receptor required for SARS-CoV-2 entry into cells) and a plasmid encoding red 
fluorescent protein (RFP), to create a HEK-293T ACE2 expressing cell line. All plasmids 
are described in more detail further below. When the pseudovirus is incubated with cells 
that express ACE2 receptors, they enter into the cells via the receptors on the cell 
surface.118 The pseudovirus genome is expressed and pseudoviral particles are formed, 
but they cannot infect further cells because they do not express any surface proteins, 
meaning the pseudovirus only has the ability of a single-round infection.118 The 
pseudovirus genome also expresses the reporter gene (Fluc), which encodes a protein that 
is detected after the addition of a substrate (Figure 2.6). The pre-incubation of 
pseudovirus and sera containing neutralising antibodies will inhibit/block the entry of the 
pseudovirus into the cell by binding to the S protein and the amount of neutralising 
antibodies present is estimated using the results of the luminescence reaction.118  
The timeline from plasmid preparation through to the completion of the initial 
virus titration can take up to 20 days. One batch of pseudovirus neutralisation takes up to 
72 hours. The procedures were carried out in a biohazard cabinet, following all necessary 





Figure 2.6: Schematic depicting the general steps of setting up a pVNT assay. 1) Pseudovirus 
plasmid transfection; 2) pseudovirus production; 3) target cell line transfection, and neutralisation assay. 
From Pseudovirus Neutralizing Antibody Assay (Luciferase), by Abnova, 2020. 
(http://www.abnova.com/service/service.asp?switchfunctionid=%7B507AA0FE-02FC-4E49-A9CE-
84232C9B2BC9%7D).165 
2.9.3.1 Plasmid preparation 
Plasmids were prepared by the research assistant in the Ussher Laboratory. To 
summarise, first E. coli Top10 (ThermoFisher) were transformed with the following 
plasmids using a heat shock method:166 
• pCSFLW (obtained from Thompson, Oxford, UK): Containing the gene for 
firefly luciferase lentiviral vector. 
• pcDNA3.1 SARS-CoV-2 S protein (obtained from Addgene): Containing the 
gene for the SARS-CoV-2 codon optimised spike protein. 
• pCCL-Sin-GFP (obtained from Addgene): Containing the gene encoding GFP. 
• pMDLg/pRRE (obtained from Addgene): Containing the genes for the proteins 
gag and pol (for virion formation). 
• pRSV-Rev (obtained from Addgene): Containing the gene encoding Rev protein 
(a transactivating protein that is essential for the regulation of HIV-1). 




for SARS-CoV-2 entry into mammalian cells. 
• Sleeping beauty transposon (obtained from Addgene): Containing the gene 
encoding RFP.  
  Transformed E. coli were grown overnight on a LB (ThermoFisher, cat. no. 
10855001) agar plate containing 100 μg/mL ampicillin. The next day a single colony was 
picked from the plate to inoculate a 10 mL starter culture with antibiotic. The starter 
culture was incubated in a 37oC shaking incubator at 250 RPM. The next day, the starter 
culture was used to inoculate a 100 mL LB broth containing 100 μg/mL ampicillin in a 
37oC shaking incubator at 250 RPM overnight. The next day, the cells were collected at 
4,000 xg for 15 minutes and the plasmids were isolated and purified using the HiPure 
Plasmid Midiprep kit (ThermoFisher, cat. no K210004).  
2.9.3.2 Cell transfection and pseudovirus production 
Cell transfection and pseudovirus production was performed alongside research 
assistant Ellie Torbati. HEK-293T cells were cultured in growth media (D10) containing 
Dulbecco’s modified Eagle medium with GlutamaxTM-1 (DMEM, ThermoFisher, cat. 
no. 10566016) supplemented with 10% heat inactivated fetal bovine serum (FBS) 
(ThermoFisher, cat. no. 10091148) and 1% penicillin/streptomycin (ThermoFisher, cat. 
no. 15140122).  
For the pseudovirus production, the day before transfection, a six well plate was 
seeded with 1.2 x 106 HEK-293T cells/2 mL of D10 media. The next day, the cells were 
washed with pre-warmed Opti-MEMTM Reduced Serum Medium (ThermoFisher, cat. no. 
31985070) and 2 mL of Opti-MEM was added to each well and incubated for 1 hour. 
Transfection was performed using Lipofectamine 3000 (ThermoFisher, cat. no 
L3000001) at a ratio of plasmids 1:1:1:1:1.5 (gag-pol:rev:Spike:GFP:Luciferase), in 
which 1 equals 0.75 μg of plasmid. 1 mL of media was taken out from the flask and the 
mixture of DNA/lipofectamine was added gently to the cells (dropwise). Plates were 
incubated in the 37oC incubator for 16 hours. The next day, the media was changed with 
D10 media and 24 hours later, the viruses were collected.  
A stable HEK-293T-ACE2 cell line was produced in the same manner as above, 
using a DNA mix containing a 1:1 (1 μg) ratio of pcDNA3.1 ACE2 plasmid and the 




As the pseudovirus carried the gene encoding firefly luciferase and GFP, the 
success of the transfection could be assessed by fluorescent microscopy. The transfected 
cells were incubated until there was sufficient GFP expression, then pseudovirus-
containing supernatant was collected from the transfected cells. 200 µL of the supernatant 
was transferred to a separate Eppendorf tube for titration and the remaining volume was 
transferred into cryovials in 500 µL aliquots and stored at -80oC in an RDVV allocated 
box. 
Similarly, as the plasmid pcDNA3.1 ACE2 also encoded the gene for RFP, the 
success of transfection could be monitored by fluorescent microscopy. Expression of 
ACE2 was also confirmed by immunostaining with anti-ACE-2-Alex fluor 488 
(ThermoFisher) and flow cytometry. ACE2-expressing cells were sorted on a FACS Aria 
to generate a stable ACE2-expressing HEK-293T cell line. The ACE2 expressing HEK-
293T cell line was maintained at 37oC at 5% CO2. The cells were split every three days 
with fresh growth media. 
2.9.3.3 Pseudovirus titration 
The pseudovirus was diluted by five-fold serial dilutions for a total of nine 
dilutions, in a flat-bottom 96-well plate. HEK-293T-ACE2 cells were harvested as above 
and diluted to a concentration of 1x104 cells/mL with D10 media. 50 µL of the cells were 
then added to all wells with the pseudovirus and mixed up and down at least five times. 
Two extra wells served as cell only controls (50 µL of the cells mixed with 50 µL of D10 
media). All other wells had 200 µL PBS added to avoid the effect that evaporation has 
on edge well culture medium.121 The plate was centrifuged at 500xg for 3 minutes then 
incubated for 48 hours at 37oC at 5% CO2 in a RDVV designated incubator. After 
incubation, the plate was centrifuged at 500xg for 3 minutes and the supernatant was 
carefully removed. 35 µL PBS was added to each well, followed by 35 µL of Bright-
GloTM (ProMega, cat. no. E2620); the solution was mixed by pipetting up and down at 
least 5 times. The plate was then incubated for 5 minutes in the dark at room temperature 
(RT). 65 µL of solution from each well was transferred to the corresponding well of a 
black-bottom 96-well plate. The plate was centrifuged at 500xg for 3 minutes then read 
on a luminometer (Varioskan Flash, ThermoScientific). Pseudovirus titres were 
expressed as relative luminescence unit per mL of pseudovirus supernatants (RLU/mL). 




pseudovirus wells, to account for background signal, then multiplying by the dilution 
factor, to account for original dilution, then averaging the results. This value was then 
further multiplied by 2 (to account for the dilution with the cells) and then by 20 to get 
RLU/mL (as 50 µL was the volume assayed). The amount of pseudovirus required for 
the neutralisation assay is 1x106 RLU/mL.121  
2.9.3.4 Neutralisation assay 
Each pVNT batch included a pseudovirus titration (acting as the virus control, 
VC), up to 8 samples, a negative virus control (NC) (containing the S protein but no Fluc 
gene), 2 wells of cell only controls (CC), and 2 wells of serum only (SC) wells. Refer to 
Figure 2.7 for the design layout of the initial virus-serum dilution plate and Figure 2.8 
for the final plate layouts. 
 
Figure 2.7: Plate design for the pVNT assay. First plate – virus-serum dilutions. The grey wells 
indicate wells with PBS. The yellow wells indicate the positive virus control (VC) and negative virus 
control (NC). The blue wells indicate the serum samples (S1-S8). Adapted from Quantification of SARS-
CoV-2 neutralizing antibody by a pseudotyped virus-based assay, by J. Nie, et al. (2020) 
(https://doi.org/10.1038/s41596-020-0394-5).121 Permission obtained from Springer Nature Limited, 
license number 5085720925024. 
A 1 in 5 dilution of the VC and NC, and 1 in 10 dilutions of the serum samples 
were prepared in Eppendorf tubes with D10 media. In a 96-well U-bottom microplate, 
60 µL of D10 media was added to wells C2 through to G11. For the VC (column 2) and 
the NC (column 11), 75 µL of the 1 in 5 dilution was added to the first wells (B2 and 
B11 respectively). The VC was then diluted by five-fold serial dilutions down the plate 
for a total of six dilutions (removing 15 µL on the last well); the NC was diluted in the 
same manner. For each sample, 120 µL of the 1 in 10 dilution was added to the first well 




down the plate, for a total of six dilutions (removing 60 µL on the last well). 60 µL of 
the 1 in 5 pseudovirus dilution was added to all serum wells, mixing up and down at least 
5 times. Any unused wells in the 96-well U-bottom plate were filled with 200 µL PBS. 
The plate was centrifuged at 500xg for 3 minutes and the virus-serum mix was incubated 
for 2 hours at 37oC at 5% CO2. During the incubation step. HEK-293T-ACE2 cells were 
harvested, counted and diluted to a concentration of 1x104 cells/mL in D10 media, and 
50 µL added to each well of two flat-bottom 96-well plates as per Figure 2.8. 
 
Figure 2.8: Plate design for the pVNT assay. Final set of plates. The grey wells indicate wells with 
PBS. The yellow wells indicate the positive virus control (VC) and negative virus control (NC). The 
green wells indicate the cell only wells (CC) and serum only wells (SC). Adapted from Quantification of 
SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay, by J. Nie, et al. (2020) 
(https://doi.org/10.1038/s41596-020-0394-5).121 Permission obtained from Springer Nature Limited, 
license number 5085720925024. 
 After the incubation of the virus-serum dilution plate, it was centrifuged at 500xg 
for 3 minutes. 50 µL of each dilution was transferred to the cell plates in duplicate, as per 
Figure 2.8. 50 µL of media was added to the CC wells, and 50 µL of a neat serum was 




centrifuged at 500xg for 3 minutes and the plates incubated for 48 hours at 37oC at 5% 
CO2 in an RDVV designated incubator. After incubation, the plates were centrifuged at 
500xg for 3 minutes and the supernatant removed. Luciferase production and reading 
was performed as described above in section 2.9.3.3. 
 Results were analysed in a Microsoft Excel spreadsheet template. The average 
RLU of the cell only wells were subtracted from all the other readings. The percentage 
inhibition for each of the sera dilutions was calculated using the following formula: 
Percentage inhibition = 1- [RLU serum dilution / RLU 1 in 5 diluted pseudovirus] x 100. 
Note: The final sera dilutions were multiplied by four since the sera were diluted 1:1 with 
the pseudovirus and a further 1:1 in media containing the HEK-293T-ACE2 cells. The 
virus titration versus RLU was plotted and sample percent inhibition versus serum 
dilution was plotted. The serum neutralisation titre was defined as the reciprocal of the 
highest dilution that inhibited >50% of pseudovirus. In addition, to allow for quantitative 
correlation with the sVNT, the half maximal inhibitory concentration (IC50) was 
calculated using a non-linear regression curve fit (GraphPad Prism software). 
2.9.4 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
Participants who had PCR testing before or during the first lockdown period were 
tested using one of four assays that were in use during this time (due to reagent shortages 
and to maintain testing capability), all performed at SCL Dunedin, within the 
Microbiology or Molecular departments: 1) an in-house real time RT-PCR assay 
targeting the E-gene  based on the Drosten assay107 and implemented on the open access 
channel of the Hologic Panther Fusion®; 2) a multiplex tandem real-time RT-PCR 
SARS-CoV-2, Influenza, and RSV (8-well) assay (AusDiagnostics Pty Ltd, Sydney, 
NSW, Australia); 3) TaqPath™ COVID-19 Combo assay (Thermo Fisher Scientific, 
MA, USA), a multiplex real-time RT-PCR; and 4) the Aptima® SARS-CoV-2 Assay 
(Hologic, Inc, San Diego, CA, USA), a transcription mediated amplification assay. The 
RT-PCR results were retrospectively collated as part of the study; I did not perform these 
assays. 
2.9.5 Peripheral blood mononuclear cell (PBMC) isolation 
Although not part of my thesis research, we obtained ethics approval to collect 
additional blood samples from the participants to isolate and store PBMCs to investigate 




CoV-2.102 Three 10 mL (EDTA BD VacutainerTM (Becton Dickinson, Auckland, NZ) 
tubes were collected on 67 participants (mainly PCR-confirmed cases).  
PBMCs were isolated by the LymphoprepTM (Axis-Shield, cat. no. 1114544) 
density gradient centrifugation method. In brief, 15 mL of RT LymphoprepTM was added 
to a 50 mL conical tube. The EDTA blood was diluted 1:1 with PBS (37oC) and then 
carefully layered onto the LymphoprepTM, followed by centrifugation at 800xg for 30 
minutes with the brake off. The plasma layer was then removed and the enriched cell 
fraction carefully harvested to a new 50 mL conical tube. RT PBS was added to the 
enriched cell fraction to a total volume of 50 mL and centrifuged at 250xg for 10 minutes. 
The supernatant was tipped off, leaving the cell pellet at the bottom. The cell pellet was 
mixed with 50 mL RT PBS and re-centrifuged. The supernatant was discarded and the 
cell pellet washed two more times. A 20 µL sample was taken from the from the last 
wash before centrifuging, for counting using a haemocytometer; cell viability was 
assessed with Trypan Blue stain (0.4%) (ThermoFisher, cat. no. 15250-061). The 
supernatant was aspirated and the cells resuspended in ice cold freezing media (fetal 
bovine serum + 10% dimethyl sulfoxide) at a cell concentration of 1x107 cells/mL. 1 mL 
aliquots were prepared and placed in an isopropanol bath that has been pre-cooled on ice 
and transferred to a -80oC freezer. The vials are transferred to liquid nitrogen the 
following day. 
We attempted to isolate PBMCs from blood collected in regions outside of 
Dunedin, within 24 hours of collection, but these isolations were unsuccessful (n=22), 
after which we only collected bloods for PBMC isolation on participants from Dunedin, 
who could present to the Dunedin Hospital SCL collection room early in the morning so 
PBMC isolation could take place within a few hours (n=45). In total, 18 sessions of 
PBMC isolation were performed, with batches of up to six samples in each session. 
Isolation was performed primarily by staff at the Ussher Laboratory, but I was involved 
in the blood collection and participated in four of the isolation sessions. 
2.10 Statistical analysis 
Graphs were generated, and statistical analyses performed using GraphPad Prism 
version 9.1.1 (225), with the exception of the Rogan-Gladen estimator and Bayesian 




using R (version 3.6.3) within R Studio (version 1.2.5033). Statistical analyses used for 
specific analyses are described in figure legends 
Descriptive analyses were performed when appropriate, with the characteristics 
of the study participants expressed as numbers with percentages and where appropriate, 
medians with ranges. To assess sensitivity, serological assays were compared against 
PCR diagnosed COVID-19. Equivocal results were considered negative for the statistical 
analyses. For the higher-risk group, true sero-positivity was defined by positivity in two 
or more of the five assays. False positivity was defined as positivity in only one of the 
five assays.  95% CIs were reported where appropriate. Categorical variables were 
described as proportions and percentages, and compared using the Chi-square or Fisher’s 
Exact tests. Concordance between assays was calculated using the 112 samples that were 
tested on all assays (except the Roche assay, where only 85 samples were tested) and 
qualitative analysis performed using overall positive agreement (OPA), negative positive 
agreement (NPA), Cohen’s kappa statistic, and the quantitative analysis of Pearson’s 
correlation coefficient. Cohen’s kappa statistic is a standard and robust metric that 
estimates the level of agreement (beyond chance) between two diagnostic tests. Ranging 
between 0 and 1, a kappa value of ≤0.40 denotes poor agreement, a value between 0.40 
and 0.75 denotes fair/good agreement, and a value ≥0.75 denotes excellent agreement.167 
Comparison of multiple data groups of paired data (with a normal data distribution) were 
analysed using one-way ANOVA pairwise comparison, with post hoc testing using 
Tukey’s multiple comparison. Comparison of data groups with non-paired data (with a 
non-normal data distribution) were compared using a two-tailed Mann-Whitney U test. 
For all analyses involving the calculation of a P-value, a P-value <0.05 was considered 
significant, and the following symbols represents the level and meaning of statistical 
significance: ns (not significant) =P>0.05; *=P≤0.05; **=P≤0.01; ***=P≤0.001; 
****=P≤0.0001. To estimate prevalence in the higher-risk group (considering the 
uncertainties in the sensitivity and specificity of the Abbott Architect assay), the Rogan-
Gladen estimator was used. Bayesian statistical analysis was used to assess the effect of 
secondary orthogonal testing for the prevalence in the higher-risk group (with a 95% 
credible intervals). For the pVNT the half maximal inhibitory concentrations (IC50) were 




Chapter 3: Clinical performance of SARS-CoV-2 
serological assays 
3.1 Introduction 
SARS-CoV-2 assays with different antigen targets and/or different assay formats 
might give different results and it is important to understand such differences. Abbott 
released their N-based SARS-CoV-2 IgG Architect assay in mid-April 2020 and it was 
chosen as the main screening assay for our serosurvey because, at the time, it appeared 
an appropriate option and an Abbott Architect analyser was available, which is a random-
access, high-throughput analyser making it ideal for large-scale serosurveys. However, 
SARS-CoV-2 serological assays were very new and the clinical performance of these 
assays were not well characterised, so we did not know which assay would be best, so 
we decided to assess the clinical performance of the Abbott Architect assay, alongside 
several other SARS-CoV-2 serological assays. Although we expected the sensitivity of 
the assays to be sufficient, we knew that due to the likely low COVID-19 disease 
prevalence in NZ, the PPV of assays would be very low if the specificity was not high, 
risking false positive results. The results from clinical performance data would also 
provide guidance on which assays (or combination of assays) would be suitable for 
various testing purposes in NZ’s current status as a low disease prevalence population. 
Other than the sVNT, the serological assays investigated are only able to detect 
BAbs rather than NAbs. If the purpose of testing is to assess potential immunity, then it 
is important to assess the correlation of these assays with assays detecting NAbs. A BAb 
assay that can also estimate NAb levels would be preferable to performing a separate 
NAb assay. The sVNT assay was utilised for estimating NAbs because the PRNT could 
only be performed in a BSL3 laboratory and is not suitable for high-throughput testing. 
A small number of samples were tested using the pVNT assay to assess its correlation 
with the sVNT (Chapter 7); while pVNT can be performed in a BSL2 laboratory it is also 







Refer to the Supplementary Tables S1-S4 (Appendix B) for the raw data. 
3.2.1 Participant characteristics 
3.2.1.1 Specificity samples 
All specificity samples used were de-identified (female) antenatal sera, collected 
pre-pandemic.   
3.2.1.2 Sensitivity samples 
The sensitivity samples consisted of 78 participants who previously had PCR-
confirmed SARS-CoV-2 infection. The median age was 51 years (range 17-81 years), 
with 59% female and 41% male. The median time of symptom onset to serum collection 
was 14 weeks (range 11-17 weeks). Participants were asked to self-report on the 
occurrence of COVID-19 consistent symptoms during their infection (Table 3.1). Thirty-
five (45%) of the participants reported no symptoms or mild symptoms only; 39 (50%) 
of the participants reported moderate symptoms. Four participants (5%) were 
hospitalised during their infection; three participants were classified as having 
moderately-severe symptoms (4%), and one participant (1%) was classified as having 
severe symptoms (given supplemental oxygen therapy). No participants were admitted 
to the intensive care unit and thus none classified as critical. Of the six main COVID-19 
symptoms (shortness of breath, sore throat, new or worsening cough, fever, anosmia, and 
coryza), 97% of the PCR-confirmed participants reported at least one of these symptoms. 
The most common symptom was sore throat (71%) and the majority of participants 
reported the presence of at least four of these six symptoms (Table 3.1). 
3.2.1.3 Concordance samples 
The results of samples run on the various serological assays were used in the 
concordance calculations. 112 samples were tested on six of the seven serological assays 
(all except Roche), comprising 78 PCR-confirmed cases, 25 higher-risk participant 
samples (positive or grey-zone), and nine probable cases. 85 of these samples were also 
tested on the Roche assay (78 PCR-confirmed cases and seven probable cases). To enable 
better comparison of correlation coefficients between the assays, the results of the pre-
pandemic antenatal sera were not included because a different sample set was used for 




Table 3.1: Patient demographics and symptoms reported for the PCR-confirmed cases (n=78) 
Sex No. (%) 
Female 46 (59) 
Male 32 (41) 
Age (years) 
Median (range) 
51 (17 – 81) 
No. (%) 
0-18 2 (3) 
19-49 36 (46) 
50-64 34 (44) 
≥65 6 (8) 
Time of symptom onset to 
serum collection (weeks) 
Median (range) 
14 (11-17) 
Disease severity* No. (%) 
1 – asymptomatic/mild 35 (45) 
2 – moderate 39 (50) 
3 – moderately severe 3 (4) 
4 – severe 1 (1) 
5 – critical 0 (0) 
Reported symptom No. (%) 
Shortness of breath 33 (42) 
Sore throat 55 (71) 
Cough 39 (50) 
Fever 41 (53) 
Anosmia 48 (62) 
Coryza 44 (56) 
Number of main COVID-19 symptoms No. (%) 
0 symptoms 2 (3) 
1 of 6 symptoms 7 (9) 
2 of 6 symptoms 12 (15) 
3 of 6 symptoms 15 (19) 
4 of 6 symptoms 23 (29) 
5 of 6 symptoms 15 (19) 
All 6 symptoms 4 (5) 
*Disease severity was classified on the basis of the case’s symptoms and the level of hospital care provided, 
as follows: 1 – asymptomatic to mild: coryza, and/or sore throat; 2 – moderate: fever, or cough, or shortness 
of breath; 3 – moderately severe: admitted to hospital for assessment; 4 – severe: admitted to hospital and 
given supplemental oxygen therapy; 5 – critical: admitted to ICU. 
3.2.2 Assay performance 
The sensitivity and specificity of the seven SARS-CoV-2 serological assays were 
compared. The majority of the assays investigated were semi-quantitative, but with a 
qualitative result of positive or negative, based on pre-defined cut-offs, which were used 
to calculate the sensitivity and specificity for each assay. The overall performance of the 




samples graphed on a dot plot to show the spread of the results in relation to the assay 
cut-offs. 
The pre-pandemic antenatal samples and PCR-confirmed cases were also tested 
on the Euroimmun Anti-SARS-CoV-2 IgA ELISA (S-based), however the performance 
of the assay was deemed unsuitable, due to its suboptimal performance, with a sensitivity 
of 73.1% (95% CI: 61.8-82.5) and specificity of 96.7% (95% CI: 94.0-98.4). Refer to 
Table S1 and Table S2 for these raw results (Appendix C). 
Table 3.2: Sensitivity and specificity of the serological SARS-CoV-2 assays investigated. 
 Assay  
 SARS-CoV-2 
antigen 
Sensitivity (%, #) 
(95 % CI) 
Specificity (%, #) 
(95 % CI) 
Abbott Architect SARS-CoV-2 IgG  
(using manufacturer cut-off of ≥1.40)  
 
N protein  
76.9 (60/78)  
(95% CI: 66.4-84.9)  
99.7 (299/300)  
(95% CI: 98.2-99.99)  
Abbott Architect SARS-CoV-2 IgG  
(using revised cut-off of ≥0.50)  
 
N protein  
94.9 (74/78)  
(95% CI: 87.5-98.0)  
98.3 (295/300)  
(95% CI: 96.2-99.3)  
Roche Elecsys Anti-SARS-CoV-2 
pan- Ig 
 
N protein  
100% (78/78)  
(95% CI: 95.3-100.0)  
Not performed 
Wantai SARS-CoV-2 pan-Ig ELISA  
 
RBD/S protein  
94.9 (74/78)  
(95% CI: 87.5-98.0)  
99.3% (298/300)  
(95% CI: 97.6-99.9)  
In-house SARS-CoV-2 two-step IgG 
ELISA  
 
RBD/S protein  
91.0 (71/78)  
(95% CI: 82.6-95.6)  
100 (300/300)  
(95% CI: 98.7-100.0)  
Euroimmun Anti-SARS-CoV-2 
ELISA (IgG)*  
 
S1 protein  
89.7 (70/78)  
(95% CI: 81.0-94.7)  
100 (300/300)  
(95% CI: 98.7-100.0)  





(95% CI: 89.3-99.0) 
100 (100/100)** 
(95% CI: 96.3-100.0) 
GenScript cPass® sVNT   
 Neutralising 
antibodies  
88.5% (69/78)  
(95% CI: 79.5-93.8)  
100% (300/300)  
(95% CI: 98.7-100.0)  
* Equivocal results considered negative   






Figure 3.1: Distribution of quantitative results obtained for each assay. Results are represented as dot plots, to review the scatter of values, especially around the assay 
cut-offs. Pre-specified assay cut-offs are shown as dashed horizontal lines. For the purposes of plotting values on a log scale, values of zero were set to the lowest non-zero 
value. Data are presented for sera from 78 PCR-confirmed cases (expected positive result, median of 14 weeks since onset of symptoms) run across all assays; and varying 
numbers of pre-pandemic antenatal samples (expected negative result) run across seven of the assays (note: n=300 for Abbott Architect, Wantai, in-house ELISA, 





Sensitivity ranged from 76.9% (95% CI, 66.0-85.7) for the Abbott Architect 
assay, to 100% (95% CI, 95.3-100.0) for the Roche assay (Table 3.2). The sensitivity of 
the Abbott Architect assay was unexpectedly low and prompted a ROC analysis that 
showed a cut-off of 0.55 S/C could achieve much greater sensitivity (93.6%) without a 
significant loss in specificity (98.7%) (Figure 3.2). A conservative revised cut-off of 0.50 
S/C was chosen, which would give a sensitivity of 94.9% (95% CI, 87.5-98.0) and 
specificity of 98.3% (95% CI, 96.2-99.3). A grey-zone approach was therefore utilised 
for analysis of the higher-risk participants in the serosurvey, who were only screened 
with the Abbott Architect assay, to rule out potential false negatives (Chapter 4).  
 
Figure 3.2: A receiver operating characteristic curve for the Abbott Architect assay. ROC curve is 
shown in blue, and was derived from the quantitative values of samples from 78 PCR-confirmed samples 
and 300 pre-pandemic/known negative samples. The location of the manufacturer’s cut-off (1.4 S/C) and 
the grey-zone cut-off (0.5 S/C) are included, showing the large gain in sensitivity for the grey-zone cut-
off. The line of no-discrimination is shown in red. 
3.2.2.2 Abbott Architect seronegative PCR-confirmed cases 
Eighteen of the 78 (23%) PCR-confirmed cases tested negative on the Abbott 
Architect assay using the manufacturer’s cut-off of ≥1.40 S/C (Table S2, Appendix C), 
with values ranging from 0.14-1.39 S/C. Eleven of these were positive on all six of the 
other assays, one was positive on five other assays, one was positive on four other assays, 
three were positive on three other assays, one was positive on two other assays, one was 
positive on one other assay, and none were negative on all the other assays. These 18 




(not fully evaluated) and IgA on the Euroimmun SARS-CoV-2 IgA spike assay. 14/18 
samples were positive for either IgA or IgM. For this group of 18 seronegative 
participants on the Abbott Architect assay, there was no significant difference in the 
median severity score or time since the onset of symptoms when compared to the ‘true’ 
seropositive samples (calculated using a two-tailed Mann-Whitney U test, P>0.05 for 
both groups). 
3.2.2.3 Specificity 
Specificity was high across all assays ranging from 99.3% (95% CI, 97.6-99.9) 
for the Wantai assay to 100% (95% CI, 98.8-100.0) for the four of the assays (Abbott 
Alinity, in-house ELISA, Euroimmun and the sVNT) (Table 3.2). One sample tested 
positive on the Abbott Architect assay (2.00 S/C) and two tested positive on the Wantai 
assay (1.29 and 1.65 S/CO), which were low-level positives. Two samples were positive 
on step one of the in-house two-step ELISA but classified as negative due to a negative 
result on step two on the confirmatory spike ELISA. One sample was equivocal on the 
Euroimmun assay but was considered negative. There were no samples that were positive 
(or equivocal) on more than one assay. 
3.2.2.4 Cross-reactivity 
The antenatal sera used to determine specificity showed broad reactivity with S1 
protein antigens from human CoVs (HKU1 and NL63), but not SARS-CoV-2 (Figure 
3.3). Note, the one sample that reacted to the SARS-CoV-2 S1 protein was not positive 





Figure 3.3: Serum IgG reactivity of pre-pandemic antenatal sera with human CoV S1 proteins. 
ELISA were performed with sera (n=300) against S1 proteins of α-coronavirus NL63 and β-coronavirus 
HKU1 as well as the S1 protein of SARS-CoV-2. The solid horizontal lines indicate the median values 
with 95% CIs. Assay threshold is indicated by the dotted horizontal line. One-way ANOVA was 
conducted and determined statistically significant between group means, with a P-value of <0.0001. Post 
hoc testing using Tukey’s multiple comparison was then conducted, **** = P<0.0001. 
3.2.3 Clinical performance in relation to disease prevalence 
The PPV (Figure 3.4A) and NPV (Figure 3.4B) values of the six assays where 
the sensitivity and specificity were both assessed (all assays except Roche), were 
compared (also refer Table S5, Appendix C). The Abbott Architect and Wantai assays 
were the only assays with imperfect specificity (99.7% and 99.3% respectively). These 
specificity values are very high but the PPV of these assays in a population of low disease 
prevalence, for example, 0.05% (likely similar to NZ’s SARS-CoV-2 prevalence 
following the first outbreak), would be very low at 10.4% (95% CI, 1.6-45.1) for the 
Abbott Architect assay and 6.7% (95% CI, 1.8-22.1) for the Wantai assay. The PPV is 
not greater than 80% for these two assays until the prevalence exceeds 10%. Low disease 
prevalence does not have as much of an impact on the NPV, with only a slight reduction 





Figure 3.4: Comparison of assay PPV and NPV at various population SARS-CoV-2 seroprevalence. 
PPV and NPV values were calculated using samples from 78 PCR-confirmed cases (expected positive 
result, median of 14 weeks since onset of symptoms) and varying numbers of pre-pandemic sera 
(expected negative result, n=300 for Abbott Architect, Wantai, in-house ELISA, Euroimmun, and sVNT; 
n=100 for Abbott Alinity). A) PPV. The only assays with imperfect specificity were the Abbott Architect 
(99.7%) and the Wantai (99.3%). B) NPV. The NPV of all assays remained high at all estimated disease 




3.2.4 Assay concordance 
3.2.4.1 Summary 
Due to the semi-quantitative format of the majority of the assays (and varying 
measuring ranges), the concordance was best compared using the qualitative result, but 
both the qualitative and quantitative concordance were investigated. 85 samples were 
tested on all seven of the serological assays (78 PCR-confirmed cases and seven probable 
cases). 56 samples (66%) tested positive on all seven assays, and six samples (7%) tested 
negative on all seven assays. 23 samples (27%) had at least one discordant result between 
the assays. Of note, 11 (13%) samples were negative only with the Abbott Architect assay 
(48% of all the discordant results). (Table S2, Appendix C). Figure 3.5 compares the 





Figure 3.5: Antibody levels for the samples tested on the serological assays investigated. Samples include all PCR-confirmed cases, all probable cases, and higher-risk 
samples in the grey-zone (0.5-1.39 S/C) or positive (≥1.4 S/C) results on the Abbott Architect assay. n=112, except n=85 for Roche, as no higher-risk participant samples 




OPA, PPA, NPA, Cohen’s kappa statistic, and Pearson’s correlation coefficient 
were calculated for the seven serological assays using the 112 samples tested on all assays 
except the Roche assay (where only 85 samples were tested) (Table S6, Appendix C). 
Figure 3.6A shows the qualitative concordance between the assays using a kappa statistic 
matrix, and Figure 3.6B shows the quantitative concordance between the assays using a 
Pearson’s correlation coefficient matrix. Figure 3.7 shows the results of the assays 
plotted against each other.  
Excluding the sVNT assay for now, data showed that the Abbott Alinity and 
Wantai assays had the best qualitative agreement with a kappa statistic of 0.976 (95% CI, 
0.929-1.000) and an OPA of 99.1% (95% CI, 94.6-100). The assays that showed the least 
qualitative agreement were the Abbott Architect and Roche assay with a kappa statistic 
of 0.308 (95% CI, 0.110-0.506) and an OPA of 77.6% (95% CI, 67.6-85.3). Stronger 
qualitative concordances were observed between the four S-based assays (kappa statistics 
ranging from 0.845-0.976) than with the N-based assays (kappa statistics ranging from 
0.518-0.781). However, as mentioned above, the N-based assays (Abbott Architect and 
Roche assays) had poor qualitative concordance with each other.  
Quantitative agreement between the assays was slightly different to the 
qualitative agreement, with the best agreement between the in-house ELISA and the 
Euroimmun assays, with a Pearson’s coefficient of 0.857 (95% CI, 0.798-0.899), and the 
worst quantitative agreement was between the Roche and Abbott Alinity assays, with a 
Pearson’s coefficient of 0.355 (95% CI, 0.154-0.528). Also, for quantitative agreement, 
there was not a stronger concordance between the S-based assays, than with the N-based 
assays (which was seen with the qualitative agreement), and while the Abbott Architect 
and Roche assays had poor qualitative agreement, their quantitative agreement was 










Figure 3.6: Qualitative and Quantitative agreement between assays. A) Kappa coefficient showing qualitative agreement. B) Pearson’s correlation coefficient showing 
quantitative agreement. Samples include all PCR-confirmed cases, all probable cases, and higher-risk samples in the grey-zone (0.5-1.39 S/C) or positive (≥1.4 S/C) results 
on the Abbott Architect assay. n=112, except n=85 for Roche, as no higher-risk participant samples tested on this assay. Red outline indicates coefficients between N-based 









Figure 3.7: All results of the assays plotted against each other. A) Results of the SARS-CoV-2 BAb 
assays plotted against each other. B) Results of the SARS-CoV-2 BAb assays plotted against the sVNT 
(NAbs). Note: Samples included for the Abbott Architect, Wantai, in-house ELISA, and Euroimmun 
assays are all PCR-confirmed cases, all probable cases, and higher-risk samples in the grey-zone (0.5-
1.39 S/C) or positive (≥1.4 S/C) results on the Abbott Architect assay, and 300 pre-pandemic sera 
(n=412). Samples included for the Abbott Alinity assay are all PCR-confirmed cases, all probable cases, 
and higher-risk samples in the grey-zone (0.5-1.39 S/C) or positive (≥1.4 S/C) results on the Abbott 
Architect assay (n=112). Samples included for the Roche assay are all PCR-confirmed cases, and seven 






3.2.4.2 Neutralising antibody assays 
The sVNT was used to assess the presence of neutralising antibodies (NAbs). For 
the PCR-confirmed group, 88.5% (69/78) had detectable NAbs by the sVNT assay 
(Table 3.2), demonstrating most individuals retain functional antibodies for at least three 
months post-infection.  
Figure 3.6A showed the in-house ELISA had the best qualitative agreement with 
the sVNT, with a kappa statistic of 0.914 (95% CI, 0.832-0.997), and an OPA of 96.4% 
(95% CI, 90.9-98.9). The Roche assay showed the least qualitative agreement with the 
sVNT, with a kappa statistic of 0.493 (95% CI, 0.239-0.748), and an OPA of 88.2% (95% 
CI, 79.5-93.7). The kappa coefficient matrix revealed a stronger qualitative concordance 
between the sVNT and S-based assays (kappa statistics ranging from 0.843-0.914) than 
with the N-based assays (kappa statistics ranging from 0.493-0.598). 
Quantitative agreement with the sVNT and the other assays was similar to the 
qualitative agreement, with best agreement between the in-house ELISA, with a 
Pearson’s coefficient of 0.914 (95% CI, 0.877-0.940), and the worst quantitative 
agreement with the Roche assay, with a Pearson’s coefficient of 0.588 (95% CI, 0.429-
0.712) (Figure 3.6B). The S-based assays had stronger quantitative agreement with the 
sVNT (Pearson’s coefficients ranging from 0.686-0.914), than the N-based assays 
(Pearson’s coefficients ranging from 0.588-0.685). 
3.2.4.3 Correlation of antibody level with disease severity, sex, and age 
The antibody levels of the PCR-confirmed cases were stratified by disease 
severity, sex, and age, and compared on all the assays (Figure 3.8). When the PCR-
confirmed cases were stratified by disease severity, there was a small but significant 
increase in the level of NAbs detected by the sVNT in those with more severe disease 
(P<0.01) (Figure 3.8). The S-based assays also showed a small but significant increase, 
and the N-based assays showed no significant difference. There was no significant 
difference in the level of SARS-CoV-2 antibodies between male and females in all the 
serological assays investigated. When stratifying the cases by age (<60 years and ≥60 
years), there were significantly higher antibody levels in those ≥60 years, on the Roche 





Figure 3.8: Comparison of SARS-CoV-2 antibody levels in varying disease severity, sex, and age. 
Results are from all PCR-confirmed cases (n=78). Disease severity: Level 1, n=35; Disease severity: 
Level 2-4, n=43; Male, n=32; Female,  n=46; <60 years, n=62; ≥60 years n=16. Two-tailed Mann-
Whitney U tests were used to determine if there was a statistically significant difference between the 
median antibody levels within the groups. Level of significance shown if statistically significant 






SARS-CoV-2 serological testing has an important role to play in the management 
of this pandemic. Serology could complement COVID-19 diagnosis, including where 
individuals have been symptomatic for some time but are PCR negative, or in patients 
who have presented late after disease onset.62 Serology could also be used to assess the 
prevalence of infection in a population to determine disease spread, determine if herd 
immunity has been reached, identify immune persons as part of border control, and 
monitor vaccine response.77 Testing of large numbers of samples requires high-
throughput assays. Assays also need to have high sensitivity and specificity during 
different phases of infection (acute versus convalescence versus long-term), varying 
disease severities, and varying disease prevalence. 
3.3.1 Sensitivity and specificity 
Using a cohort of PCR-confirmed cases to assess sensitivity, the Abbott Architect 
assay was found to have a sub-optimal sensitivity of 76.9%, at 11-17 weeks post-
infection, which is lower than previously published data,134,168-170 and the manufacturer’s 
claim (100% after 14 days).153 The main reason for this is likely because there was a 
median of 14 weeks (range 11-17 weeks) between symptom onset and serum collection, 
and anti-N antibodies have been reported to decay relatively quickly post-infection.3,86-
88,171 In contrast, the sensitivity of the S-based assays was higher (89.7-96.2%), which is 
in keeping with the thought that anti-S antibodies persist longer than anti-N 
antibodies.87,124,171 Yet, this is also in contraindication to my finding that the N-based 
Roche assay had the best sensitivity (100%), however, the Roche assay is a ‘pan-Ig’ 
assay, measuring IgG, IgA and IgM antibodies, not IgG alone like the majority of the 
other assays. Another reason for the lower than expected sensitivity for the Abbott 
Architect assay may be that most of the cases in the Southern DHB region were not 
hospitalised, and there is some evidence that antibody levels correlate with disease 
severity.65,80,82,88,97,172,173  
There are conflicting reports on the relative sensitivity of anti-N and anti-S IgG 
antibodies. Some studies have demonstrated anti-N IgG antibodies are more sensitive 
during the early phase of infection,133,174 while others report anti-S IgG antibodies appear 
slightly earlier than anti-N antibodies,175 and others who found they were detectable 




that anti-N antibodies persist as long as anti-S antibodies.85,177,178 My findings do mirror 
that of a study in Austria, which showed the Abbott Architect assay loses sensitivity 
faster than the Roche assay.89 The Austrian group performed a large seroprevalence study 
(n=1259) in April 2020, after a large SARS-CoV-2 outbreak in early March, 2020, and 
estimated the seroprevalence in the region at 45%.89 6.5 months later they re-tested 801 
participants and found many participants who originally tested positive had become 
negative on the Abbott Architect assay but remained positive on the Roche N-based pan-
Ig assay.89 Other studies have shown SARS-CoV-2 pan-IgG assays have a greater 
sensitivity than those measuring IgG alone.179,180  
Eighteen of the 78 PCR-confirmed cases were negative on the Abbott Architect 
assay, but positive on at least one of the other assays. This could be due to Abbott 
Architect assay being N-based as discussed above, however, all of these samples were 
positive on the Roche (pan-Ig) N-based assay. It is unlikely the Roche assay had higher 
sensitivity because of its pan-Ig format alone, because while the other pan-Ig assay 
investigated here (Wantai assay) had a high sensitivity (94.9%), there was an IgG only 
assay with higher sensitivity (Abbott Alinity S-based assay at 96.2% sensitivity). 
Interestingly, while 14/18 of these negative Abbott Architect results were positive on the 
IgA or IgM assays (S-based), several of these were negative on the Wantai pan-Ig S-
based assay. There was also no significant difference in disease severity, or time since 
onset of symptoms in this group, compared to the whole group (which could have 
potentially contributed to why they were negative on the Abbott Architect assay). It has 
been suggested that the antigen bridging format of the Roche assay may increase the 
sensitivity, where an increase in antibody affinity or avidity of the antibodies produced 
as the B cells mature might compensate for the reduction in the antibody concentration, 
or that the range of N protein epitopes recognised by the antibodies might change over 
time.84 Therefore, the reduced sensitivity observed in the Abbott Architect assay might 
be due to a combination of differences in the format of the assay, differences in the 
recombinant target antigen used, differences in the participants’ immune responses to 






Although all the PCR-confirmed cases were positive on at least one assay, two 
samples were negative on all assays except the Roche assay. Generally, a small 
proportion of PCR-positive individuals will be persistently negative by serology (e.g. in 
immunocompromised individuals) and these individuals may be at risk for 
reinfection.3,181 
The N protein sequence appears conserved across CoV species,76 but the S 
protein, in particular the S1 domain of the spike protein, which includes the RBD, appears 
to be strain-specific,182 therefore it was thought N-based assays might generate more false 
positives than S-based assays due to cross-reactivity, but my data showed relatively 
similar, high specificities across the assays, ranging from 99.3-100.0%. All assays had 
specificities equal to or better than that stated by the manufacturer. The Abbott Architect 
assay (used as the screening assay in the serosurvey) had a specificity of 99.7% (95% CI, 
98.2-99.99), comparable to the manufacturer’s claim of 99.6%. However, the PPV will 
be low if tested in the low COVID-19 prevalence in NZ, therefore any positive results 
should be confirmed using a different assay (preferably using a different antigen target) 
before reporting results as true positives.3 The specificity of the Roche assay was unable 
to be assessed, however the manufacturer states a specificity of 99.8% from testing of 
over 10,000 pre-pandemic samples.183 
The pre-pandemic sera did not include samples from known human CoV 
infections or samples from common respiratory infections, or other disease states that 
may potentially result in cross-reactivity in SARS-CoV-2 serological assays. However, 
the CoV ELISAs showed the pre-pandemic sera had broad reactivity with other CoV 
antigens but not with SARS-CoV-2. This is unsurprising, as other studies show most sets 
of pre-pandemic sera react with CoV proteins, because they are common respiratory 
infections.184,185 While manufacturers usually provide cross-reactivity data, it was limited 
for the assays investigated (due to their fast-tracked release). My collaborators at the 
University of Auckland demonstrated that for the in-house ELISA, bacterial pneumonia 
and other common respiratory infections, including rhinovirus, respiratory syncytial 
virus, and influenza do not cross-react with the RBD and S proteins used in the assay, 






PPV and NPV are more clinically useful than sensitivity and specificity. At a 
disease prevalence of 0.05% (likely slightly higher than NZ’s true prevalence during the 
first outbreak), the assays with lower specificity could potentially have a high number of 
false positive results if used alone. Seroprevalence studies in low prevalence populations 
require a testing protocol that results in a high PPV. For example, an assay with a 
sensitivity of 100% and a nearly perfect specificity of 99.9%, in a population with a 
disease prevalence of 0.05%, there would be a 66.7% chance of a positive result being a 
false positive. This highlights the need for an orthogonal testing algorithm to reduce false 
positive results in low disease prevalence populations, while maintaining accuracy and a 
high NPV. Employing a grey-zone for Abbott Architect assay resulted in a significantly 
increased sensitivity, and by using additional assays in an orthogonal testing approach 
for the serosurvey samples (Chapter 4), the specificity of the testing algorithm was 
restored. While four of the assays were calculated to have 100% specificity, their true 
specificity would unlikely be perfect if a much larger number of samples were tested. 
3.3.3 Assay concordance 
The concordance between the assays was best compared using qualitative means 
because the majority of the assays are semi-quantitative only, with the qualitative result 
used for clinical interpretation. Furthermore, the vastly different cut-offs and measuring 
ranges mean quantitative agreement can be misleading. Overall, there was good 
concordance between the S-based assays. The Abbott Architect was the least identical to 
the other assays (due to the high number of false negative results) but as already 
discussed, this was likely impacted by the delay in sample collection. The lowest 
concordance was between the two N-based assays (Abbott Architect and Roche, kappa 
statistic of 0.308), likely due to the reasons already discussed. One study comparing these 
two assays during an earlier phase of infection/recovery (27-49 days, compared to our 
80-122 days) demonstrated excellent concordance, with a kappa statistic of 0.87 (95% 
CI, 0.81-0.94).186 The largest contributor of discordant results was the Abbott Architect 
assay, with 11/23 of the discordant samples being due to samples testing negative on the 
Abbott Architect but positive on all of the other assays, further demonstrating that using 
the Abbott Architect assay alone (using the manufacturer’s cut-off) would not be suitable 




3.3.4 Neutralising antibodies 
The concordance of the assays with the sVNT was of particular interest because 
immunity status might be conferred by the presence of NAbs.171 In this study NAbs were 
measured using the sVNT assay. At 11-17 weeks post-onset of symptoms, NAbs were 
present in 88.5% of PCR-confirmed cases, with a lower level of NAbs amongst 
individuals with mild symptoms.3 A decline in the level of SARS-CoV-2 NAbs post-
infection have been reported by others,67,68,82,141 but further research is needed to fully 
understand the immunokinetics of NAbs and the implications this may have for 
reinfection and vaccine response.3 The longitudinal response of these antibodies was 
investigated further in Chapter 6. 
Not surprisingly, S-based assays had the best qualitative and quantitative 
concordance with the sVNT, since the S protein is the primary target for SARS-CoV-2 
NAbs.3,171 The in-house ELISA (step-1, RBD target) had the best correlation with the 
sVNT, which suggests anti-RBD IgG correlates the best with NAb levels, which is in 
keeping with reports that the majority of SARS-CoV-2 neutralising epitopes are located 
in the RBD.123,187,188 
The ability to measure NAbs quickly and safely by the sVNT assay could be 
particularly useful during the pandemic, especially when BSL3 laboratories are 
limited.123 Alternatively anti-RBD/anti-S BAb assays could also be used as a suitable 
marker to estimate the level of NAbs in individuals, which is ideal since these assays can 
be scaled up for high-throughput testing. In most situations, it would be more useful to 
test for BAbs rather than NAbs (if trying to determine recent or past infection), but if 
assessing vaccine response/immunity or if screening sera of COVID-19 recovered 
patients for convalescent plasma therapy then NAb responses is important.189 
3.3.5 Disease severity, sex, and age correlation with SARS-CoV-2 antibody responses 
My results corroborate findings by other researchers, which have shown a link 
between the level of antibody response and SARS-CoV-2 disease 
severity.65,81,82,88,97,172,173 The cohort of PCR-confirmed cases did not include a large 
number of severe cases, but nonetheless, a small but significant increase was found in 
the level of antibodies for NAb assay,3 and to a lesser degree, the S-based assays, in the 
group with moderate-to-severe symptoms as compared of those with asymptomatic or 




suggests SARS-CoV-2 disease severity is a determining factor for both the level of 
antibody response as well as the neutralising capacity of the antibodies produced. Other 
studies have also reported a greater correlation of disease severity with NAbs rather than 
BAbs.190 Overall, these results suggest individuals with mild disease may not produce a 
strong antibody response and these cases may be missed if using serology, and that 
asymptomatic or mild cases may not produce NAbs to a level that will protect them from 
reinfection and thus they should consider vaccination, and that convalescent plasma 
donations would be best obtained from those individuals recovered from a more severe 
infection.189 
My results did not show any correlation of the level of SARS-CoV-2 antibody 
response with sex. Some studies have reported that females produce higher levels of 
antibodies than males,191 while others have reported the opposite.192,193 One study 
reported no difference in antibody levels in those with mild infection, while in those with 
severe infection there were more female patients with high antibody levels,194 which may 
explain why no difference was seen, since my study had few patients with severe disease. 
Older age was associated with higher antibody levels, but only in some of the 
assays (Roche, Wantai, and Euroimmun, which represents a mixture of pan-Ig, IgG, N-
based, and S-based assays), but not for NAbs. The cohort of the PCR-confirmed cases 
was relatively small (n=78), therefore age was only stratified into two groups (<60 years 
and ≥60 years). This age cut-off was chosen as studies have shown COVID-19 mortality 
increases significantly after 60 years.195 There are numerous studies reporting that 
increasing age is associated with higher BAb and NAb levels,191,192 so it is unclear why 
the association was only seen in some assays in this study. It may be that the association 
between age and antibody levels is more evident in individuals with severe disease, since 
age and disease severity are closely correlated (most likely due to age-dependent 
comorbidities),196 so the limited number of participants with severe disease may have 
affected these results. The spread of ages in the PCR-confirmed cohort was also limited, 
with no participants under 17 years, and only two (<3%) over 70 years. Further 
investigations are needed to determine whether there are other factors causing these 





3.3.6 SARS-CoV-2 antibody testing considerations 
The purpose of testing is a major consideration when designing a SARS-CoV-2 
serological assay testing algorithm, as different purposes may require assays targeting 
different antibody isotypes and/or antigen targets.3 Seroprevalence studies simply require 
an assay that can detect the presence of past infection, therefore it would not matter if the 
assay was N- or S-based, as long as the sensitivity and specificity were excellent, thus, 
an automated, high-throughput assay such as the Roche may be best. An assay with 
excellent sensitivity but imperfect specificity could also be employed, if a confirmatory 
assay with excellent specificity was used for any positive results in the screening assay. 
The same is true when utilising serology to aid in diagnosis (except IgM and IgA should 
also be considered). If monitoring a spike-based vaccine response, an assay measuring 
anti-S antibodies is required, but an assay that correlates with NAbs would be desirable, 
of which any of the S-based assays we investigated would be ideal. In a population where 
extensive vaccination with an S-based vaccine has taken place, then an N-based assay 
would be required to detect past infection (since a vaccinated individual should have 
acquired S protein antibodies but not N protein antibodies). In these situations, to 
determine past infection, it may be pertinent to test for both N and S protein antibodies, 
noting that depending on which assay is used, if the time since onset of symptoms has 
been some months, then anti-N antibodies could be falsely negative. If both N and S 
antibodies are positive, this could indicate natural infection. Reviewing results in view 
of the individuals clinical and exposure history is pertinent. 
3.3.7 Limitations and further research 
The slight female predominance in this study is noted (59%), but this is similar 
to the Southern DHB demographics for the PCR-confirmed cases (54% female).5 The 
PCR-confirmed cohort did not include any children, and we did not capture sufficient 
clinical data to characterise features, such as being immunocompromised, which might 
have clarified why some of the participants with PCR-confirmed SARS-CoV-2 infection 
had negative antibody results on some assays. It was also assumed the PCR-confirmed 
cases all had SARS-CoV-2 infection, but it is possible, although highly unlikely (given 
they were all positive on at least one assay), that there could be false positives within this 
group. These factors could impact the sensitivity calculations. The delay in blood 




sensitivity. There is potential bias by only using female antenatal sera for the specificity 
testing, and the specificity and cross-reactivity testing could have also been more 
thorough with the inclusion of samples from individuals with diseases or conditions with 
the potential to cause cross-reactivity in serological assays, however such samples are 
difficult to obtain Due to financial, timing, and logistical restraints, not all the samples 
could be run on all the assays. Since there were few negative samples run on all the 
assays, this may have impacted the concordance results (in particular the NPA results). 
There was a limited assessment of precision and reproducibility but this data is available 
within the manufacturer’s kit inserts for the commercially available assays. 
Further research should be undertaken to further understand the immunokinetics 
of the antibodies detected by the various new SARS-CoV-2 serological assays now 
available, using more well-defined cohorts of disease severity, and time since infection 
(acute through to long-term). Multiple assays employing the same target antigen and 
same format should be compared before making any assumptions about the 
immunokinetics of these antibodies, in particular, comparison of additional N-based 
antibody assays would be interesting. Additionally, comparison of fully quantitative 
assays should be undertaken, now that these are available; several assays have been 
standardised using a WHO standard to allow for the harmonisation and comparison of 
results across different laboratories (including the Abbott Alinity S-based assay), mainly 
for the purpose of vaccine development and response.197 Furthermore, with the 
introduction of numerous different vaccines and the emergence of new SARS-CoV-2 
variants, it would be prudent to re-assess the clinical performance of these assays against 
samples from individuals vaccinated or infected with the new variants as they may 
perform differently. 
3.4 Conclusions 
Overall, the results demonstrate sensitivity (but not so much specificity) of 
SARS-CoV-2 serological assays appear to be affected by the format of the assay (target 
antigen and detected immunoglobulin isotype). The Abbott Architect N-based assay had 
poor sensitivity, and it could be said, as others have found, that S-based assays generally 
perform better than N-based assays, particularly when the time since infection has been 
many months. However, the finding that the Roche N-based assay had the best sensitivity 




appears to be assay dependent. There is much heterogeneity between the results of SARS-
CoV-2 serological assays. Studies using assays with different antigen targets, different 
assay technologies, varying sample sets (from asymptomatic to severe infection), and 
differences in the time since infection all appear to affect the results, therefore it is 
important to choose an assay(s) suitable to the clinical purpose and understand the 
potential for false negative and false positive results.  
Due to the use of a much-reduced cut-off of the Abbott Architect assay, owing to 
its unexpectedly low sensitivity, and the use of five additional assays, whose sensitivity 
were superior, we are confident our serosurvey results are as accurate as they could be. 
In the future, if a serosurvey was to be carried out months after potential infection, then 
an assay with a better sensitivity should be employed, such as any of the other assays, 
but a high-throughput assay such as the N-based Roche assay would be suitable 
(particularly in our now partly vaccinated population, vaccinated by an S-based vaccine), 




Chapter 4: Frequency of SARS-CoV-2 IgG 
antibodies among higher-risk individuals in the 
Southern Region of NZ 
4.1 Introduction 
Due to the restriction of PCR testing during the early stages of the SARS-CoV-2 
outbreak in NZ, owing to a narrow case definition and a shortage of PCR testing reagents, 
there was the question of whether any cases were missed during this period. This could 
be answered by testing a large number of individuals who were at higher risk of having 
COVID-19 for SARS-CoV-2 IgG antibodies. The Southern DHB region was an ideal 
location to perform this research since the Southern DHB region had the largest number 
of cases per capita during the first outbreak of SARS-CoV-2, significantly higher than 
the national average, and also includes the tourism hub of Queenstown, where 
community transmission took place.3,5  
When setting up this study, there was little published data on the seroprevalence 
of SARS-CoV-2 anywhere in the world and therefore little guidance on how to set up a 
serosurvey protocol, including which assays would be appropriate and how long blood 
collection could be delayed before risking false negative results. It was apparent the 
seroprevalence of SARS-CoV-2 in the NZ population was very low and thus an assay 
with high specificity would be needed otherwise the PPV of assays would be low. It was 
decided to use a high-throughput assay with sufficient specificity for initial screening and 
using other assays, with different assay formats, for confirmatory testing. Testing of 
borderline and positive results would minimise the risk of false negatives and false 
positives but also had an additional purpose of providing further data for the assessment 
of the concordance of the serological assays (Chapter 3). This study, however, was not a 
true seroprevalence study. We actively recruited higher-risk individuals to increase the 
chances of finding undetected cases. It was the first serosurvey in NZ with the results 
being of interest to both local and national public health authorities because it would 
reveal whether the public health response to the outbreak was sufficient enough to stop 





4.2.1 Participant characteristics  
For the 1127 higher-risk participants, the median age was 46 years (range 4-90 
years), with 76% female and 24% male. 37% had a PCR test before the start of the study 
(all negative), and 62% self-identified as frontline healthcare workers. Participants were 
asked to self-report on the occurrence of COVID-19 consistent symptoms before or 
during the lockdown period. Of the six main COVID-19 symptoms (shortness of breath, 
sore throat, new or worsening cough, fever, anosmia, coryza), 43% of the participants 
reported at least one of these symptoms, with the common symptom being a sore throat 
and the majority of participants reporting the presence of none of these symptoms. Refer 
to Table 4.1. 
Table 4.1: Patient demographics and symptoms reported for the higher-risk participants (n=1127) 
Sex No. (%) 
Female 856 (76) 
Male 271 (24) 
Age (years) 
Median (range) 
46 (4 – 90) 
No. (%) 
0-18 17 (2) 
19-49 626 (56) 
50-64 416 (37) 
≥65 68 (6) 
Higher risk category No. (%) 
Frontline healthcare workers  702 (62%)  
Tourism worker  60 (5%)  
Queenstown resident  208 (19%)  
Reported symptom No. (%) 
Shortness of breath 139 (12) 
Sore throat 340 (30) 
Cough 40 (4) 
Fever 127 (11) 
Anosmia 65 (6) 
Coryza 294 (26) 
Number of main COVID-19 symptoms No. (%) 
0 symptoms 637 (57) 
1 of 6 symptoms 204 (18) 
2 of 6 symptoms 144 (13) 
3 of 6 symptoms 79 (7) 
4 of 6 symptoms 39 (3) 
5 of 6 symptoms 24 (2) 




4.2.2 Summary of serosurvey results 
As described in Chapter 3, the Abbott Architect assay’s sensitivity was 
unexpectedly low and after a ROC analysis, a conservative revised cut-off was chosen as 
0.50 S/C. A grey-zone approach was utilised for testing of the higher-risk participants, 
testing any samples with results 0.50 S/C and above on all five other assays, to rule out 
potential false negatives (and false positives). Figure 4.1 shows the distribution of the 
results of the higher-risk participants. Refer to Table S3, Appendix C for the raw results. 
 
Figure 4.1: Scatter plot showing the distribution of results for all higher-risk participant samples 
on the Abbott Architect assay (n=1127). The greyed-out zone indicates the grey. Positive results (n=11) 
are red, grey-zone (n=14) results are grey, and negative results (n=1102) uncoloured.  
Figure 4.2 shows a heatmap of results the twenty-five samples that were grey-






Figure 4.2: Heat map comparing results of 25 samples run on six SARS-CoV-2 serological assays. 
The samples were the higher-risk participant samples in the ‘grey-zone’ (0.5-1.39 S/C) (n=14) or positive 
(≥1.4 S/C) (n=11) results on the Abbott Architect screening assay. Refer to Table 2.4 (Chapter 2) for a 




Fourteen Abbott Architect results fell in the grey-zone (0.5–1.39 S/C) (Table S3, 
Appendix C). Thirteen of these (93%) were negative on all five other assays and 
classified as seronegative. One of the samples with a grey-zone result (study number 
1116), was positive on all five other assays (with travel history and symptoms) and 
considered seropositive.  
Eleven individuals in the higher-risk group (0.98%) had positive results on the 
Abbott Architect assay (Figure 4.2, Table S3, Appendix C). Eight of these were also 
positive on one or more of the other five assays, indicating true seropositivity. Three were 
from one family (study numbers 1121, 1126, and 1127). Three Abbott Architect positive 
results were considered false positive because they were negative on all five other assays 
(study numbers 1117, 1118, and 1124).  
Thus, in total nine additional possible COVID-19 infections were detected, one a 
PCR-confirmed case diagnosed outside of the Southern DHB region; six with consistent 
travel history (Western Europe/UK) and symptoms, and two close contacts of PCR-
confirmed cases, reporting COVID-19 consistent symptoms (Table 4.2). Seven of the 
nine seropositive higher-risk participants self-reported at least one COVID-19 consistent 
symptom. Three of the seropositive individuals had a PCR test during the Level 4 
lockdown period (study numbers 1122, 1123, and 1125). Study number 1122 was a 
household contact of a PCR-confirmed case who self-reported at least one COVID-19 
consistent symptom but returned a negative PCR test. Study number 1123 was the known 
case from out of the region and thus a positive PCR test (we are unsure how this 
individual came to be enrolled in the study but they had returned to the Southern DHB 
region and we included their results nonetheless). Study number 1125 was a close (work) 
contact of a PCR-confirmed case and self-reported non-specific symptoms (headache and 




Table 4.2: Summary of higher-risk participants who were classified as seropositive or false positive. PCR test results, symptom history and travel history information 










Symptoms reported Details 






21/07/20 NT N/A 
Fever, muscle aches, shortness of 
breath, diarrhoea 
Queenstown Lakes District resident. 





1/07/20 NT N/A Fatigue 










15/07/20 NT N/A 
Fever, headache, muscle aches, 
diarrhoea 








3/07/20 NT N/A 
Runny nose or congestion, 
sore/scratchy/tickly throat, loss of 
smell, loss of taste, fatigue 




2/07/20 4/04/20 ND Sore/scratchy/tickly throat, fatigue 
Household contact of PCR-confirmed 
case. Arrived NZ late March. 





3/07/20 31/03/20 D 
Sore/scratchy/tickly throat, loss of 
taste, headache, muscle aches, fatigue, 
cough 
PCR-confirmed case (outside of 














Symptoms reported Details 

















Close (work) contact with PCR-






24/06/20 NT N/A 
Fever, sore/scratchy/tickly throat, 
headache, muscle aches, fatigue 




25/06/20 NT N/A 
Fever, sore/scratchy/tickly throat, 
headache, muscle aches, fatigue, 
nausea/vomiting 
Queenstown Lakes District resident Yes. Italy March 2020 




4.2.3 Estimation of actual SARS-CoV-2 prevalence 
 9/1127 (0.8%) seropositive individuals were detected in the higher-risk group, 
but due to the uncertainties in the sensitivity and specificity of the Abbott Architect assay 
this prevalence calculation may be incorrect, therefore, two further statistical analyses 
were performed.3 The Rogan-Gladen estimator198 allowed the actual prevalence in the 
higher-risk group to be estimated, considering the sensitivity and specificity of the Abbott 
Architect assay. Using the Abbott Architect assay with the manufacturer’s cut-off of 1.40 
S/C, the Rogan-Gladen estimation gives a prevalence of 0.8% (95% CI, 0.0-2.0%).3 
Using the Abbott Architect assay with the revised cut-off of 0.50 S/C, the estimated 
actual prevalence is 2.0% (95% CI, 0.8-3.2%).3  
To incorporate the effect of orthogonal testing (using a second assay, with a 
different target), Bayesian statistical analysis for prevalence estimation was 
performed.199 Applying the secondary tests to the eleven samples with positive results on 
the Abbott Architect assay, using the manufacturer’s cut-off of 1.40 S/C, the estimated 
actual prevalence is 0.9% (95% credible interval: 0.4-1.7%).3 Applying the secondary 
tests to the 25 samples with positive results on the Abbott Architect assay, using the 
revised cut-off of 0.5 S/C, the estimated actual prevalence is 0.8% (95% credible interval: 
0.4-1.5%).3  
4.3 Discussion 
This study of over 1000 participants in our region, self-identifying as being higher 
risk than the overall population for COVID-19 identified a further nine infections 3. All 
had epidemiological risk factors for infection, including travel to Europe during their 
outbreak and/or being a close contact of a known case (and therefore were likely self-
isolating after their exposure).3 Only three of these participants had a PCR test (all testing 
negative, although the timing of the test in relation to any symptoms is unclear), with one 
case retrospectively found to be a known case from out of the region. The remaining 
seven did not have a PCR test, likely because they were symptomatic overseas or did not 
meet NZ’s original case definition.3 Undiagnosed infection was not detected among 
casual contacts of known cases, frontline healthcare workers, or tourism workers.3  
Of the nine seropositive participants, only three infections previously unidentified 




1119, 1122, and 1125) since one was already known (study number 1123), four 
participants were symptomatic overseas and had likely recovered upon arrival in NZ 
(study numbers 1116, 1121, 1126, and 1127), and one likely was a false positive result, 
although was classified as seropositive (study number 1120), which will be discussed 
further below. It was not intended to recruit participants who likely were infected and 
recovered overseas, but due to the nature of the study and the recruitment procedures, 
this did happen as individuals were curious as to whether they had COVID-19. 
Study number 1120 was initially classified as having true seropositivity because 
the sample was positive by more than one assay. This sample was low level positive on 
both the Abbott Architect and Euroimmun assay but negative on the four other assays. 
The participant’s travel history was Italy in January, which was most likely too early for 
infection, and they reported no symptoms. As part of the antibody persistence study 
(Chapter 6), this participant provided three follow-up samples, up until 6.5 months from 
their initial sample, and their antibody level on the Abbott Architect assay remained 
stable over this period, whilst all other seropositive participants had a reduction in their 
antibody levels over time. Another of the samples classified as a false positive (study 
number 1118) also provided three follow-up samples and also had a stable antibody level 
on the Abbott Architect assay. The manufacturer of the Abbott Architect’s states the 
specificity of the assay is 99.6% (similar to our finding of 99.7%, refer Chapter 3), 
therefore a finding of 4/1127 false positives is not unexpected, but it does suggest the 
specificity of the Abbott Architect may be less than the other assays, considering all four 
of these samples were negative on the other assays (other than one having a positive 
result on the Euroimmun assay), noting this may be due to the Abbott Architect assay 
having a different target antigen than the other assays. 
Although the data is not shown here, study numbers 1118 and 1120 (likely false 
positive results on the Abbott Architect assay), have a history of high anti-nuclear 
antibody (ANA) titres, with no clinical disease. ANAs can often be a cause of 
interference, producing false positive serology results. One group investigating the cross-
reactivity of SARS-CoV-2 serology assays in patients with auto-immune diseases, found 
six LFA assays and one in-house IgG assay were able to give correct negative results for 
a panel of pre-pandemic 68 serum samples from individuals with a range of various auto-




samples from individuals with rheumatoid arthritis and systemic lupus erythematosus (of 
which the presence of ANA is synonymous with).200 This highlights the importance of 
secondary testing to minimise the risk of false positive results. 
Several of the higher-risk group in this retrospective survey reported that they 
were household contacts of known cases and had symptoms and thus potentially should 
have been classified as probable cases, but they were not identified as probable cases by 
the MoH and were not under public health management, therefore these participants were 
still classified as a higher-risk participant. Additionally, because the higher-risk group 
and symptoms were self-reported by the participants, there is the potential for recall bias. 
There may have been cases of infection missed since the Abbott Architect assay 
(used as the screening assay) had sub-optimal sensitivity, however, utilising the grey-
zone approach, based on a ROC analysis, and orthogonal testing, the sensitivity was 
improved to 94.9% (and specificity maintained).3 An additional 14 samples were tested 
on the five secondary assays using this grey-zone approach, with all samples, except one, 
testing negative on all the other assays.3 The only false negative Abbott Architect result 
in the higher-risk participants (which tested positive on all five other assays) was close 
to the Abbott Architect manufacturer’s cut-off.3 This demonstrates the importance of 
validating assays and the use of customised cut-offs when clinically required. We were 
extra cautious using such a low cut-off for secondary testing but it provided confidence 
that there were not any other false negatives. 
The imperfect sensitivity and the unknown prevalence among the population 
tested in our region meant it was difficult to estimate the true number of cases of infection 
that may have been missed by the testing protocol.3 The Rogan-Gladen and Bayesian 
estimations for actual prevalence in the higher-risk group provided more accurate 
estimates of actual prevalence, but they were similar to the original estimates, 
demonstrating the prevalence estimate did not appear to strongly depend on the cut-off 
used in the screening test.3 It must be noted that since higher-risk participants were 
actively recruited for the serosurvey, the seroprevalence in the community of the 
Southern DHB region is likely much lower than our estimate (and it should be noted that 





This study demonstrates the importance of choosing an appropriate serological 
assay when performing serosurveys, as it was discovered the Abbott Architect assay was 
not ideal due to its suboptimal sensitivity (when infection was some months prior) as 
discussed in Chapter 3. The sensitivity and specificity of the assay are both extremely 
important. If antibody levels are indeed lower in less severe cases, and if there is a 
significant decrease in antibody levels over time (as I found later; refer Chapters 3 and 
Chapter 6), then the assays used for serosurveys need to be able to detect these low levels 
of antibodies.201 This also shows that the manufacturer’s stated assay performance should 
be interpreted with caution as they may have been validated against data sets that are not 
comparable to those samples that would be tested in a serosurvey.201  
Serological testing has been used in NZ to identify a previously unidentified 
cluster.202 In September 2020, an individual from the Waikato region returned a weak 
positive PCR test and serological testing found the individual and five of their household 
contacts had SARS-CoV-2 IgG antibodies, supporting historical infection (likely 
contracted from a symptomatic family member visiting from Italy).202 The six individuals 
became symptomatic but self-isolated during their illness; this cluster is now believed to 
be the earliest known cluster in NZ.202 The authors suggested SARS-CoV-2 may have 
been silently spreading in the community much earlier than it was suspected initially and 
the identification of this cluster demonstrates the narrow case definition (due to limited 
testing capacity) was indeed an issue in NZ during the early stages of the outbreak.202 A 
similar situation could have well been occurring in the Southern region of NZ and 
illustrates why a serosurvey such as ours was important to conduct. 
The epidemiology of COVID-19 in NZ during the initial outbreak was relatively 
unique: NZ is an island nation with a low population density (by world standards); border 
measures were put in place swiftly due to the pandemic being well signalled overseas; 
the outbreak coincided with NZ’s autumn season; cases did not overwhelm the hospitals; 
and, NZ has a well-coordinated network of public health units and microbiology 
diagnostic laboratories.3 Thus, it is reasonable to believe the majority of cases in the 
Southern DHB region were identified by targeted PCR testing, based on epidemiological 
risks and symptoms, and public health intervention limited community spread by 






The high female predominance in this study (76%) is noted. This is hypothesised 
to be due to the high number of frontline healthcare workers (62%), which is a female-
dominated occupation, and females may possibly, in general, be more willing to 
participate in such studies.3 In the Southern DHB region, 54% of the PCR-confirmed 
cases were female, and nationwide it was approximately 50%.5 
As already mentioned, this study is not a true seroprevalence study since we 
actively recruited higher-risk participants, therefore the seropositivity rate calculated in 
the higher-risk group in the Southern DHB region cannot be extrapolated to the general 
population. The study also attracted several individuals with a history of travel and 
COVID-19 consistent symptoms who likely were interested in finding out if they did 
indeed have COVID-19 overseas; this was not an objective of our study but the majority 
of the seropositive higher-risk participants fell into this category. We also used various 
methods of recruitment, which changed during our enrolment period (widened to boost 
numbers), which introduces potential recruitment bias. 
We cannot exclude that undiagnosed cases may have been missed using the 
Abbott Architect assay as the screening test, particularly because of the delay in specimen 
collection after the outbreak (11-17 weeks post potential infection) as this may have 
impacted the Abbott Architect assay’s sensitivity.3 Every effort was made to mitigate 
against this by employing a lower cut-off for the Abbott Architect screening assay and 
utilising numerous secondary assays for all samples above the revised cut-off.3  
Our study has also highlighted the importance of understanding the interferences 
of assays and reasons for false positive results. Further research should include extensive 
in-house validation of SARS-CoV-2 serological assays by investigating diseases and 
conditions known to cause cross-reactivity in serological assays (this is only done to 
some degree by the manufacturers), however, obtaining sera for such validation studies 
can be a challenge.  
4.4 Conclusions 
This study suggests there were very few undiagnosed SARS-CoV-2 infections in 
the Southern DHB region during the first outbreak, despite testing restrictions during this 




countries experiencing large outbreaks, or those who had close contact with a known 
case, thus indicating the public health response was sufficient enough to stop widespread 
undetected community spread. The study also demonstrated the importance of using 
orthogonal testing algorithms for serosurveys as the sensitivity and specificity of the 




Chapter 5: The likelihood of SARS-CoV-2 
infection among those diagnosed as ‘probable’ 
cases 
5.1 Introduction 
During the first outbreak in NZ there were 1503 cases of COVID-19 reported, of 
which 1153 (77%) were PCR-confirmed cases and 350 (23%) were probable cases.5 In 
the SDHB region, there were 217 COVID-19 cases in total, of which 187 (86%) were 
PCR-confirmed and 30 (14%) were probable cases. The NZ Ministry of Health’s 
definition of a probable case was:  
A symptomatic close contact of a confirmed case (epi-link) OR a case that 
meets the clinical criteria where other known aetiologies that fully explain the 
clinical presentation have been excluded and either has laboratory suggestive 
evidence or for whom testing for SARS-CoV-2 is inconclusive.21 
Due to the narrow case definition during the early phase of the first outbreak, some 
probable cases did not have a PCR test (due to testing restrictions). During this period 
the case definition stated symptomatic household/close contacts of PCR-confirmed cases 
should not be tested (unless they had specific severe symptoms, were a health care 
worker, or were recommended by public health), and thus were considered a probable 
case, and to self-isolate at home.21 The majority of probable cases did however have a 
PCR test (especially as the PCR testing capacity improved). If the PCR test was negative 
in these individuals, they were still often classified as a probable case, were included in 
NZ’s official COVID-19 tally, and treated as if they had infection.203 Reasons for a 
negative PCR test in these individuals could be that they were never infected with SARS-
CoV-2, or they had been infected but the PCR test gave a negative result due to early or 
late sampling during the illness, or a false negative due to a sampling or analytical issue. 
Serology could have been be useful in these situations (depending on the timing of the 
testing), which may have saved public health resources (quarantine, contact tracing) and 
also would have benefited the individual. The results of our study may indicate to public 






5.2.1 Participant characteristics 
For the nine probable cases tested, the median age was 49 years (range 10-59 
years). Six were female and three males. The median time of symptom onset to serum 
collection was 13 weeks (range 11-14 weeks) (Table 5.1). 
Seven participants had a negative PCR test during their symptomatic period. The 
remaining two did not have a PCR test (one due to fainting before the PCR test and the 
other due to a leaked sample).  
Participants were asked to self-report on the occurrence of COVID-19 consistent 
symptoms during their illness (refer to Chapter 2 for the list of symptoms and illness 
severity classification). Of the six main COVID-19 symptoms (shortness of breath, sore 
throat, new or worsening cough, fever, anosmia, coryza), all of the probable cases 
reported at least one of these symptoms (Table S4 Appendix C). The most common 
symptom was coryza and the majority of participants reported the presence of three of 
















Table 5.1: Patient demographics and symptoms reported for the probable cases (n = 9)  
Sex No. (%) 
Female 6 (67) 





0-18 1 (11) 
19-49 4 (44) 
50-64 4 (44) 
≥65 0 (0) 




Disease severity* No. (%) 
1 – asymptomatic/mild 6 (67%) 
2 – moderate 3 (33%) 
3 – moderately severe 0 (0) 
4 – severe 0 (0) 
5 - critical 0 (0) 
Reported symptom No. (%) 
Shortness of breath 4 (44) 
Sore throat 4 (44) 
Cough 2 (22) 
Fever 4 (44) 
Anosmia 2 (22) 
Coryza 6 (67) 
Number of main COVID-19 symptoms No. (%) 
0 symptoms 0 (0) 
1 of 6 symptoms 2 (22) 
2 of 6 symptoms 2 (22) 
3 of 6 symptoms 3 (33) 
4 of 6 symptoms 2 (22) 
5 of 6 symptoms 0 (0) 
All 6 symptoms 0 (0) 
*Disease severity was classified on the basis of the case’s symptoms and the level of hospital care provided 
as follows: 1 – asymptomatic to mild cold-like symptoms (n=35); 2 – moderate: cough, fever and chills 
(n=39); 3 – moderately severe: admitted for assessment (n=3); 4 – severe: admitted and given supplemental 
oxygen therapy (n=1); 5 – critical: admitted to ICU (n=0). 
5.2.2 Summary of results 
Of the nine probable cases, one was positive on six of the seven assays while 
another was positive on five of the seven assays, suggesting these two cases likely had 
COVID-19 infection (22.2%; 95% CI, 5.3-55.7%) (Figure 5.1, Table 5.2). The seven 




values ranging from 0.01–0.04 S/C, suggesting these individuals were unlikely to have 





Figure 5.1: Heat map comparing results of the samples from the nine probable cases. Results of 
samples run on seven SARS-CoV-2 serological assays. Note: Study number ‘Probable-4’ had insufficient 




















Probable-1 26/06/20 24/03/20 13 
28/3/20 
+ 13/04/20 
ND x 2 Fever, sore/scratchy/tickly throat, loss of smell, muscle aches, diarrhoea 2 




ND x 3 
Fever, sore/scratchy/tickly throat, cough, short of breath, muscle aches, 
diarrhoea 
1 
Probable-3 24/06/20 18/03/20 14 10/04/20 ND Sore/scratchy/tickly throat, headache, muscle aches, fatigue 1 




N/A Runny nose or congestion, headache, muscle aches, fatigue 1 
Probable-5 25/06/20 29/03/20 13 
02/04/20 + 
14/04/20 
ND x 2 
Runny nose or congestion, shortness of breath, headache, muscle aches, fatigue, 
cough 
1 




ND x 4 
Fever, runny nose or congestion, shortness of breath, loss of smell, loss of taste, 
headache, muscle aches, fatigue, diarrhoea 
2 
Probable-7 24/06/20 9/04/20 11 
08/04/20 + 
11/04/20 
ND x 2 Runny nose or congestion, shortness of breath, headache, muscle aches, fatigue 1 




N/A Runny nose or congestion, sore/scratchy/tickly throat, headache, fatigue 1 
Probable-9 17/07/20 7/04/20 14 8/04/20 ND 
Fever, runny nose or congestion, shortness of breath, headache, muscle aches, 
fatigue, diarrhoea 
2 
F = Female; M = Male; N/A = Not applicable; D = Detected; ND = Not detected *Disease severity was classified on the basis of the case’s symptoms and the level of hospital 
care provided, as follows: 1 – asymptomatic to mild: coryza, and/or sore throat; 2 – moderate: fever, or cough, or shortness of breath; 3 – moderately severe: admitted to hospital 





A surprising finding was that seven of the nine individuals classified as having 
‘probable’ infection (and included in NZ’s official COVID-19 tally) were seronegative, 
despite testing on seven serological assays.3 While recognising the delay of 
approximately three months in serum collection and its possible impact on the sensitivity 
of the assays, the majority of these individuals likely did not have infection. 
While a suspected case did not require PCR testing to be classified as a probable 
case (during the early phase of the first outbreak, due to PCR testing restrictions), only 
two of the probable cases in this study did not have a PCR test result, but this was due to 
pre-analytical issues (one a child who fainted before testing, and one leaked specimen). 
The seven probable cases who did have a PCR test all returned negative results, and while 
this indicates PCR testing was reasonably good at detecting true infection, it is not 
failproof, because one of these seven individuals were seropositive. Potential false 
negative PCR tests were also seen in the serosurvey of the higher-risk participants 
(Chapter 4), where two seropositive participants had negative PCR tests (however, the 
timing of these tests in relation to any symptoms they had was unclear). While PCR 
testing usually has a very high analytical sensitivity, the timing of sampling, sampling 
technique, and sampling location can affect the sensitivity, and may result in false 
negative results.109 
All the probable cases in this study reported at least one COVID-19 consistent 
symptom, with the majority of the participants (67%) being classified as having mild 
symptoms only. Of the two seropositive participants, one reported only mild symptoms 
(including two COVID-19 consistent symptoms), and the other participant reported 
moderate symptoms (including three COVID-19 consistent symptoms). The seronegative 
participants likely had a non-COVID-19 mild respiratory illness. Of note, one participant 
(study number Probable-6) had four COVID-19 consistent symptoms, and was classified 
with a disease severity ranking of ‘2’ but was seronegative, and returned four negative 
PCR tests (but several members of their household were PCR-confirmed cases). 
SARS-CoV-2 is a highly transmissible virus204 and therefore it is interesting the 
majority of these participants did not get infected when in such close contact with the 




once they were no longer as infectious (if returning from overseas), but still able to return 
a positive PCR test, or that the infected household members isolated themselves from the 
rest of the household and were very careful to avoid infecting others (mask-wearing, 
socially distancing, separate rooms for sleeping/eating/washing, etc). There have been 
several studies investigating the secondary attack rate (SAR) of SARS-CoV-2, 
particularly within households. The definition of SAR is the “number of household cases 
occurring within the incubation period upon exposure to a primary case divided by total 
susceptible household contacts”.205 Unsurprisingly, studies have shown the amount of 
time a contact has with a known case is directly proportional to the SAR rate.206 A large 
systematic review of studies investigating the SAR rate for SARS-CoV-2 found the 
results varied but that a large percentage (50-95%) of close contacts did not develop 
infection, even with sustained contact with a known case, which may indicate some sort 
of natural immunity (potentially from previous CoV infections).205 The SAR rate has 
been reported to be as low as 4.6% in Taiwan207 but as high as 49.6% in China,208 but 
most studies report a SAR rate below 20%,205 which is surprisingly low but consistent 
with my findings. Studies within households have shown that the time from symptom 
onset in the primary case to the symptom onset in household contacts also appears to 
vary, but reports estimate it to be approximately six days, and that transmission was 
minimal if the primary case was asymptomatic,206 indicating the importance of self-
isolation of close contacts for an appropriate length of time. Additional studies indicate 
the SAR rate is higher between spouses, than with children, or other adult household 
members,207,208 which may be a possible reason why few of our probable cases were 
seropositive (however I do not have this information for our cases). 
It is apparent serology testing of probable cases would have been useful, 
considering a significant proportion of cases during the first outbreak were classified as 
probable cases (23% nationwide),5 as this could significantly reduce NZ’s COVID-19 
tally. Serology testing of these individuals at the time of their symptoms would likely not 
have been useful due to the poor sensitivity of serology testing during the acute phase of 
infection, although IgM testing may have had some clinical value. However, serology on 
an acute specimen alone could not have excluded these individuals as having infection 





5.3.1 Limitations and further research 
A major limitation of this study is only nine probable cases from the Southern 
DHB region were able to be recruited for this study (only 30% of the total probable cases 
from the region), therefore it is difficult to make assumptions about the remainder of the 
probable cases in the region, and the rest of the country. In the Southern DHB region 
43% of probable cases were female,5 so the slightly high female predominance (67%) of 
the participants in this study is noted, but as discussed in earlier chapters, with the 
recruitment of the other cohorts, it may be that females, in general, are more willing to 
participate in such studies. 
Also, insufficient clinical data was captured to investigate the probable cases 
further (whether they tested for other respiratory viruses and more detailed information 
on their contact with PCR-confirmed cases). It would be interesting to investigate the 
seronegative probable cases further, to determine whether they have some sort of natural 
immunity against SARS-CoV-2, possibly due to prior infection with other human 
coronaviruses. Cross-reactivity studies of this set of sera with other human coronavirus 
antigens would be of interest, as well as studying their T cell responses to SARS-CoV-2 
peptides, similar to studies by Grifoni et al (2020).102 PBMCs from several of these 
probable cases were harvested and stored for such purposes, and the majority of the sera 
from these individuals are stored in the SRSSB serum bank, thus such studies would be 
possible. 
5.4 Conclusions 
Our findings suggest the majority of those diagnosed as probable cases likely did 
not have COVID-19 infection, even though they had close contact with known cases. 
Additionally, this study highlights the potential role of serology in the diagnostic 
algorithm where PCR is negative despite symptoms and epidemiological risks. Further 
testing of NZ’s remaining 341 probable cases from the first outbreak (and new suspected 
cases going forward) may be warranted. However, due to the transmission dynamics of 
SARS-CoV-2, it is prudent to be cautious and treat such individuals as having infection, 




Chapter 6: Persistence of SARS-CoV-2 antibodies 
6.1 Introduction 
The next aim was to determine how long SARS-CoV-2 IgG antibodies and NAbs 
persist post-infection. This is important as the measurement of these antibodies may be 
used to assess herd immunity, indicate how long potential immunity may last and when 
the risk of reinfection may occur, aid in vaccine development, monitor vaccine responses 
long-term, and potentially aid in therapies (such as convalescent plasma donation).85,209 
There has been concern about how useful seroprevalence study results will be if 
antibodies decline below assay detection limits by the time samples are collected, as large 
numbers of false negative results may occur.81 Therefore, we need to understand how 
long different SARS-CoV-2 antibodies persist and what methods are suitable for 
detecting these antibodies. Antibody responses to infections are diverse and produce 
different antibody isotypes (which have different functions), and different antibodies 
against various antigens, all of which may have different kinetics over time.57 
At the start of my study there were few reports on the persistence of SARS-CoV-
2 antibodies because the virus was new. While antibody kinetics were well described 
during the acute phase of infection, long-term kinetics were not and many of the studies 
had conflicting reports of how long the antibodies persist, due to differences in assays 
used and varying cohort characteristics. Some studies focused on mild or asymptomatic 
participants, but most focussed on individuals with more severe infection, early in the 
convalescent period. These studies were performed overseas, in countries experiencing a 
much more widespread outbreak compared to NZ. Most cases of COVID-19 are mild-
to-moderate46 and therefore studying persistence in a cohort who predominantly had 
mild-to-moderate disease (such as the PCR-confirmed cases in my study cohort) may 
provide more data more relevant to NZ. Also, there have been no new reported COVID-
19 cases in the Southern DHB region since the first outbreak, therefore the participants 
in this study have a low probability of re-exposure to the virus, which is a relatively 
unique situation worldwide and means they would have had no boosting to the immune 




In this part of the study, antibody levels in individuals with known COVID-19 
infection were measured over multiple time points, from 3-4 months post-infection, 
through to 10-12 months post-infection, using several assays with different assay 
formats. This would allow the comparison of different SARS-CoV-2 antibodies over 
time (anti-N IgG antibodies, anti-S IgG antibodies, and NAbs). This may help guide what 
antibodies (and assays) should be used in different clinical scenarios (short- or long-term 
post-infection).  
6.2 Results 
6.2.1 Participant characteristics 
6.2.1.1 PCR-confirmed cases group 
Of the original 78 PCR-confirmed cases enrolled in the study, 42 participated in 
the antibody persistence study (54% participation rate). The participant rate dropped with 
each additional blood collection, with 31 returning for a third collection, and 21 returning 
for a fourth. Blood samples were collected approximately every two months after the first 
time point until approximately eight months (approximately 3-4 months post-infection, 
through to approximately 10-12 months post-infection).  
To compare the longitudinal antibody response and to account for the differences 
in time since onset of symptoms and blood collections dates between the participants, 
assay positivity rates across a nine-week rolling window were calculated. Participants 
were grouped by weeks post-onset of symptoms (11-20 weeks, n=78, 21-30 weeks, n=41, 
31-40 weeks, n=27 and 41-50 weeks, n=26). There were 26 participants with a sample in 
both the first and last time-point window. For the 42 participants in the first time-point 
window, the age distribution and disease severity were similar to that in the sensitivity 
studies (Chapter 3), but there was a slight bias towards female participants in the antibody 
persistence study (64% female, 35% male) as compared to the sensitivities study (59%). 
The median age was 52 years (range 17-81 years). The median time of symptom onset to 
serum collection for the first time-point samples was 14 weeks (range 11-17 weeks). 
Sixteen (38%) of the participants reported no symptoms or mild symptoms only, while 
25 (60%) of the participants reported moderate symptoms. One participant (2%) was 
hospitalised during their infection and were classified as having severe symptoms (given 




(shortness of breath, sore throat, new or worsening cough, fever, anosmia, coryza), 98% 
of participants reported at least one of these symptoms. The most common symptom was 
sore throat (71%) and the majority of participants reported the presence of two or four of 
these six symptoms (Table 6.1). 
6.2.1.2 Higher-risk participants 
Of the original higher-risk group with the presence of SARS-CoV-2 antibodies 
(including false positives), 6/12 (50%) were recruited for the antibody persistence study. 
Four were classified as seropositive, and two were suspected to have false positive 
serology on the Abbott Architect assay due to being negative on five or six other 
serological assays. All six participants returned for a third collection, and four for a 
fourth. The median age was 50 years (range 10–61 years), with 50% female and 50% 
male. Four (67%) participants self-reported no symptoms or mild symptoms only and 
two (33%) participants self-reported moderate symptoms. Of the six main COVID-19 
consistent symptoms, 50% of participants self-reported at least one of these symptoms. 
The most common symptom was sore throat (50%), and the majority of participants 
reported the presence of no symptoms. (Table 6.1). Results were analysed separately for 
the higher-risk participants, given there was no data on time since the onset of symptoms 
















(all, n= 42) 
PCR-confirmed cases 
(with a sample in both the 
first and last time-point 




Sex No. (%) No. (%) No. (%) 
Female 24 (64) 16 (62) 3 (50) 
Male 15 (36) 10 (38) 3 (50) 
Age (years) 
Median (range) Median (range) Median (range) 
52 (17-81) 53 (27-81) 50 (10-61) 
No. (%) No. (%) No. (%) 
0-18 2 (5) 0 (0) 2 (33) 
19-49 17 (40) 9 (35) 1 (17) 
50-64 19 (45) 13 (50) 3 (50) 
≥65 4 (10) 4 (15) 0 (0) 
No. of participants in each 
time-point window*  
No. (%) No. No. (%) 
Time-point 1  42 (100) 26 6 (100) 
Time-point 2 42 (100) 28 6 (100) 
Time-point 3  31 (74) 19 6 (100) 
Time-point 4 21 (50) 26 4 (67) 
Time of symptom onset to 
first serum collection 
(weeks) 
Median (range) Median (range) Median (range) 
13 (11-14) 14 (13-17) 13 (11-14) 
Disease severity** No. (%) No. (%) N/A 
1 – asymptomatic/mild 16 (38) 11 (42) N/A 
2 – moderate 25 (60) 15 (58) N/A 
3 – moderately severe 0 (0) 0 (0) N/A 
4 – severe 1 (2) 0 (0) N/A 
5 - critical 0 (0) 0 (0) N/A 
Reported symptom No. (%) No. (%) No. (%) 
Shortness of breath 17 (40) 9 (35) 0 (0) 
Sore throat 30 (71) 17 (65) 3 (50) 
Cough 21 (50) 13 (50) 0 (0) 
Fever 25 (60) 15 (58) 2 (33) 
Anosmia 25 (60) 15 (58) 1 (17) 
Coryza 19 (45) 9 (35) 1 (17) 
Number of main COVID-19 
symptoms 
No. (%) No. (%) No. (%) 
0 symptoms 1 (2) 1 (4) 3 (50) 
1 of 6 symptoms 3 (7) 4 (15) 1 (17) 
2 of 6 symptoms 11 (26) 7 (27) 1 (17) 
3 of 6 symptoms 7 (17) 3 (12) 1 (17) 
4 of 6 symptoms 11 (26) 6 (23) 0 (0) 
5 of 6 symptoms 7 (17) 4 (15) 0 (0) 
All 6 symptoms 2 (5) 1 (4) 0 (0) 





*Time-point 1: 11-20 weeks post onset of symptoms; Time-point 2: 21-30 weeks post onset of symptoms; 
Time-point 3: 31-40 weeks post onset of symptoms; Time-point 4: 41-50 weeks post onset of symptoms.  
**Disease severity was classified based on the case’s symptoms and the level of hospital care provided as 
follows: 1 – asymptomatic to mild: coryza, and/or sore throat; 2 – moderate: fever, or cough, or shortness 
of breath; 3 – moderately severe: admitted to hospital for assessment; 4 – severe: admitted to hospital and 
given supplemental oxygen therapy; 5 – critical: admitted to ICU. 
6.2.2 Qualitative changes in antibody levels over time 
When comparing the antibody levels from the first time-point window (11-20 
weeks post-onset of symptoms) and the last time-point window (41-50 weeks), the 
percentage of participants with anti-N IgG antibodies (tested on the Abbott Architect 
assay) dropped significantly from 76.9% to 15.4% (Figure 6.1). However, the positivity 
rate of the anti-S IgG antibody assays (in-house ELISA and Abbott Alinity), and the NAb 










Figure 6.1: Longitudinal positivity of SARS-CoV-2 serological assays. Ranging from 11 to 50 weeks post-onset of symptoms in the PCR-confirmed cohort, using results 
from all time point samples from PCR-confirmed cases (11-20 weeks, n=78; 21-30 weeks, n=41; 31-40 weeks, n=27; 41-50 weeks; n=26). A) Line graph showing the decline 
in the Abbott Architect assay’s positivity rate over time, as compared to the other three assays whose positivity rates are relatively stable. B) Numbers and percentages of the 




Antibody levels for each participant on each assay were also plotted against time 
(Figure 6.2), which also demonstrates the significant reduction in antibody levels for the 
N-based assay (Abbott Architect) as compared to the relatively stable S-based assays. 
Refer to Table S7, Appendix C for the raw results. 
There were 26 participants with a sample in both the first and last time-point 
windows and in terms of intra-individual change for these participants, of the 23 
participants with a positive result on the Abbott Architect assay during the first time-
point window (11-20 weeks post-onset of symptoms), 19 had negative results by the last 
time-point window (41-50 weeks), whereas for the Abbott Alinity assay, none of the 
participants with a positive result in the first time-point window had negative results by 
the last time-point window, for the in-house ELISA only 5/26 participants changed from 
positive to negative, and for the sVNT, only 2/26 changed from positive to negative. All 
samples that were negative on an assay at the first time-point were consistently negative 
across all subsequent time-points.  
An apparent bi-modal distribution in the last two time-point windows was noted 
in the sVNT results (Figure 6.2), with a group with high NAb levels and a group with 






Figure 6.2: Reactivity of the different SARS-CoV-2 serological assays over time. Samples include 
PCR-confirmed cases from all timepoint samples (42 unique participants, n=173 total samples). Each 
line represents one participant and each dot a different sample collection. Assay thresholds are indicated 




6.2.3 Quantitative changes in antibody levels over time 
The Abbott Alinity assay was the only fully quantitative assay (utilising a full 
calibration curve) but the other assays were semi-quantitative and still gave a numerical 
result. The changes in quantitative results over the different time-point windows were 
analysed for each assay (Figure 6.3). So as not to skew the data, only the results from 
the 26 PCR-confirmed cases who had a sample in both the first and last time-point 
windows were used in this analysis, but it should be noted that the number of participants 
in the second and third time-point windows were slightly different due to some 
participants having no samples in one time-point but two in the next, due to timing of the 
blood collections. For all the assays, the median antibody level was the highest in the 11-
20 week window. The N-based Abbott Architect assay had a steady decline in antibody 
levels over time, with a significant decrease in the median antibody level between the 
first time-point window and the last (P<0.0001), with the majority of these participants 
changing from seropositive to seronegative over this period (83%). The S-based Abbott 
Alinity assay only had a slight but statistically significant decrease (P=0.017) in the 
median antibody levels between the first time-point window and the last, but no 
participants changed from seropositive to seronegative during this period. There was no 
statistically significant difference in the median antibody levels between the first time-
point window and the last for the in-house ELISA assay (S-based) and the sVNT (NAbs). 
The apparent bi-modal distribution of NAb levels, as seen above in Figure 6.1, can also 






Figure 6.3: Scatter plots showing the distribution antibody levels across the four time-point 
windows for each assay investigated. Samples included are the PCR-confirmed cases who provided a 
sample in both the first and last time-point windows (11-20 weeks, n=26; 21-30 weeks, n=28; 31-40 
weeks, n=19; 41-50 weeks; n=26). The solid horizontal lines indicate the median values with 95% CIs. 
Assay thresholds are indicated by dotted horizontal lines. A two-tailed Mann-Whitney U test was used to 
determine if there was a statistically significant difference (P<0.05) between the median antibody levels 
between each time-point window. Any significant differences are indicated by the asterisk. *=P≤0.05; 






6.2.4 NAb persistence 
NAb levels were estimated using the sVNT assay in samples from the PCR-
confirmed cases. Approximately 88% of the participants had the presence of NAbs 
during the first time-point window (11-20 weeks post-onset of symptoms), and by last 
time-point window (41-50 weeks) there was no significant change in the level of NAbs, 
with 92% of participants still having the presence of NAbs (Figure 6.1).  
Figure 6.1 showed that the majority of the participants had a decrease in NAbs 
over time, but there was also a subset of participants whose NAb levels were maintained, 
and a subset whose NAb levels had increased. Of the 26 participants who had a sample 
in the first and last time-point window, seven (27%) had an increase in NAb 
concentration by the last-time point window. 2/26 (8%) had increases on the Abbott 
Alinity and in-house ELISA assays, and none had an increase on the Abbott Architect 
assay. 
In Chapter 3, it was suggested the level of NAbs was dependant on the disease 
severity because at 3-4 months post-onset of symptoms for the 78 PCR-confirmed cases, 
there was a significant difference in the median antibody level between those with 
asymptomatic/mild symptoms and those with moderate-to-severe symptoms. Here, it was 
analysed whether this relationship persists with time. Figure 6.4 demonstrates that by 
the second time-point window onwards (21-30 weeks post-onset of symptoms), the level 
of NAbs did not differ significantly between these two disease severity groups, noting 





Figure 6.4: Violin boxplot showing the differences in NAb levels over time with regard to disease 
severity. Samples included are all the time-point samples from the PCR-confirmed cases (11-20 weeks, 
n=78; 21-30 weeks, n=41; 31-40 weeks, n=27; 41-50 weeks; n=26). Individuals with asymptomatic or 
mild symptoms (disease severity level 1) had significantly lower levels of neutralising antibodies than 
those with moderate-to-severe symptoms (disease severity level 2-4) at the first time-point window. No 
significant difference was found by the second time-point window onwards. A two-tailed Mann-Whitney 
U test was used to determine if there was a statistically significant difference (P<0.05) between the 
median antibody levels between disease severity levels at each time point. Any significant differences are 
indicated by an asterisk. **=P≤0.01 
In the earlier Figure 6.1 the sVNT results appeared to show a bi-modal 
distribution in the level of NAbs in the later time-points. Figure 6.4 suggests this 
distribution is not due to disease severity (noting these participants only had 
asymptomatic/mild or moderate symptoms), and Figure 6.5 suggests it is not due to sex 
or age. However, there was a small but significance increase in the level of NAbs in the 
last time-point window in participants who had a NAb level higher than the median NAb 
level in the first time-point window, than those with lower initial levels (P=0.014). 
Differences between ethnicities were not calculated as >70% of these participants 





Figure 6.5: NAb levels in the PCR-confirmed cases at the last time-point window. A violin boxplot 
showing the differences in NAb levels at the last time-point window, in regard to initial NAb level (from 
the first time-point window), sex, and age. Samples included are the PCR-confirmed cases who a sample 
in both the first and last-time point windows (n=26). A two-tailed Mann-Whitney U test was used to 
determine if there was a statistically significant difference (P<0.05) between the median antibody levels 
between each group. Any significant differences are indicated by the asterisk. *=P≤0.05. 
6.2.5 Antibody persistence in the higher-risk group 
The antibody levels for each assay from the six higher-risk participants were also 
plotted against time since their first blood collection (Figure 6.6). Two participants 
suspected of being false positive on the Abbott Architect remained positive with stable 
antibody levels on the Abbott Architect assay (and consistently negative on the other 
assays), supporting the notion they were false positive results, whereas the participants 
classified as seropositive had a similar decay pattern to the PCR-confirmed cases, with a 
rapidly decreasing antibody level on the Abbott Architect assay, and relatively stable 






Figure 6.6: Values for Abbott Architect, in-house ELISA, Abbott Alinity and sVNT assays for the 
higher-risk participants. (n=6) plotted over time (each line represents one participant and each dot a 
different sample collection). Blue lines represent the ‘true’ seropositive individuals. Red lines represent 
the participants suspected to have false positive results on the Abbott Architect assay. Assay thresholds 
are indicated by dotted horizontal lines. Note: The lowest Alinity values were given an arbitrary value of 





6.2.6 Antibody level post-infection and post-vaccination 
I was fortunate to test two of the PCR-confirmed cases after each of their two 
doses of the Pfizer-BioNTech SARS-CoV-2 vaccine, using the quantitative S-based 
Abbott Alinity assay  (Table 6.2). The anti-S antibodies in the samples pre-vaccination 
for both participants were relatively low-level positive. The levels rapidly increased after 
the first vaccine dose but did not increase significantly further after the second vaccine 
dose. 
Table 6.2: Abbott Alinity results on two PCR-confirmed cases, pre- and post-vaccination. Results 
























1 14 N/A 377.60 15 N/A 521.10 
2 31 N/A 104.90 23 N/A 370.40 
3 42 N/A 75.20 32 N/A 242.80 
4 62 N/A 67.80 44 N/A 195.9 
5 63 7* 48900 55 14* 24227 
6 67 10** 46700 57 7** 28733 
Abbott Alinity SARS-CoV-2 IgG II Quant assay: Units = AU/mL; cut-off = 50 AU/mL 
N/A = not applicable 
*post first vaccination **post second vaccination 
6.3 Discussion 
6.3.1 Summary of kinetics 
The long-term kinetics of SARS-CoV-2 antibodies was unknown at the start of 
the pandemic. Some earlier longitudinal studies on SARS-CoV-2 IgG suggested the 
antibodies declined quickly, within a few months post-infection,81 but these studies 
primarily focused on anti-N antibodies. More recent studies indicate that while anti-N 
antibodies decline quickly, anti-S, anti-RBD and NAbs are relatively stable, up until at 
least 5-8 months.67,80,84-86,88,89,97,210 
From the result of my earlier chapters, it was already clear the magnitude and 
longevity of the SARS-CoV-2 immune response is highly variable. Studies have shown 
the majority of the SARS-CoV-2 serological assays have comparable and sufficient 




different assays become apparent as time since infection increases, as early as 3-4 months 
as seen in my initial results where the N-based Abbott Architect assay had significantly 
lower sensitivity than the S-based assays. This part of the study provides further insight 
into the persistence of SARS-CoV-2 antibodies by analysing samples from PCR-
confirmed cases at multiple time-points, up until 10-12 months post-onset of symptoms. 
Notably, this study was performed in a population where the participants were very 
unlikely to have been re-exposed to the virus, which would affect the results, which 
would be difficult to replicate in overseas populations. 
Anti-N antibodies declined significantly faster than anti-S antibodies. For the N-
based Abbott Architect assay only 15% of the PCR-confirmed cases were seropositive 
during the last time-point window (approximately 10-12 months post-onset of 
symptoms), whereas at least 80% were seropositive on the other assays. For the S-based 
assays, the majority of the participants who were seropositive during the first time-point 
window were still seropositive by the last time-point window.  
These results suggest N-based IgG assays, such as the Abbott Architect, would 
not be suitable for applications such as long-term seroprevalence studies (if it has been 
months since the outbreak), identifying individuals for convalescent plasma therapy 
donation, or testing of individuals to identify COVID-19 infection from many months 
prior. This also means N-based assays may not be useful to distinguish vaccine-induced 
antibodies versus infection-acquired antibodies in an individual with a positive anti-S 
antibody as the anti-N antibody could be falsely negative if infection was many months 
prior. Using a lower assay cut-off may mitigate the problem but if the Abbott Architect 
assay’s cut-off was lowered from 1.40 S/C to 0.50 S/C (which was used for the grey-zone 
in the serosurvey in Chapter 4), the sensitivity of the assay would only increase from 
15% to 42% in the last time-point window (and would result in a much lower specificity). 
As discussed in Chapter 3, the pan-Ig Roche N-based assay appears to have 
greater longitudinal sensitivity than the Abbott Architect N-based assay. I was unable to 
test the time-point samples on the Roche assay, but there are numerous reports of similar 
studies that included the Roche assay,84,85,89 which demonstrate the Roche assay can 
detect anti-N antibodies until at least eight months post-infection and thus may be an 
appropriate choice for seroprevalence studies and possibly for diagnostic purposes 




discussed in the earlier chapters, there could be several reasons for the differences 
between the Abbott Architect and Roche assay, despite both being N-based, from the 
assay format (IgG versus pan-Ig, CMIA versus ECLIA, possible variations in the N 
recombinant antigen, or something inherent in the assay/instrumentation technology). It 
is apparent the persistence of SARS-CoV-2 antibodies measured using similar antigen 
targets can differ significantly.65,82,85,89 
My results are consistent with the results of my collaborators at the University of 
Auckland, who developed a multiplex assay to detect IgG, IgM, and IgA, and IgG 
subclass responses against the N, RBD, and S proteins of SARS-CoV-2.86 Their sample 
cohort included (but was not limited to) the majority (but not all) of my time-point 
samples. They demonstrated through their multiplex assay and sVNT that the positivity 
of anti-RBD antibodies, anti-S antibodies, and NAbs remained stable up to 4-8 months 
post infection (99%, 96%, and 90% respectively), but anti-N antibodies declined 
significantly faster (with only 54% remaining positive by the last time-point).86  
Similar studies to mine did not use a fully quantitative anti-S IgG antibody assay. 
The inclusion of the fully quantitative Abbott Alinity assay in this study has shown that 
anti-S antibodies also decline, but at a much slower rate, as shown by none of the 
participants becoming seronegative over the four time-points on this assay, and only a 
slight, but significant decrease in the median antibody level between the first and last 
time-point windows. This was not unexpected as the wide measuring range of the Abbott 
Alinity assay highlights subtle changes more easily than the semi-quantitative assays 
whose results are calculated from a single cut-off calibrator value.  
6.3.2 NAb persistence 
The persistence of NAbs, rather than BAbs, is of interest because high levels of 
SARS-CoV-2 NAbs might correlate with protection against infection or reinfection.93 
The likelihood of SARS-CoV-2 reinfection is relatively unknown, although there have 
been increasing reports of reinfection worldwide.72,73,211 There are examples of NAbs and 
anti-S antibodies likely protecting against reinfection, as shown by examples of 
protection of individuals at high risk of exposure from reinfection in outbreaks,93 in 
healthcare workers,212 and in vaccine studies with non-human primates,213 which 
suggests these antibodies have an important functional role in immunity. Estimating 




of NAbs from the first time-point window and the last (88% and 92% respectively), 
illustrating that for at least 10-12 months post-infection, the majority of individuals retain 
functional antibodies, even in those without severe disease since all but one of the 
samples in the last time-point window were from non-hospitalised individuals.3  
Interestingly, approximately 27% of the participants who had a sample in the first 
and last time-point window, showed an increase in NAb concentration by the last time-
point, which could be due to affinity maturation of B cells during the immune response 
to SARS-CoV-2.100 An increase in NAbs in some individuals has been reported by 
others,214,215 but in some of the studies they could not be certain the increase was not due 
to re-exposure to the virus; but even so, if that was the case, it shows the immune system 
still responds to the virus.215 In contrast, other studies have reported that NAbs decline 
after an initial increase,67,68 including one study where 93% of the COVID-19 patients 
they investigated had a decrease in NAb concentration over a three month period.68 My 
study assessed NAbs over a much longer period, demonstrating that in some individuals, 
NAbs can increase after an initial decrease, any months post-infection. There appeared 
to be a subset of participants whose NAb levels increased, a subset whose were relatively 
maintained, and a subset whose NAb levels declined.  
Other studies have shown that individuals with asymptomatic or mild disease 
appear to have more rapidly declining NAbs than those with severe disease.97,214 My 
results did not show this, although there were few with severe disease. In Chapter 3, I 
reported a small but significant difference in NAb concentrations in individuals with 
moderate-to-severe symptoms, compared to those with asymptomatic/mild symptoms, 
using the first time-point samples. This might be due to individuals with severe disease 
producing more antibodies due to a stronger immune response from greater stimulation 
of B-cells, and more long-lived plasma cells being produced.216 However, my 
longitudinal data shows that from the second time-point window onwards (21-30 weeks 
post-onset of symptoms) there was no longer a difference between these severity groups. 
This should be investigated further, using more well-defined disease severity groups with 
more severe cases than included in this study (there was only one participant with severe 
symptoms in the last time-point window). 
A bi-modal distribution was noted in the NAb levels in samples in the third and 




disease severity levels, ages, and sex, in samples from the last time-point window did not 
show any significant difference, but there was a slight but significant difference in the 
levels of NAbs in the last time-point window based upon the levels of NAbs in the first 
time-point window, so perhaps individuals who produce a robust immune response early 
on are able to increase their NAb response as time goes on. The reasons for the 
differences in NAb kinetics remain incompletely explained, but because the majority the 
participants in this part of the study only had mild/asymptomatic to moderate infection, 
disease severity could still play a role (as shown in other studies).100,217 Other reasons for 
differences in NAb kinetics could be due to differences in T cell responses (including if 
some participants had past exposure to other human CoVs). The longitudinal kinetics for 
NAbs appears to be complicated and should be further assessed with additional 
longitudinal data, using well defined sample cohorts and comparison should also be made 
with cVNT and pVNT assays. 
The antibody response is not the only component of the immune response to 
SARS-CoV-2 infection, with T cell responses playing an important role.99,102 Also, while 
antibody levels may drop over time, they will likely be boosted upon re-exposure 
(including vaccination) by memory B cells.89,218 I was able to test two of the PCR-
confirmed participants after they had received their Pfizer-BioNTech SARS-CoV-2 
vaccinations, and found that vaccination induced a much higher immune response than 
natural infection, which has been reported by others.219,220 Also, as seen by the decline in 
anti-S antibodies in these participants, it was clear that individuals with natural infection 
should be vaccinated to reduce the risk of reinfection of SARS-CoV-2. 
A key question is how long will immunity to SARS-CoV-2 last? The true answer 
to this may not be made clear for years, but estimates can be made by estimating antibody 
half-life using antibody decay curves and extrapolating the data to estimate when the 
antibody level will fall below a level considered not to be protective against reinfection 
(yet to be determined). In order to get a more accurate estimate, this should be done using 
NAbs, as although they have not been proven as a correlate of protection, they are thought 
to have a functional role in SARS-CoV-2 immunity.86 Antibody half-life modelling is 
not straightforward. Others have predicted SARS-CoV-2 NAbs follow a biphasic decay 
model,86,221-223 with an initial growth period after infection, followed by a rapid decay, 




which suggests the NAb response may be long-lived.221 I did not perform half-life 
estimation because it was not suitable to apply these models to my data as it is missing 
samples from the important early time-points. Additionally, the decay rate may be 
correlated to disease severity,221 and my data set had a limited number of participants 
with severe disease. However, my collaborators at the University of Auckland did 
incorporate some of my time-point samples in their estimations of NAb half-life and had 
the finding of a biphasic growth and decay model as described above.86,221 
6.3.3 Antibodies in the seropositive higher-risk participants 
The time since infection for the seropositive higher-risk participants could not be 
ascertained, therefore, these results were analysed separately from the PCR-confirmed 
cases. The results for the true seropositive participants demonstrated the same pattern as 
the PCR-confirmed cases, with declining anti-N antibodies and relatively stable anti-S 
antibodies, but interestingly, two higher-risk participants who were suspected of having 
false positive results on the Abbott Architect (due to testing negative on five serological 
assays), showed no decrease in anti-N antibodies level over time, which supports the 
notion they were false positive results. Repeat testing of a sample over time may suggest 
false positivity if the level remains stable (if a secondary assay is not available).  
6.3.4 Antibody levels in individuals post-infection, post-vaccination 
The two PCR-confirmed participants tested on the Abbott Alinity assay before 
and after they received their Pfizer-BioNTech SARS-CoV-2 vaccinations showed the 
anti-S IgG antibody levels of both participants pre-vaccination were positive, but 
relatively low, but after one dose of the vaccine the levels increased substantially. 
However, the second vaccine dose did not appear to offer a substantial benefit over a 
single dose. This is similar to other reports, including one study investigating antibody 
response post-vaccination with the Pfizer-BioNTech vaccine, using the Abbott anti-spike 
IgG assay (essentially the same assay as the Abbott Alinity assay), which demonstrated 
individuals with prior infection had a similar antibody response after a single dose as 
compared to infection-naïve individuals after two doses, and suggested a single dose is 
sufficient for those with prior infection.224 The Abbott Alinity kit insert estimates that a 
SARS-CoV-2 IgG concentration of approximately 4000 AU/mL corresponds to a 95% 
probability of having high levels of NAbs (which is stated as a PRNT50 titre of 1:250).
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Alinity assay during the first time-point window (3-4 months post-infection) (Figure 6.2) 
and demonstrates vaccination would be useful to those post-infection. However, it should 
again be noted that protection does not just rely on the antibody response, and but also 
includes other components (e.g. T cells).99,102 
6.3.5 Limitations 
This study does have some limitations. Firstly, the baseline antibody levels for 
the participants could not be obtained, with the first time-point being approximately 3-4 
months post-onset of symptoms. Due to the logistics of blood collection and differences 
in disease onset between participants, I was not able to get blood samples from every 
patient in every time-point window, but I attempted to mitigate this by using rolling time-
point windows, however, there were still not equal numbers in all time-point windows. 
Also, very few of the participants had a severe infection, which may have affected the 
analysis of antibody level versus disease severity. I was unable to test the samples on all 
the assays I investigated in the earlier parts of our study (due to financial constraints and 
logistics) but it would have been interesting to test these samples on another N-based 
assay (such as the Roche pan-Ig assay, or even better, an IgG-only N-based assay), as 
these assays might have different antibody kinetics. However, my collaborators at the 
University of Auckland did test the majority of my time-point samples an in-house 
multiplex assay which included anti-N IgG antibodies and found similar results to mine.86 
Also, while the sVNT assay estimates NAbs, it would also be prudent to test such samples 
using a cVNT, or at least a pVNT to more accurately estimate NAbs. Lastly, all 
participants had naturally acquired antibodies, but the longitudinal kinetics of vaccine-
induced antibodies could be different (especially if prior infection) and should be 
investigated. 
6.4 Conclusions 
Anti-N SARS-CoV-2 IgG antibodies as measured by the Abbott Architect appear 
to decline significantly faster than anti-S IgG antibodies and NAbs, which are relatively 
stable up to at least 10-12 months post-infection, even with only mild-to-moderate 
infection. This study is unique as the participants were from a population where there 
was essentially no risk of re-exposure to the virus, owing to the effective public health 
response to the outbreak in NZ and vaccination had not yet commenced, therefore there 









Chapter 7: Establishment of an in-house SARS-
CoV-2 pseudovirus neutralisation test 
7.1 Introduction 
It is important to measure SARS-CoV-2 NAbs as it is likely that they are an 
immune correlate of protection.225 NAbs appear to correlate with immunity, however, the 
NAbs themselves may not necessarily be the sole reason for providing protection but 
they may correlate with other protective functions.225 Therefore measuring NAbs may 
provide a useful way to estimate the level of immunity post-infection or post-vaccination. 
ELISA and automated BAb assays are high throughput, but the results may not 
always correlate with the gold standard conventional VNT (cVNT) methods for 
measuring NAbs.160 However, cVNT methods (as described in Chapter 1) are very 
laborious and dangerous as they use live virus, requiring a BSL3 containment facility. 
The pVNT is safer because it uses a viral vector, genetically modified to be replication 
incompetent, but it is still a laborious method and requires a BSL2 laboratory. In the 
earlier aims of my research the sVNT assay was used to estimate NAbs because the sVNT 
is a simple, fast, and safe method.122  
The original aim was to establish an in-house pVNT assay and subsequently use 
the assay to test a subset of the pre-pandemic antenatal samples to assess specificity, and 
all the PCR-confirmed cases to assess sensitivity, and correlate the results with the sVNT, 
to verify the suitability of the sVNT assay to estimate NAbs. However, as previously 
mentioned, due to time constraints and other events out of my control, I was unable to 
complete this. The optimisation of the pVNT is ongoing at the Ussher Laboratory at the 
University of Otago. This chapter briefly describes the results of the setup, initial 
optimisation and results of several samples, of a lentiviral pseudovirus assay for testing 








7.2.1 Production of a HEK-293T-ACE2 cell line 
As described in Chapter 2, HEK-293T cells were transfected with the pcDNA3.1 
ACE2 plasmid, which encodes human ACE2, to create a HEK-293T-ACE2 stable cell 
line, which would allow lentivirus pseudotyped with the spike protein of SARS-CoV-2 
entry into the cells. This plasmid also encodes the gene for red fluorescent protein (RFP), 
which allowed the success of transfection to be monitored by fluorescent microscopy. 
Figure 7.1 shows the fluorescent microscopy of the transfected cells, after sorting on a 
FACS Aria to increase the yield of HEK-293T ACE2 expressing cells. This demonstrated 
that approximately 90% of the HEK-293T cells were successfully transfected.  
A   B   
C  
Figure 7.1: Transfection of HEK-293T cells with pcDNA3.1 ACE2. Olympus IX71 Microscope. 
Magnification 10X. Scale bar: 50 µm. A). Bright-field view (all cells). B) Red fluoresence protein (RFP; 
excitation 558 nm, emission 583 nm), demonstrating approximately 90% of the cells were expressing 
RFP, which is also encoded by pcDNA3.1 ACE2. C) Green fluorescence protein (GFP; excitation 475 
nm, emission 509 nm) expression, showing only background signal (as this was prior to pseudovirus 
infection). 
7.2.2 Replication of SARS-CoV-2 pseudovirus in HEK-293T-ACE2 cells 
The pseudovirus was produced by co-transfecting HEK-293T cells with three 
plasmids as previously described (Chapter 2). One of the plasmids encoded the lentiviral 




green fluorescent protein (GFP), which allowed the monitoring of the infection of HEK-
293T-ACE2 cells by fluorescent microscopy. Figure 7.2 shows the fluorescent 
microscopy of the infected cells 24 hours post-transfection, which demonstrated that the 
pseudovirus had infected approximately 30% of the total cells. 
A    B  
C    D  
Figure 7.2: SARS-CoV-2 pseudovirus is able to infect HEK-293T-ACE2 cells. Olympus IX71 
Microscope. Magnification 20X. Scale bar: 100 µm. A). Bright-field view (all cells). B) Red fluoresence 
protein RFP; (excitation 558 nm, emission 583 nm) expression, demonstrating cells expressing RFP and 
presumed to express ACE2. C) Green fluorescence protein (GFP; excitation 475 nm, emission 509 nm) 
expression, demonstrating approximately 30% of the cells were infected with pseudovirus. D) Images C 
and D merged, showing not all the HEK-293T-ACE2 expressing cells were infected with pseudovirus. 
7.2.3 Serum:virus matrix pVNT 
To determine which dilution of pseudovirus and which dilutions of sera would be 
appropriate for the pVNT assay, a serum:virus matrix pVNT assay was performed. A 
serum with a likely high NAb concentration (94% on the sVNT assay) was tested at 
multiple dilutions, each with various dilutions of pseudovirus. A titration of the 
pseudovirus in the absence of sera was also performed on the same plate, using the same 
dilutions (Figure 7.3A). Others have suggested a pseudovirus concentration of 1x106 
RLU/mL is necessary for a pVNT assay.121 The neat pseudovirus stock concentration 
was determined to be 1.1x106 RLU/mL, calculated by multiplying the 5500 RLU 
(detected on the 1:5 pseudovirus dilution) by 5, then by 2 (1:2 dilution with cells), then 




deemed suitable. Additionally, as seen in Figure 7.3A, the 1:5 dilution through to the 
1:25 dilution of pseudovirus stock showed an approximately linear relationship between 
the pseudovirus concentration and RLU. Figure 7.3B shows that an initial 1:10 dilution 
of serum would be suitable if using a 1:5 pseudovirus dilution.  
 
Figure 7.3: Results from the serum:virus matrix pVNT. A) Initial titration curve of the pseudovirus. 
The x-axis shows the dilutions of the pseudovirus. The y-axis shows the luciferase activity (measured in 
RLU). B) Pseudovirus inhibition at various pseudovirus concentrations and various dilutions of a serum 
sample. The x-axis shows the dilutions of the serum. The y-axis shows the luciferase activity (measured 




7.2.4 Pseudovirus titrations 
A pseudovirus titration was included on each batch of pVNT assay. The 
pseudovirus titrations from each batch are shown in (Figure 7.4). There were large 
variations in RLU values between the batches. A value of >5000 RLU for the initial 
pseudovirus dilution (1:5) was desired, but this could not be achieved with some of the 
batches. However, some of the sera RLU values within the same batch were greater than 
the 1:5 pseudovirus dilution without serum, demonstrating technical issues with the 
assay. 
 
Figure 7.4: Pseudovirus titration curves for pseudovirus batches. Graph titles indicate the batch 
name. The x-axis shows the dilution of the pseudovirus. The y-axis shows the luciferase activity 
(measured in RLU). 
7.2.5 Neutralisation assays 
Refer to Chapter 2 for the description of the set-up of the pVNT assay. Refer to 
Table S8, Appendix C for the raw values. Non-linear regression curves (inhibitor vs 
response) were generated for each sample run on the four pVNT batches performed 




(the highest dilution factor that still yields a positive result, which is considered >50% 
inhibition of the pseudovirus). The curve was also used to calculate the 50% inhibitory 
concentration of infection (IC50)  
There was poor precision between some of the sample replicates and numerous 
outliers, as seen in the raw values (Table S8, Appendix C). Some of the pre-pandemic 
antenatal samples had RLUs that were close to 50% inhibition at some of the dilutions 
(samples ANS-10 and ANS-13). Regardless, the results of all the pre-pandemic antenatal 
sera (n=7) (Figure 7.5A) were negative and the results of all the PCR-confirmed cases 






Figure 7.5: Neutralisation assays. Non-linear regression (inhibitor vs response curve) was used to plot 
the results (solid lines). The open circles represent the actual inhibition values. Negative values were set 
to zero. The x-axis shows the dilutions of the sera (final titre, which was the initial serum dilution 
multiplied by 4 to account for the dilution with the pseudovirus and cells). The y-axis shows the 
percentage of inhibition of the pseudovirus (1 – [RLU serum dilution/RLU 1:5 pseudovirus dilution] x 
100). The horizontal dashed line represents 50% inhibition of the pseudovirus, above which the sera is 
considered to be positive for NAbs. A) Neutralisation assay using pre-pandemic antenatal sera (n=7). B) 
Neutralisation assay using sera from PCR-confirmed SARS-CoV-2 cases (n=8). Note: samples PCR-
Confirmed-46 and PCR-Confirmed-74 were run on batches where the dilutions used were different from 




The reciprocal IC50 values (representing the sera titres) were used to assess the 
correlation between the pVNT and sVNT (Figure 7.6). The assays had good degree of 
correlation, using the few samples tested, with a Pearson’s correlation coefficient of 
0.867 and r2 of 0.752. 
 
Figure 7.6: Correlation of pVNT NAb titres and sVNT NAb levels. Pre-pandemic antenatal sera 
(n=7) and PCR-confirmed sera (n=8). The x-axis shows the pVNT titre (calculated from the reciprocal 
value of the IC50 as calculated from the non-linear regression curve in Figure 7.5). The dotted horizontal 
line represents the positivity threshold for the sVNT assay. Vertical lines represent the sera dilutions used 
in the pVNT. 
7.3 Discussion 
On the whole, the in-house pVNT assay established worked, but there were many 
RLU values in the most batches that were unsatisfactory, with poor precision between 
replicates, and outliers. There did not appear to be a pattern to the variations, suggesting 
it may be due to pipetting errors, however, with subsequent batches it became clear there 
were other reasons for the poor results. Troubleshooting indicated an issue with the 
seeding of the cell line and further optimisation of the pVNT assay will be required before 




There were challenges with establishing the protocol. While there were numerous 
publications to refer to,118,121,160 they all differed slightly (different plasmids, cell lines, 
dilutions, and incubation lengths, etc), therefore it was difficult to know what protocol to 
begin with. This part of the study has shown me that it takes time to optimise a new 
method, as well as getting familiar with performing new techniques. 
Despite many outliers in the results, the pVNT correlated well with the sVNT. 
The creators of the sVNT assay compared the sVNT to both a cVNT and pVNT and 
found all three had an overall good correlation, with the sVNT/cVNT combination 
having a slightly better correlation than the sVNT/pVNT or cVNT/pVNT combination.95 
The pVNT and sVNT overcome the issues of safety that come with cVNTs, but the pVNT 
and sVNT only provide an estimate of authentic virus neutralisation as they only detect 
specific NAbs (anti-S and anti-RBD antibodies respectively), however, these antibodies 
are still a good marker to estimate NAbs.95,117 The PRNT and pVNT may also give 
heterogeneous results in different laboratories due to the use of different pseudovirus 
strains, cell culture conditions, and cell lines, and the technical nature may result in 
further variation and imprecision between assays.117 To make the results comparable 
between laboratories, it would be important to fix the pseudovirus dose.121 
The main purpose of assessing the pVNT was to validate the sVNT, which was 
used for the majority of the NAb testing in my study, which it appeared to do. The sVNT 
was the most suitable assay to measure NAbs because of its safety, efficiency, and ability 
to be standardised scaled for high throughput testing.122 
7.3.1 Limitations and further research 
Initially, only three samples were performed on each batch and quality control 
samples were not included. It would be preferable to run a serum sample with a known 
pVNT titre with each batch to assess the accuracy and precision of the assay. However, 
the pseudovirus titration acted as an internal positive control.  
Numerous SARS-CoV-2 variants have emerged since the start of the pandemic. 
The NAbs produced by individuals infected with the initial variant may not be protective 
against the new variants. Therefore, additional pVNT assays using spike proteins from 





The results demonstrate that the pVNT assay requires further optimisation. Issues 
that arose during the set-up of the pVNT were likely a combination of issues with 
technique and with assay components. It demonstrates there are many variables in the 
pVNT protocol that can introduce error into the results. But overall the results 
demonstrated the pVNT correlates well with the sVNT, further validating the use of the 





Chapter 8: Concluding Remarks 
Initially, my main research question was: were any COVID-19 cases missed in 
the Southern DHB region of NZ during the initial outbreak, due to limited PCR testing 
and/or asymptomatic infection? Serological testing of individuals at higher-risk of having 
COVID-19 was undertaken to attempt to answer this question. However, the data on the 
clinical performance of these very new assays were very limited, therefore first I needed 
to assess the clinical performance of the serological assays. Further assays became 
available and they were also assessed. The opportunity was also taken to collect 
additional samples from the PCR-confirmed cases to analyse the longitudinal dynamics 
of SARS-CoV-2 antibodies. Thus, the simple serosurvey study evolved into an extensive 
study of SARS-CoV-2 antibodies. When I started this research there was little knowledge 
about SARS-CoV-2 antibodies, but every day new literature was being published. This 
meant that by the time I finished, there were similar studies already published. But my 
study had some unique findings and did consolidate the findings of others, and has been 
used to guide SARS-CoV-2 serology testing and reporting in the clinical laboratory 
where I work.  
Although my research was extensive, each aim built on the results from the 
previous aims. One of the main findings from my study was that the Abbott Architect N-
based assay had poor sensitivity when the time since infection has been many months 
and that S-based assays generally performed better than N-based assays, however, the 
finding that the Roche N-based pan-Ig assay had the highest sensitivity complicated this 
statement. The results demonstrated SARS-CoV-2 IgG antibodies tested on different 
assays using different antigen targets and different assay formats, as well as the different 
clinical characteristics of the testing cohort (including time since infection and disease 
severity) can give rise to varying results. This highlights the need to choose an assay 
appropriate for the testing purpose and to consider adjusting the assay threshold and/or 
use an orthogonal testing algorithm. This is what we did for the Abbott Architect 
screening assay for our serosurvey of higher-risk participants. In hindsight, the Abbott 
Architect assay was not the most appropriate assay to use as the screening test for our 
serosurvey, but we reduced the assay threshold and tested any samples above this 




both false positives and false negatives in our serosurvey. The answer to whether any 
cases were missed in the Southern DHB region is very few, despite the PCR testing 
restrictions. Of the 1127 higher-risk participants tested, nine previously undiagnosed 
seropositive individuals were identified, all of whom had epidemiological risk factors, 
with the majority of these individuals likely infected overseas. These results support the 
elimination status of the country at the time this study was conducted. An interesting 
finding was that the majority of those diagnosed as probable cases likely did not have 
COVID-19 infection, even though they had close contact with known cases, which 
highlights the potential role of serology in the diagnostic algorithm where PCR is 
negative despite symptoms and epidemiological risks. 
The antibody persistence study further consolidated the findings of the clinical 
performance data - that anti-N antibodies appear to decline significantly faster than anti-
S antibodies, and that NAbs are relatively stable (up to at least 10-12 months post-
infection, even with only mild-to-moderate infection). Importantly, in this study there 
was a very low probability that the PCR-confirmed cases had immune boosting from re-
exposure, thus the antibody responses measured can be attributed to the initial exposure, 
which is likely a unique situation, given the widespread infection in many other countries. 
While only a small comparison of NAb measurement by sVNT and pVNT was 
completed, the correlation appeared to be good and showed that the quick, easy and safe 
sVNT method was an appropriate choice of assay to estimate NAbs in the samples in my 
study. The pVNT was found to be time-consuming and laborious, requiring special 
handling techniques, technical experience, and extensive optimisation to set up, and the 
procedure includes many variables that could introduce inaccuracy and imprecision in 
the results. 
My results show is that there is much heterogeneity in the humoral immune 
response to SARS-CoV-2 and in the results of serological assays, particularly when using 
different assay formats. Further research is needed, to understand the longer-term kinetics 
of these antibodies (both post-infection and post-vaccination) and particularly in relation 
to new emerging variants and any new serological assays being developed, and whether 
these antibodies are an immune correlate of protection. The research I have performed is 
important in these unique times and I am proud to have been part of the scientific 
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Summary
During New Zealand’s first outbreak in early 2020 the
Southern Region had the highest per capita SARS-CoV-2
infection rate. Polymerase chain reaction (PCR) testing
was initially limited by a narrow case definition and limited
laboratory capacity, and cases may have been missed.
Our objectives were to evaluate the Abbott SARS-CoV-2
IgG nucleocapsid assay, alongside spike-based assays,
and to determine the frequency of antibodies among PCR-
confirmed and probable cases, and higher risk individuals
in the Southern Region of New Zealand.
Pre-pandemic sera (n=300) were used to establish assay
specificity and sera from PCR-confirmed SARS-CoV-2
patients (n=78) to establish sensitivity. For prevalence
analysis, all samples (n=1214) were tested on the Abbott
assay, and all PCR-confirmed cases (n=78), probable
cases (n=9), and higher risk individuals with ‘grey-zone’
(n=14) or positive results (n=11) were tested on four
additional SARS-CoV-2 serological assays.
The median time from infection onset to serum collection
for PCR-confirmed cases was 14 weeks (range 11–17
weeks). The Abbott assay demonstrated a specificity of
99.7% (95% CI 98.2–99.99%) and a sensitivity of 76.9%
(95% CI 66.0–85.7%). Spike-based assays demonstrated
superior sensitivity ranging 89.7–94.9%. Nine previously
undiagnosed sero-positive individuals were identified, and
all had epidemiological risk factors.
Spike-based assays demonstrated higher sensitivity than
the Abbott IgG assay, likely due to temporal differences in
antibody persistence. No unexpected SARS-CoV-2 in-
fections were found in the Southern Region of New
Zealand, supporting the elimination status of the country at
the time this study was conducted.
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INTRODUCTION
The novel virus Severe Acute Respiratory Syndrome Coro-
navirus 2 (SARS-CoV-2) and the disease it causes, COVID-
19, were first detected in Wuhan, China in December 2019.1
The World Health Organization (WHO) declared COVID-19
a public health emergency of international concern on 30
January 2020, and a pandemic on 11 March 2020.2 As of 8
February 2021, there have been over 106 million confirmed
COVID-19 cases worldwide, with over 2.3 million deaths.3
During New Zealand’s (NZ) first outbreak of COVID-19
(28 February to 22 May 2020) a total of 1154 polymerase
chain reaction (PCR)-confirmed and 350 ‘probable’ (symp-
tomatic household contacts of PCR-positive cases who had
negative PCR testing) cases were identified with 22 COVID-
19 related deaths.4
NZ initially responded to the pandemic in early February
2020 by stopping foreign nationals from affected countries
entering NZ and enforcing self-isolation for NZ citizens and
permanent residents travelling from these countries.5 On 21
March 2020, a four-tier alert system was introduced; the
country started in Level 2, and quickly moved to the highest
alert Level 4 restrictions on 26 March.5 Alert Level 4 is a
national lockdown with a strict stay at home order for all but
essential workers.6 NZ remained at Alert Level 4 for
approximately 5 weeks before a stepped de-escalation to
Alert Level 1 on 8 June 2020.5
This serological study is focused on the Southern District
Health Board (SDHB) region in NZ which had the largest
number of cases per capita during the first outbreak of
COVID-19 (216 total cases; ~66/100,000 population),
significantly higher than the national average (~30/100,000).4
This region also includes the tourism hub of Queenstown,
where community transmission took place. PCR testing for
SARS-CoV-2 was initially restricted during the first outbreak
in NZ due to a narrow case definition and limited access to
diagnostic reagents.
Reverse transcription-PCR (RT-PCR, henceforth referred
to as PCR) from a nasopharyngeal and/or oropharyngeal swab
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or lower respiratory tract sample is the gold standard method
for detecting acute SARS-CoV-2 infection whereas serolog-
ical tests can provide information on past infection, including
where patients have been symptomatic for some time and are
PCR negative.7 SARS-CoV-2 has four structural proteins:
Spike (S), Membrane (M), Envelope (E), and Nucleocapsid
(N), with the majority of the serological assays developed to
detect antibodies against the S and/or N protein.7 Differing
degrees of protein sequence conservation between the N and S
proteins [including S1 and receptor binding domains (RBD)],
and proteins from other coronavirus species, together with
differences in the magnitude and kinetics of the antibody
response to these antigens may impact assay performance.8
Several serological assays are now commercially available,
including for use on high-throughput, random access analy-
sers such as the Abbott Architect.
The aims of this study were threefold. Firstly, to investi-
gate the sensitivity and specificity of the Abbott Architect
SARS-CoV-2 IgG assay based on the N-protein, together
with a series of plate-based assays that utilise the S protein
and/or S protein domains, including a surrogate viral
neutralisation assay. Secondly, to determine the frequency of
SARS-CoV-2 IgG antibodies among higher risk individuals
in the Southern Region of NZ to determine whether cases
were missed during the outbreak due to limited PCR testing
and/or asymptomatic infection. The third aim was to use
serological testing to assess the likelihood of infection among
those diagnosed as ‘probable’ cases.
MATERIALS AND METHODS
Study protocol
This study was performed at Southern Community Laboratories, Dunedin,
NZ, in conjunction with the Southern District Health Board (SDHB), Well-
South (the local primary healthcare organisation), University of Otago,
University of Auckland, and the Institute of Environmental Science and
Research (ESR). Ethical approval for this project was obtained from the NZ
Health and Disability Ethics (HDEC) Committee (20/NTB/101).
Patient cohorts
In total 1214 individuals gave informed consent and participated in the study,
with bloods collected between 4 June and 4 August 2020, 4–10 weeks after
active transmission in the community in the Southern Region ceased. Of
these, 78 were PCR-confirmed cases, nine were probable cases, and 1127
individuals were in the higher risk group.
Case definitions
Confirmed and probable cases were classified according to the NZMinistry of
Health (MoH) guidelines. Confirmed cases were positive by PCR; probable
cases were PCR negative, a household contact of a confirmed case, and had a
clinically compatible illness with other causes excluded.9 COVID-19
consistent symptoms were defined by the MoH as any acute respiratory
infection with at least one of the following symptoms (with or without fever):
new or worsening cough, sore throat, shortness of breath, coryza, anosmia.10
The higher risk group was considered to be of higher risk than the general
population of having undiagnosed COVID-19 infection, either by contact with
a PCR-confirmed case or because of workplace duties (frontline healthcare
workers, tourism workers), or were Queenstown residents. While some of the
higher risk group may appear to fit the definition of a probable case, they were
not under public health management and therefore were not categorised as
probable cases; their contact and symptoms were self-identified retrospectively.
The severity of COVID-19 infection in the PCR-confirmed group were
classified on the basis of their symptoms and the level of hospital care pro-
vided: 1, asymptomatic to mild cold-like symptoms (n=35); 2, moderate:
cough, fever and chills (n=39); 3, moderately severe: admitted for assessment
(n=3); 4, severe: admitted and given supplemental oxygen therapy (n=1); 5,
critical: admitted to ICU (n=0).
To determine assay specificity, 300 de-identified antenatal sera collected
from early-mid 2019 (pre-pandemic), were used (after being stored at –20oC
for up to 12 months as per laboratory protocols). To determine sensitivity,
samples from the 78 PCR-confirmed cases were used.
The PCR-confirmed and probable cases, and their contacts were contacted
for recruitment via the local public health unit. The remaining higher risk
individuals were recruited via posters and media (print, television, and social
media). Participants completed a Research Electronic Data Capture
(REDCap) online survey.11 The questionnaire included demographic details
and a set of questions, including which higher risk category they associated
with, if they had any contact with known COVID-19 cases, and whether they
recalled having symptoms consistent with COVID-19 before or during the
lockdown period (alert Level 3 and 4, between 23 March and 12 May 2020)
(Table 1).
PCR assays
Participants who had PCR testing were tested using one of four assays that
were in use during the first outbreak, all performed at SCL Dunedin: (1) an in-
house real time RT-PCR assay targeting the E-gene based on the Drosten
assay12 and implemented on the open access channel of the Hologic Panther
Fusion (Hologic, USA); (2) a multiplex tandem real-time RT-PCR SARS-
CoV-2, Influenza, and RSV (8-well) assay (AusDiagnostics, Australia); (3)
TaqPath COVID-19 Combo assay (ThermoFisher Scientific, USA), a multi-
plex real-time RT-PCR; and (4) the Aptima SARS-CoV-2 Assay (Hologic), a
transcription mediated amplification assay.
Serological assays
A summary of the assays utilised is shown in Table 2. The primary assay was
the Abbott Architect SARS-CoV-2 IgG chemiluminescent microparticle
immunoassay (CMIA; Abbott, USA), which uses recombinant N protein
coated microparticles. Samples were analysed on the Abbott Architect
i2000SR Immunoassay Analyzer following manufacturer’s instructions. Test
performance for the Abbott assay was assessed using the manufacturer’s cut-
off for positivity (1.4 S/C).
The in house two-step ELISA was adapted from published protocols13 as
described.14 In step one, serum diluted 1:100 was screened against RBD, with
IgG binding detected with a peroxidase-labelled anti-human IgG secondary.
Samples with an optical density (OD, 450–570 nm) above the cut-off (>0.2)
were titrated in a 3-fold dilution series against the S protein in step two and
considered positive if they had an OD>0.2 in at least two consecutive wells in
the confirmatory S protein ELISA; the result was reported as the highest titre
above the cut-off (>0.2).
The Wantai SARS-CoV-2 ELISA (Beijing Wantai Biological Pharmacy
Enterprise, China) measures total antibody (IgA, IgG and IgM) against the
RBD of the S protein. The Euroimmun SARS-CoV-2 IgG ELISA (Euro-
immun Medizinische Labordiagnostika, Germany) measures IgG antibodies
against the spike S1 subunit. The Wantai and the Eurommun ELISAs were
performed according to the manufacturer’s instructions.
The cPass surrogate viral neutralisation test (sVNT) (GenScript, New
Jersey, USA) measures the presence of neutralising antibodies that are
capable of blocking the interaction between RBD and hACE215 and was
performed according to the manufacturer’s instructions. Samples with a
percentage inhibition 20% were defined as having neutralising antibodies.
To assess cross-reactivity of the antenatal sera (n=300) with other human
coronaviruses (HCoV), ELISA were performed using S1 antigens from the
HKU1, NL63, and SARS-CoV-2 (Sino Biological, China) at a 1:300 sera
dilution as described.11
Testing protocol
The 300 specificity samples and the serum from PCR-confirmed and
probable cases were tested on all five assays. All sera from the higher risk
group (n=1127) were tested on the Abbott assay. Samples from the higher
risk group that classified as positive (1.4 S/C), or as negative but 0.5
S/C [i.e., 0.5–1.39 S/C, defined as the ‘grey-zone’ on the basis of a
receiver operating characteristic (ROC) curve] were tested on all assays
(n=25).
646 CRAIGIE et al. Pathology (2021), 53(5), August
Statistical analysis
Statistical analysis, including ROC curve, was performed using Prism 8
(GraphPad, USA) or R (version 3.6.3) within R Studio (version 1.2.5033); a p
value of 0.05 was considered statistically significant. To assess sensitivity,
serological assays were compared against PCR diagnosed COVID-19.
Equivocal results were considered negative for the statistical analyses. For
the higher risk group, true sero-positivity was defined as positivity in two or
more of the five assays. False positivity was defined as positivity in only one
of the five assays.
RESULTS
Participant characteristics
As shown in Table 1, the median age of the mostly female
(75%) participants was 46 years (range 4–90 years). Of the
1127 higher risk participants, 37% had had a PCR test (all
negative), 62% self-identified as frontline healthcare workers
in the SDHB region, and 41% retrospectively reported one or
more symptoms consistent with COVID-19 in the two weeks
leading up to and during the February–May 2020 COVID-19
outbreak. For the PCR-confirmed and probable cases, the
median time of symptom onset to serology specimen
collection was 14 weeks (range 11–17 weeks).
Assay performance
The overall performance of the assays is summarised in
Table 3. Specificity was high across all assays ranging from
99.3% [95% confidence interval (CI) 97.6–99.9%] to 100%
(95% CI 98.8–100.0%) (Supplementary Tables 1–4,
Appendix A). The antenatal sera used to determine specificity
showed broad reactivity with S1 protein antigens from HCoV
(HKU1 and NL63), but not SARS-CoV-2 (Supplementary
Fig. 1, Appendix A).
Sensitivity ranged from 76.9% (95% CI 66.0–85.7%) for
the Abbott assay, to 94.9% (95% CI 87.4–98.6%) for the
Wantai assay (Fig. 1, Table 3). Eighteen of the 78 (23.1%)
PCR-confirmed cases tested negative on the Abbott
(Supplementary Table 2, Appendix A). The raw values for
these ranged from 0.14–1.39 S/C. Eleven of these were
positive on three or more of the other assays, four were
positive on two of the other assays, one was positive on one
of the other assays, and two were negative on all the other
assays.
The sensitivity of the Abbott assay was unexpectedly low
and prompted a ROC analysis that showed a cut-off of 0.55 S/
C could achieve much greater sensitivity (93.6%) without a
significant loss in specificity (98.7%) (Supplementary Fig. 2,
Appendix A). Therefore, a grey-zone approach was utilised
for analysis of the higher risk group to rule out potential false
negatives. Any samples that fell between 0.5–1.39 S/C were
measured on the other four assays.
Neutralising anti-SARS-CoV-2 antibodies
The sVNT assay was used to assess the presence of
neutralising antibodies (NAbs). For the PCR-confirmed
group, 88.5% (69/78) had detectable NAbs (Supplementary
Table 2, Appendix A), illustrating the majority of in-
dividuals retain functional antibodies for at least 3 months
post-infection. When the PCR-confirmed patients were
stratified by disease severity, there was a small but significant
increase in the level of NAbs in those with more severe
disease (p<0.05) (Supplementary Table 3, Appendix A).
Antibody detection among higher risk individuals
Eleven individuals of the higher risk group (0.98%) had
positive results on the Abbott assay (Fig. 1). Eight of these
were also positive on one or more of the other four assays,
indicating true sero-positivity. Three Abbott positive results
were therefore considered false positives as they were nega-
tive on all four other assays. There were 14 Abbott results that
fell in the grey-zone (0.5–1.39 S/C). Thirteen (93%) were
negative on all four other assays and classified as seronega-
tive. One individual was positive on all four other assays
(with travel history and symptoms) and considered sero-
positive (Supplementary Fig. 3, Appendix A).
Thus, in total we detected nine additional possible COVID-
19 infections; one was a PCR-confirmed case diagnosed
outside of the Southern Region; six had consistent travel
history (Western Europe/UK) and symptoms; and two were
close contacts of PCR-confirmed cases reporting consistent
symptoms.
Estimation of actual prevalence in the higher risk group
We detected 9/1127 (0.8%) sero-positive individuals in the
higher risk group but to estimate the true number of cases of
infection that may have been missed, we conducted the
following statistical analyses to assess the reliability of this
estimate. The Rogan–Gladen estimator16 allowed us to es-
timate the prevalence in the higher-risk group, taking into
account the uncertainties in the sensitivity and specificity of
the test. Using the Abbott assay with a threshold of 1.4 S/C,
the estimated prevalence in the higher-risk group is 0.8%
Table 1 Patient demographics
Total PCR-confirmed cases Probable cases Higher risk group
Total 1214 (100%) 78 (6%) 9 (1%) 1127 (93%)
Age, years
Median 46 51 49 46
Range 4–90 17–81 10–59 4–90
Gender
M/F 306/908 32/46 3/6 271/856
Higher-risk group category
Frontline healthcare workers 702 (62%)
Tourism worker 60 (5%)
Queenstown resident 208 (19%)
One or more COVID-19 consistent symptoms reported 466 (41%)
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(95% CI 0.0–2.0%). Using the Abbott assay with a threshold
of 0.5 S/C, the estimated prevalence is 2.0% (95% CI
0.8–3.2%). To incorporate the effect of secondary orthogonal
testing (testing with a second assay, using a different target),
we carried out a Bayesian statistical analysis for prevalence
estimation.17 Applying the secondary tests to the 11 samples
that tested positive on the Abbott assay with a threshold of
1.4 S/C, the estimated prevalence in the higher-risk group is
0.9% (95% credible interval 0.4–1.7%). Applying the sec-
ondary tests to the 25 samples that tested positive on the
Abbott assay with a threshold of 0.5 S/C, the estimated actual
prevalence is 0.8% (95% credible interval 0.4–1.5%).
Antibody detection among probable cases
Of the nine probable cases, one was positive on four of the
five assays while another was positive on three of the five
assays, suggesting likely infection (Fig. 1; Supplementary
Table 4, Appendix A). The remaining seven were negative
by all five assays, and the Abbott assay raw values of these
ranged from 0.01–0.04 S/C, suggesting that these were un-
likely to have had COVID-19 infection.
DISCUSSION
Serological testing can be useful as an epidemiological tool to
estimate the overall prevalence of infection in the commu-
nity, a public health tool during an outbreak to identify recent
infections and inform contact tracing procedures, and to assist
in clinical diagnosis.18 It is also possible, once the correlates
of protection against reinfection are defined, that serological
testing based on the S protein could be used to confirm evi-
dence of past infection or vaccination.
Using a cohort of PCR-confirmed cases to assess sensi-
tivity, we found suboptimal performance of the Abbott assay
at 11–17 weeks post-infection with a sensitivity of 76.9%,
somewhat lower than the previously published data19–22 and
manufacturer’s claim (100% after 14 days). Several factors
likely contributed to this. Firstly, most of the cases in the
SDHB region were not hospitalised, and there is some
evidence that antibody levels correlate with disease
severity.23 Secondly, a median of 14 weeks (range 11–17
weeks) had lapsed between symptom onset and serum
collection, and N protein antibodies have been reported to
decline relatively quickly post-infection.24–27 In contrast, the
sensitivity of the plate-based assays based on the S protein
antigens was higher (89.7–94.9%), in keeping with the
notion that antibodies against the S protein persist for a longer
duration than those to the N protein.28 Beyond antibody ki-
netics, it is also possible that the Abbott chemiluminescent
immunoassay technology contributed to the reduced sensi-
tivity observed, as studies comparing the Elecsys Anti-
SARS-CoV-2 assay (Roche Diagnostics, Germany) with
two commercially available S protein antibody assays,
demonstrated N protein antibodies persisting as long as S
protein antibodies out to 83 days post-symptom onset.29
Two of the PCR-confirmed cases were negative on all five
serological assays. A small proportion of PCR-positive pa-
tients will be persistently negative by serology.30
In our hands, the Abbott assay specificity was 99.7% (95%
CI 98.2–99.99%), comparable to the manufacturer’s claim
(99.6%). However, given the very low prevalence of
COVID-19 infection in NZ, the positive predictive value will
be relatively low. Thus, we suggest an orthogonal testing
algorithm as a supplemental assay before reporting results as
true positives.
S protein is the main target for SARS-CoV-2 NAbs, which
are antibodies that typically block entry of the virus into
cells.24 In this study NAbs were measured using a sVNT15
with 88.5% of the PCR-confirmed cases having detectable
NAbs 11–17 weeks post-infection, with lower NAbs among
those with mild symptoms. A decline in NAb levels has been
noted in some recent reports,23 but further studies are needed
to fully understand these immunokinetics and the implica-
tions this may have for protection against reinfection and
vaccines based on the S protein and RBD.
This study of over 1000 individuals who self-identified as
being higher risk than the overall population for COVID-19
in our region, identified a further nine infections. Of these,
Table 2 Summary of the investigated SARS-CoV-2 assays
Assay SARS-CoV-2
antigen target
Company Positivity threshold Platform Sensitivitya Specificitya
Abbott Architect
SARS-CoV-2 IgG
N protein Abbott, USA 1.40 S/C Abbott Architect
(CMIA)
0–100% (day 0 to 14





RBD/S protein In house RBD: 0.2 OD
Spike: 300 titre




RBD/S protein Beijing Wantai
Biological Pharmacy,
China
1 A/CO Manual ELISA 94.5% (dependent on
specimen collection






S1 protein Euroimmun, Germany 1.1 ratio Manual ELISA 10 days = 60.2%




GenScript, USA 20 % inhibition Manual sVNT 95.0% 100%
CMIA, chemiluminescent microparticle immunoassay; N, Nucleocapsid; NA, not applicable; RBD, receptor binding domain; S, Spike; sVNT, surrogate virus
neutralisation test.
a Sensitivity and specificity according to manufacturer.
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all had epidemiological risks including travel to Europe
during their outbreak, and/or being a close contact of a known
case. Only two of these individuals had PCR testing
performed; the remaining seven did not as they were symp-
tomatic overseas or did not meet the original case definition.
Undiagnosed infection was not detected among front line
healthcare workers, tourism workers, and casual contacts of
known cases. It is possible that cases of infection may have
been missed as the Abbott assay, which was used as our
initial screening assay, demonstrated sub-optimal sensitivity.
However, the grey-zone approach utilised, based on a ROC
analysis, improved the sensitivity of the assay to 94.9%.
Given the imperfect sensitivity, and unknown prevalence
among the tested population in our region, it is difficult to
estimate the true number of cases of infection that may have
been missed. By applying Rogan–Gladen and Bayesian es-
timations for actual prevalence in the higher risk group we
were able to obtain more precise estimates of actual preva-
lence and found that the estimates do not appear to depend
strongly on the threshold used in primary test, as evidenced
by the concordance of the obtained estimates.
The epidemiology of COVID-19 in NZ in early 2020 is
relatively unique: NZ is an island nation with low population
density by world standards; the pandemic was well signalled
overseas allowing border measures to be put in place; the
pandemic coincided with the Southern Hemisphere autumn
(fall); our hospitals were not overwhelmed with cases; and
our setting has a well-coordinated network of microbiology
laboratories and Public Health units. Therefore, it is plausible
that the majority of cases were identified by targeting PCR
Table 3 Sensitivity and specificity of the investigated SARS-CoV-2 assays
Assay SARS-CoV-2 antigen Sensitivity (%) Specificity (%)
























CI, confidence interval; N, Nucleocapsid; RBD, receptor binding domain; S, Spike; sVNT: surrogate virus neutralisation test.
a Equivocal results considered negative.
Fig. 1 Antibody levels for the examined assays for the samples tested on all five assays [all PCR-confirmed cases, all probable cases, and higher risk samples in the
‘grey-zone’ (0.5–1.39 S/C) or positive (1.4 S/C) results on the Abbott assay] (n=112). Dashed horizontal lines show assay specific cut-off.
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testing on the basis of symptoms and epidemiological risks,
and were comprehensively isolated by Public Health inter-
vention, limiting community spread.
An unexpected finding was that seven of the nine in-
dividuals diagnosed with ‘probable’ infection, and included
in NZ’s official tally, were sero-negative despite being tested
on all five assays. While acknowledging the delay (approxi-
mately 3 months) in serum collection and the possible impact
on sensitivity, it is likely that at least some of these in-
dividuals did not have infection. This highlights the role of
serology in the diagnostic algorithm where PCR is negative
despite symptoms and epidemiological risks, and further
testing of NZ’s remaining 341 probable cases may be
warranted.
We note the high female predominance in this study
(75%). We hypothesise this is due to the high proportion of
frontline healthcare workers (62%), which is a female
dominated occupation, and it is possible females are more
willing to participate in such studies.
Our study has some limitations. Firstly, the antenatal sera
used to determine specificity is not representative of the
general population. Secondly, the delay in specimen
collection after the outbreak likely had an impact on the
Abbott assay sensitivity. We cannot be certain that undi-
agnosed cases were not missed using the Abbott assay as
our screening test. However, every effort was made to
mitigate against this by lowering the cut-off for the initial
Abbott screening assay. Lastly, it is important to note that
this is not a sero-prevalence study. Participants who self-
identified as higher risk were actively recruited, therefore
the sero-positivity rate calculated in this group in the
SDHB region cannot be extrapolated to the general
population.
CONCLUSION
In conclusion, our study shows that the COVID-19 outbreak
in the SDHB region in early 2020, despite the testing re-
strictions early on in the outbreak, was largely confined to the
PCR-confirmed cases and those identified as at higher risk
due to recent travel and/or close contact with a known case.
We found little evidence of undetected infection among the
individuals in the SDHB region who were considered to be at
higher risk than the average resident, due to contact with a
PCR-confirmed case, or because of workplace duties, or
because they were Queenstown residents. The N protein-
based Abbott assay demonstrated the lowest sensitivity of
the assays investigated, likely impacted by the delay in serum
collection, which appears to affect N protein antibodies over
S protein antibodies. Whilst this may lead to missed cases, the
utility of a high throughput system for large scale testing
does, to a degree, offset this significant limitation, especially
when combined with secondary S protein assays of higher
sensitivity. When designing a SARS-CoV-2 serological
assay algorithm, the purpose of testing is a major consider-
ation, with different assay combinations suitable for high-
throughput sero-prevalence purposes versus individual level
clinical diagnostics.
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Abstract
Objectives. Circulating antibodies are important markers of
previous infection and immunity. Questions remain with respect to
the durability and functionality of SARS-CoV-2 antibodies. This
study explored antibody responses in recovered COVID-19 patients
in a setting where the probability of re-exposure is effectively nil,
owing to New Zealand’s successful elimination strategy. Methods.
A triplex bead-based assay that detects antibody isotype (IgG, IgM
and IgA) and subclass (IgG1, IgG2, IgG3 and IgG4) responses
against Nucleocapsid (N) protein, the receptor binding domain
(RBD) and Spike (S) protein of SARS-CoV-2 was developed. After
establishing baseline levels with pre-pandemic control sera
(n = 113), samples from PCR-confirmed COVID-19 patients with
mild–moderate disease (n = 189) collected up to 8 months post-
infection were examined. The relationship between antigen-
specific antibodies and neutralising antibodies (NAbs) was
explored with a surrogate neutralisation assay that quantifies
inhibition of the RBD/hACE-2 interaction. Results. While most
individuals had broad isotype and subclass responses to each
antigen shortly after infection, only RBD and S protein IgG, as well
as NAbs, were relatively stable over the study period, with 99%,
96% and 90% of samples, respectively, having responses over
baseline 4–8 months post-infection. Anti-RBD antibodies were
strongly correlated with NAbs at all time points (Pearson’s
r ≥ 0.87), and feasibility of using finger prick sampling to
accurately measure anti-RBD IgG was demonstrated. Conclusion.
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Antibodies to SARS-CoV-2 persist for up to 8 months following
mild-to-moderate infection. This robust response can be attributed
to the initial exposure without immune boosting given the lack of
community transmission in our setting.
Keywords: COVID-19, immunokinetics, neutralising antibodies,
SARS-CoV-2, Spike protein
INTRODUCTION
It is now well established that antibody responses
against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are activated promptly
after infection.1 The virus, and causative agent of
the coronavirus disease 2019 (COVID-19)
pandemic, contains four structural proteins, the
most immunodominant being the Nucleocapsid
(N) protein, Spike (S) protein and the receptor
binding domain (RBD) of the S protein. Measuring
antibody responses to these antigens using
serological assays has been critical for determining
previous viral exposure in individuals, studying
community transmission and conducting
population serosurveys.1 However, much is still to
be learnt about the long-term duration and
protective capacity of these responses.
Antibody responses comprise different isotypes
and subclasses, each associated with unique
immune functions and dynamics over time.2
Following SARS-CoV-2 infection, there is an almost
concurrent rise in immunoglobulin M (IgM), IgA
and IgG, with IgM then beginning to decline
approximately 3 weeks after symptom onset.3–6
There have been conflicting reports with respect to
IgG duration, ranging from a relatively short
3 months,7 to 6 months or longer,8–10 in part due
to SARS-CoV-2 antibody dynamics being highly
antigen-dependent. Anti-N antibodies are now
known to wane faster than anti-RBD and anti-S and
may be more suited as a marker of recent COVID-19
infection, particularly since the N protein is
associated with RNA packaging and anti-N
antibodies are non-neutralising.8,11 The RBD of the
Spike protein, however, binds to the angiotensin-
converting enzyme 2 (hACE2) on human host cells
to facilitate viral entry and infection. Anti-S and
anti-RBD antibodies can block this interaction
leading to viral neutralisation and, as such, are
better markers of functional immune responses.12
Of note, the presence of neutralising antibodies
(NAbs) protected a small number of individuals
from re-infection during a SARS-CoV-2 outbreak on
a fishing vessel13 and anti-S protein IgG was
associated with reduced re-infection in a recent
study of healthcare workers in the United
Kingdom.14 This suggests NAbs and S protein
antibodies are associated with protective immunity
and may, in turn, underpin a correlate of protection
for COVID-19 vaccine development. Levels of NAbs
have proven relatively stable in recent reports,9,10,15
but further investigation is needed, particularly in
non-severe cases of COVID-19.
Bead-based serological assays capable of
simultaneously measuring antibodies to N and S
proteins, together with RBD, enable a
comprehensive view of the SARS-CoV-2 antibody
response.16–18 In this study, a triplex Luminex-
based assay that detects isotype and subclass
responses to the major SARS-CoV-2 antigens was
developed and utilised to interrogate the
composition and duration of virus-specific
antibodies up to 8 months post-infection in
COVID-19 cases in New Zealand. In parallel, levels
of NAbs were measured using a surrogate virus
neutralisation test (sVNT) previously shown to
strongly correlate with neutralisation measured
using live SARS-CoV-2 virus, and better suited to
high-throughput analyses due to improved speed
and reproducibility.12,19 By exploring the
relationship between NAbs and antigen-specific
antibody features, this study adds to growing
knowledge of the SARS-CoV-2 humoral immune
response from a setting where the probability of
re-exposure is effectively nil, owing to New
Zealand’s successful elimination strategy.20,21
RESULTS
A triplex bead-based immunoassay was
developed, with N protein, trimeric S protein and
RBD coupled to spectrally unique beads.
Compatibility of the beads in a multiplex format
was confirmed, as was comparability with
previously described ELISA for S protein and
RBD,22 and the N protein Abbott Architect SARS-
CoV-2 IgG assay,23 with highly significant
2021 | Vol. 10 | e1261
Page 2
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
SARS-CoV-2 antibodies in New Zealand AL Whitcombe et al.
correlations for all three antigens (Supplementary
figure 1). The level of SARS-CoV-2 antigen-specific
isotypes (IgG, IgM and IgA) and subclasses (IgG1,
IgG2, IgG3 and IgG4) was determined in a cohort
of 112 PCR-confirmed COVID-19 participants, 50 of
whom had multiple time points (n = 189 samples),
and the majority of whom had mild disease
(Table 1, Supplementary figure 2). The days post-
infection ranged up to 246 days, enabling the
kinetics of 21 different antibody features (three
SARS-CoV-2 antigens and seven secondary
detectors) to be temporally investigated. The cut-
off for positivity for each antibody type was
determined using a previously described panel of
pre-pandemic control samples (n = 113) that
includes donors with respiratory viruses and
bacterial pneumonia that have symptom overlap
with COVID-19.22
Isotype responses for each antigen were plotted
against time (Figure 1). Participant samples were
grouped by days/months post-infection [7–62 days
(0–2 months, n = 27), 63–124 days (2–4 months,
n = 79) and 125–250 days (4–8 months, n = 80)]
and the rate of positivity compared
(Supplementary table 1). With the exception of
anti-N protein IgM, all antigen-specific isotypes
were elevated above baseline levels in the acute
stage through to early convalescence (7–62 days
post-symptom onset). Indeed, all samples (27/27,
100%) were positive for RBD and S protein IgG
indicating universal seroconversion following
infection in these participants. After 2 months,
IgM and IgA antibody levels against all three
antigens trended down to baseline levels. In
contrast, IgG antibody levels remained elevated
against RBD and S protein with 99% (79/80) and
96% (77/80) of samples above baseline in late
convalescence (≥ 125 days), respectively.
Consistent with recent literature,8,11 anti-N
protein IgG waned faster, with only 54% (43/80)
of patients having detectable levels above
baseline in late convalescence.
To explore the contribution of IgG subclasses to
total IgG (IgGtot), the proportion of samples with
antibody subclass levels above baseline in the
three time groups were compared (Figure 2,
Supplementary table 1). The four IgG subclasses
were elevated against each antigen in the
majority of samples collected 7–62 days post-
symptom onset. IgG3 responses were particularly
strong in this earliest time group, with at least
96% of patients having a response above baseline
against both RBD and S protein (Supplementary
table 1). In samples collected 63–124 days post-
symptom onset, IgG1 and IgG3 responses
dominated for all three antigens, with IgG2
uncommonly, and IgG4 rarely, above baseline. In
the 125–250-day group, IgG1 antibodies against
RBD and S protein persisted, with 64% (51/80) and
59% (47/80) of participants having antibodies
above baseline, respectively, as did IgG3 against S
protein with 60% (48/80) above baseline. As with
IgGtot, the anti-N subclass responses waned faster
than RBD and S protein with < 30% participants
having detectable levels above baseline of any
subclass in the 125–250-day group.
NAbs were measured using a surrogate assay that
quantifies inhibition of the RBD/ACE-2 interaction12
and found to be relatively stable over the 8-month
study period (Figure 3). While there was a modest
downward trend, 89% (70/79) in the 63–124-day
group and 90% (72/80) in the late-convalescent
group (> 125 days) had detectable NAbs above the
cut-off. All but one of the late-convalescent samples
(79/80) were from non-hospitalised individuals
suggesting mild disease can induce long-lived NAbs
(Supplementary figure 3a). Correlation analysis
found IgGtot-RBD most significantly correlated with
NAbs in the early, mid- and late-convalescent groups
(Pearson’s r ≥ 0.87 across all time groups), while
Table 1. Demographics of COVID-19 study participants
Demographic characteristic
Days post-symptom onset
< 7 days 7–62 days 63–124 days 125–250 days
Participants, n (samples, n) 3 (3) 22 (27) 79 (79) 53 (80)
Age (year)
Median 61 38 51 49
Range 29–64 23–86 17–81 17–81
Gender, n (M/F) 0/3 12/10 33/46 21/32
Clinical severity
Admitted to hospital with moderately severe/severe disease, n (%) 3 (100) 15 (68.2) 4 (5.1) 1 (1.9)
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IgA-RBD was moderately associated, and IgM-RBD
not at all (Figure 3b). To further explore NAb
persistence, a comparative analysis was performed
on participants for which two or more temporal
samples were collected. There was no significant
decrease in NAbs between the first and second time
point, but a significant decline at the third time
point (median 219 days post-infection, P < 0.05)
(Supplementary figure 3b). To mitigate any skewing
of the NAb response due to disease severity, the
analysis was repeated with the hospitalised
participant removed, with no effect on the results
(Supplementary figure 3c). Individual heterogeneity
was evident in terms of both the level of NAbs, and
their waning (or otherwise) over time. Indeed,
approximately 1/3 of individuals demonstrated
increasing levels, consistent with affinity maturation
as recently proposed.24
To estimate the rate of decay for NAbs, a series
of models were applied (see Methods), and the
expected time for NAbs to halve [half-life (t1/2)]
was calculated (Figure 3c, Supplementary table 2).
Exponential decay assumes NAbs decline
immediately after infection, and estimated the
longest t1/2 of 625 days and the largest margin of
error (95% CI, 319–13 465 days). A growth and
decay model that assumes NAbs increase initially
and then decline estimated a shorter t1/2 of
425 days (95% CI, 253–1316). Using only data
from the 50 participants for which two or more
samples were available, excluding those with
increasing NAbs (i.e. still in the growth phase) and
modelling individual decay estimated a much
shorter t1/2 of 146 days (95% CI, 100–199).
Lastly, since IgGtot persists, and the bead-based
assay format is compatible with small quantities
of sera (2 µL), the feasibility of using dried blood
samples to measure IgGtot was explored. Dried
blood samples could expand the acceptability of
serological assays and enable testing in settings
where it may be logistically challenging to collect,
process and store venous blood.25 Simulated dried
Figure 1. Isotype responses for IgG (a), IgM (b) and IgA (c), against each antigen [Nucleocapsid (N) protein in light green, receptor binding
domain (RBD) in light blue and Spike (S) protein in dark blue]. Left panel shows responses in pre-pandemic controls (n = 113), and right panel
shows responses in PCR-confirmed COVID-19 patient samples (n = 189) over time. Dashed vertical lines represent the three time groups
(7–62 days, 63–124 days, and 125–250 days). Dashed horizontal lines represent baseline cut-offs calculated from the pre-pandemic control
group, and samples below these cut-offs are faded. LOESS regression (purple line) was used to visualise general trends in antibody levels, and
standard error of regression is indicated by grey shaded area.
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blood eluents collected using Mitra samplers were
compared with matched sera in a subset of
patients (n = 19). IgGtot measurements from Mitra
eluents correlated strongly with serum samples,
against all three antigens (r2 = 0.9957, 0.9929 and
0.9918 for N, RBD and Spike, respectively)
(Figure 4).
DISCUSSION
The duration of antibody responses following
SARS-CoV-2 infection is, in essence, being studied
in real time globally. Initial studies that purported
early antibody waning were based on the N
protein, now known to induce antibodies with a
relatively short half-life,8 or linear extrapolations
of S protein data collected 2–3 months
post-infection.7 More recent analyses (5–8 months
post-infection) show that S protein, RBD and
NAbs are likely more stable than originally
predicted.6,8,10,15,18,26 Here, further evidence is
provided of the durability of the SARS-CoV-2
humoral immune response over an 8-month
period. Importantly, this study was performed in a
setting where there is next to no likelihood of
immune boosting by re-exposure, given the
successful public health response to COVID-19 in
New Zealand.20,21 That 99% of sera had anti-RBD
IgG and 96% had anti-S protein IgG above
baseline levels 4–8 months after infection in a
setting with no circulating SARS-CoV-2 is notable,
particularly given the majority of participants had
non-severe infections.
Utilising a multiplex assay enabled not only IgG,
but also other isotypes and subclass responses to
be investigated. As expected, IgM had a shorter
duration than IgG, with > 75% of samples
returned to baseline in late convalescence for all
Figure 2. Rose plots showing the percentage of PCR-confirmed COVID-19 patient samples that were above baseline for IgG1 (a), IgG2 (b), IgG3
(c) and IgG4 (d). Samples are stratified into three time groups (7–62 days, 63–124 days and 125–250 days). Nucleocapsid (N) protein in light
green, receptor binding domain (RBD) in light blue and Spike (S) protein in dark blue.
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three antigens. Of the IgG subclasses, RBD and S
protein-specific IgG1 and IgG3 were dominant, in
keeping with the association of these subclasses
with convalescence and survival in COVID-19
system serology studies.16,17 While it is not
possible to link subclass responses with disease
outcomes in this study since all participants
recovered, IgG1 and IgG3 are the most potent
subclasses in terms of immune cell engagement
and effector functions.2
There are still many unknowns with respect to
correlates of protection for SARS-CoV-2 infection
Figure 3. Longitudinal neutralising antibodies. (a) Neutralising capacity (in % inhibition) of samples from days since symptom onset. Left panel
shows responses in pre-pandemic controls (n = 113), and right panel shows responses in PCR-confirmed COVID-19 patient samples (n = 189)
over time. Pre-pandemic samples were all below the 20% cut-off indicated by dashed horizontal line. Paired samples are joined by grey lines.
Dashed vertical lines represent the three time groups (7–62 days, 63–124 days and 125–250 days). LOESS regression (blue line) was used to
visualise general trend in neutralising antibody levels, and standard error of regression is indicated by grey shaded area. Percent and number of
samples from PCR-confirmed cases above 20% inhibition cut-off are indicated above the respective time points. (b) Pearson’s correlation
between % inhibition vs RBD IgG, IgA and IgM across three time groups. Non-significant correlations are coloured white. Significant correlations
are coloured in blue relative to their Pearson’s r value. P-values are corrected for multiple comparisons using the Bonferroni method,
***P < 0.001. (c). Visualisation of three modelling methods applied to predict half-life of neutralising antibodies. Left panel shows the
‘exponential decay’ (green line) and ‘growth and decay’ (red line) models, which use all samples to model decay. In the ‘growth and decay’
model, samples up to 11 days (dark grey points) are used to model the growth phase, and samples over 11 days (light grey) are used to model
exponential decay. Right panel shows the ‘individual decay’ model (black line) in which only samples with multiple paired measurements who
were in the decay stage were utilised (grey points). Samples with only one measurement (yellow faded points) or those showing increased
inhibition over time (blue faded points) were excluded.
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including the contribution of cross-reactive
memory T cells alongside B-cell-driven antibody
responses.27 For other viral infections, correlates
are based on specific levels of antibodies, with
these well-defined titres facilitating vaccine
development and immunisation strategies.15 As
such, there is a pressing need to understand
antibody persistence and time to seroreversion
following SARS-CoV-2 infection. Using three
different models, the estimated t1/2 of
5–20 months for NAbs in this study is somewhat
longer than 2–4 months calculated in other
cohorts,18,26 though all estimates have wide
confidence intervals because of the inherent
limitations of modelling responses with marked
individual heterogeneity. Nevertheless, all models
place the NAb half-life at < 2 years post-infection.
Although NAbs are not yet a proven correlate of
protection, and the impact of slow waning on
susceptibility to re-infection is as yet unknown,
NAbs and anti-S protein IgG have been associated
with protection in recent outbreaks13,14 and in
non-human primate studies28 suggesting a role
for functional antibodies in SARS-CoV-2 immunity.
Ultimately, large-scale vaccine trials will enable
accurate determination of a correlate, and
suggestions that two-dose Spike-based vaccines
may induce more potent NAbs than natural
infection29 are likely to result in responses of
increased durability and longer half-life than
estimated to date.
Overall, this study provides a comprehensive
view of SARS-CoV-2 antibodies over 8 months.
The strong correlation between anti-RBD IgG and
NAbs, combined with the demonstration in this
study and by others4,25,30 that anti-RBD can
reliably be measured from dried blood fingerpick
samples, provides feasibility for future SARS-CoV-2
immunokinetic studies that incorporate RBD IgG-
based assays. The importance of conducting such
studies at scale during vaccine roll-out is
particularly relevant in settings such as New
Zealand, where there is potential to gain novel
insight on vaccine responses given the lack of
circulating SARS-CoV-2 in the community.
METHODS
Study samples
Plasma and serum samples were collected from multiple
sources with appropriate ethical board approval. Samples
collected before the pandemic were used as negative
controls (‘pre-pandemic’, n = 113), details of which have
been described previously.22 Samples from PCR-confirmed
COVID-19 individuals were obtained from hospital
inpatients in Auckland (n = 18) (ethics HDEC 20NTB76) and
convalescent participants in the Southern Region of New
Zealand (ethics HDEC 20NTB101) as previously
described.22,23 Samples were also obtained from donors
with a prior COVID-19 diagnosis, collected at the New
Zealand Blood Service as part of a Medsafe-approved
process for convalescent plasma preparation. The final PCR-
confirmed cohort in this study comprised 189 samples from
112 participants, 50 of whom had samples collected at
multiple time points (Table 1, Supplementary figure 2).
Participant samples were grouped by days/months post-
symptom onset (infection) based on time frames in which
the samples were obtained [acute and early convalescence,
7–62 days (0–2 months, n = 27); mid-convalescence,
63–124 days (2–4 months, n = 79); and late convalescence,
125–250 days (4–8 months, n = 80)].
Antigen coupling to beads
SARS-CoV-2 RBD and the trimeric S protein antigens were
recombinantly expressed and purified from HEK293T or
HEK293F cells as previously described.22 Recombinant
Figure 4. Scatterplots showing the correlation between IgG measured from Mitra dried blood eluents and matched serum for Nucleocapsid (N)
protein (a), receptor binding domain (RBD) (b) and Spike (S) protein (c) (n = 19) in median fluorescence intensity (MFI). The dashed lines
represent the linear regression equation. R-squared and P-values are shown.
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nucleocapsid (N) protein expressed in baculovirus/insect cells
was obtained commercially (Sino Biological, Beijing, China).
Each of the three antigens was coupled to MagPlex®
magnetic microspheres (beads) by carbodiimide chemistry
using the xMAP® Antibody Coupling Kit (Luminex
Corporation, Austin, Texas, USA), according to the kit
instructions. In brief, beads were washed with activation
buffer and incubated for 20 min with EDC (1-Ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride) and
sulpho-NHS (N-hydroxysulphosuccinimide). Antigens were
coupled at a concentration of 4.5 µg per 1 × 106 beads in a
2-h incubation at room temperature. Antigen-coupled
beads were washed, enumerated using a haemocytometer,
and stored at 4°C protected from light until further use.
Multiplex assay protocol
All serum and plasma samples were heat-inactivated at 56°C
for 30 min prior to use. Samples were diluted 1:100 (IgG2,
IgG3 and IgG4), 1:400 (IgG1, IgA and IgM) or 1:800 (IgG) in
assay buffer (AB) consisting of PBS + 1% IgG-free bovine
serum albumin (BSA, MP Biomedicals, Auckland, New
Zealand). Diluted samples (30 μL) were added to wells of a 96-
well U-bottom plate (Greiner, Kremsmüsnter, Austria), and
30 μL of bead solution consisting of N, RBD and S-coupled
beads mixed in equal parts was added at a concentration of 40
beads per μL per antigen. Plates were sealed and incubated at
room temperature for 35 min at 800 rpm, followed by two
wash steps with wash buffer (AB + 0.05% Tween) using a
hand-held magnet (Luminex Corporation). To detect the
different antibody isotypes and subclasses, phycoerythrin (PE)-
labelled donkey anti-human detection antibodies (IgG1, IgG2,
IgG3 and IgG4, Southern Biotech; IgG/A/M, Jackson
ImmunoResearch, West-Grove, Pennsylvania, USA) were
diluted 1:75 and 1:80 in AB, respectively, then added to wells
and incubated at room temperature for 35 min at 800 rpm.
Following another two wash steps, beads were re-suspended
in 100 μL Drive Fluid (Luminex Corporation) and analysed on a
MagPix® machine (Luminex Corporation).
Positive COVID-19 sera (n = 10) from a commercially
available reference panel (AccuSet™ SARS-CoV-2 Performance
Panel, SeraCare, Milford, Massachusetts, USA) were pooled in
equal volumes and included on every plate as a quality control
to ensure consistency between assay runs. Background values
from no-serum wells were subtracted from the sample read-
outs to give a net median fluorescence intensity (MFI) value.
The net MFI value for each test sample was adjusted by
dilution factor, such that antibody levels are represented as
adjusted ‘units’. Baseline cut-offs for each antigen and
antibody type were calculated using receiver operating
characteristics (ROC) curve analyses. The panel of 113 negative
pre-pandemic sera were measured along with acute PCR-
confirmed COVID-19 patients with sera collected 7–40 days
post-infection (n = 18), and to maximise sensitivity, the
resulting 98% specificity cut-off for each antibody was taken
as the baseline.
Surrogate neutralisation assay
Surrogate neutralisation assays were performed using the
SARS-CoV-2 sVNT (GenScript, Piscataway, New Jersey, USA)
according to the manufacturers’ instructions as previously
described.12,22 Briefly, samples were diluted 1:20 and
incubated with an equal volume of peroxidase-conjugated
RBD for 30 min at 37°C, then added to wells pre-coated
with human ACE-2 receptor protein and incubated for
15 min at 37°C prior to washing and development.
Inhibition was calculated as (1 − OD sample/OD of negative
control) × 100. Any sample with a percentage inhibition
≥ 20% was deemed positive for NAbs. This cut-off
recomended by the manufacturer was previously shown to
result in 100% specificity in our laboratory.22
Mitra samples
To simulate remote blood sampling from a fingerprick
using volumetric absorptive microsampling, Mitra devices
(10 or 20 μL devices; Neoteryx, Torrance, California, USA)
were placed onto the surface of whole blood collected
from an EDTA tube and filled. The devices were left to dry
at room temperature and stored for a maximum of 3 weeks
or frozen at −20°C until use. To elute the dried blood, the
tip of the Mitra device was placed in elution buffer
(PBS + 1% BSA + 0.05% Tween-20) at a dilution of 1:20
(200 μL for the 10 μL device or 400 μL for the 20 μL device)
and incubated overnight at 4°C, with shaking (300 rpm).
Eluents were stored at 4°C for up to 1 week or at −80°C
until use. The ‘serum equivalent’ dilution of eluents was
calculated to be 1:40, based on the assumption that serum
constitutes 50% of the whole blood volume. To compare
antigen-specific IgG levels in eluents with levels measured
in serum, eluents were diluted appropriately and measured
alongside matched serum samples in the multiplex assay.
Overall differences in raw values between eluents and sera
were low for each antigen (average CV = 8.6%, 11.9% and
9.2% for N, RBD and Spike).
Statistical analysis
Data were analysed using Prism 8 (GraphPad, San Diego,
California, USA) or R (version 4.0.2) within RStudio (version
1.2.5042) using packages rstatix (v 0.6.0; Kassambara, 2020)
and the tidyverse (v1.3.0; Wickham, 2019). Locally estimated
scatterplot smoothing (LOESS) with a span of 0.95 was used to
visualise trends in antibody levels over time. The
Kruskal–Wallis followed by the pairwise Dunn tests was
performed to calculate statistical significance. The Bonferroni
method was used to correct for multiple comparisons. A P-
value ≤ 0.05 was considered statistically significant.
The following models were applied to NAb data.
1. Exponential decay in which an exponential decay
curve was fitted to the full data set
Inhibition¼ a expðbtÞ
where t is measured in days. This method will likely
underestimate the decay rate if the period in which
antibodies increase after infection (growth period) for some
individuals is long. It is also strongly affected by potential
differences in both the size and timing of the peak level of
NAbs between individuals. The best-fit coefficients with
95% confidence interval are a = 66 (56.7, 75.3) and
b = 0.0011 (0.00005, 0.00217).
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2. Growth and decay, which uses a two-part model
fitted to the full data set
Inhibition¼ a days if t<c
ac expðbðtcÞÞ if t ≥ c

This allows an initial growth period to account for the
underestimate that results from fitting a decay curve to
measurements still in the growth phase. However, strong
differences between individuals, particular in the timing of
the peak level of NAbs, will still affect estimations. This
model predicts a slightly faster decay speed than the
exponential decay model b = 0.0016 (0.00053, 0.00274) that
starts after 11 days [c = 11 (5.65, 16.35)].
3. Individual decay model
Of the 189 data points for NAbs, 127 are multiple
measurements from 50 individuals, of which 33 (88
measurements) are in the exponential decay stage; that is,
inhibition is decreasing with time. The individual decay
model incorporates data from these 33 individuals only. An
exponential decay curve is fitted to each individual
separately. An exponential distribution is fitted to the
individual decay rates, and the best-fit parameter and 95%
confidence interval were reported. The mean decay rate is
faster than predicted by the other models with b = 0.00476
(95% confidence interval 0.00348, 0.00691).
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Appendix B: Serosurvey forms 
• Participant information sheet (hard copy) 
• Consent form – adult (hard copy) 
• Participant information sheet for parent/legal guardian (hard copy) 
• Consent form – child (hard copy) 
• Participant information sheet and assent form – 7-11 years (hard copy) 
• Participant information sheet and assent form – 12-15 years (hard copy) 
• Questionnaire (hard copy) 
• Consent form (REDCap) 
• Questionnaire – Higher-risk participants (REDCap) 
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Participant Information Sheet  
Study title: Antibody tests for exposure to COVID-19 infection 
Locality: Southern Community Laboratories / Southern DHB 
Lead investigator: Arlo Upton, 021 0215 9863 
Ethics committee ref.: 20/NTB/101 
 
You are invited to take part in a study on antibody testing for COVID-19 exposure.  Whether 
or not you take part is your choice.  If you don’t want to take part, you don’t have to give a 
reason, and it won’t affect the care you receive.  If you do want to take part now, but change 
your mind later, you can pull out of the study at any time.   
 
This Participant Information Sheet will help you decide if you’d like to take part.  It sets out 
why we are doing the study, what your participation would involve, what the benefits and 
risks to you might be, and what would happen after the study ends.  You do not have to 
decide today whether or not you will participate in this study. Before you decide you may 
want to talk about the study with other people, such as family, whānau, friends, or 
healthcare providers.  Feel free to do this. 
 
If you agree to take part in this study, you will be asked to sign the Consent Form on the last 
page of this document.  You will be given a copy of both the Participant Information Sheet 
and the Consent Form to keep. 
 
This document is eight pages long, including the Consent Forms.  Please make sure you 
have read and understood all the pages. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
This study has three purposes: 
1. To assess the Abbott Architect SARS-CoV-19 IgG antibody test – to see how well it 
picks up people who we know have had COVID-19 infection, and if it is always 
negative in people who haven’t had COVID-19 infection 
2. To look for neutralising antibodies and cell mediated immune responses in people 
who have been diagnosed with COVID-19 infection or found to be antibody positive 
3. To estimate how many people had COVID-19 infection in the Southern District 
Health Board (SDHB) area who were not diagnosed by PCR testing 
 
Results from the first part of the study will help the laboratory understand how good the 
Abbott test is, and how reliable the results from the second part of the study are.  The results 
from the second part of the study will give the Public Health team, Ministry of Health, and 
SDHB a better understanding of the COVID-19 epidemic in the Southern region of NZ. 
 
Serology (antibody testing through a blood test) is the main way of seeing if well people 
have been exposed to an infection in the past.  With SARS-CoV-19 / COVID-19 the serology 
Hard copy: PIS
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testing results do not tell us if someone is immune or not. It also doesn’t tell you / us if you 
have a current infection. 
 
The study is being performed by Southern Community Laboratories (SCL), who are working 
with Public Health South, SDHB, and Wellsouth. If you have further questions you can 
contact one of the study investigators.   
 
The study has been approved by the COVID-19 Emergency Health and Disability Ethics 
Committee. 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
You have been asked to participate in the study because you are one of the following: 
 Person known to have had COVID-19 infection 
 Person thought to have had COVID-19 infection but your test/s were negative 
 Person living with someone with COVID-19 infection and remained without symptoms of 
infection and so not tested 
 Person thought to be at higher risk than the general population for COVID-19 infection 
o Healthcare workers 
o People living in a tourist town that had high rates of COVID-19  
o Contact with someone with COVID-19 infection 
 
The study involves you filling out a questionnaire and having a blood test at the nearest 
collection centre.   
 
For those who have already had contact with Public Health South (because you are a known 
contact of a case of COVID-19), it will also include some of your health information being 
shared from Public Health South with the research team.  This information will be the same 
as outlined below in the following paragraph. If you do not consent, your information will not 
be shared. 
 
For those who had diagnosed COVID-19 infection, it will include either Dr Upton or Dr 
Ussher looking at your health records from the hospital to see how bad (severe) your illness 
was (were you admitted to hospital?; did you get oxygen therapy?; and did you have to go to 
the intensive care unit?). 
 
The following information about you and your health will be collected: 
 Age, gender, ethnicity, area you live in, and NZ deprivation score based on home 
address 
 The at-risk group you are in (based on above information) 
 Any symptoms of COVID-19 infection that you may have had 
 If you had COVID-19, how bad your infection was 
 Results of any COVID-19 PCR testing you might have had 
 
Your blood will be collected (up to 30 ml of blood for adults [up to 50 ml if previous confirmed 
COVID-19 infection], age-based amount for children) for the following: 
1. Testing for SARS-CoV-19 IgG antibodies by the Abbott Architect test 
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2. If your blood is positive by the Abbott test, and/or if you had known COVID-19 infection, 
your blood will also be tested by another SARS-CoV-19 antibody test that has been 
developed by Dr Moreland at the University of Auckland, and in assays to measure virus 
neutralisation and other immune response to the virus at the University of Otago. 
 
We may also wish to contact you in the next year for more blood collection for other COVID-
related laboratory studies looking at immune system responses to infection.  Also, if there is 
another outbreak of COVID-19 infection in NZ in the future, we would like to be able to 
contact you to ask whether you would consent to having more blood taken.  All of this would 
have a new consent form, and as with this study, it is completely up to you as to whether or 
not you want to be involved.  It is your choice, and not being involved will not have any 
impact on your medical care with your GP/nurse or hospital. 
 
You will be asked whether you consent to your GP or nurse getting the results of the test, 
and you will be able to get your results from SCL or your GP or nurse.  If you are not sure of 
what the results mean, you will be able to discuss them with one of the study investigators 
(team). 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
The study is low risk for you. The risk of the study is having the blood test – which can be 
painful and cause bruising.  The people doing the blood test do them every day and are 
experienced professionals.  
 
The benefit to you is to find out if you may have been exposed to COVID-19 infection. 
However, it is important to remember that the test is NOT an immunity test (i.e. a positive 
test does NOT mean that you are immune to infection in the future). Also, a negative test is 
not evidence that you are clear of COVID-19. 
 
CULTURAL STATEMENT REGARDING TISSUE COLLECTION AND STORAGE 
You may hold beliefs about a sacred and shared value of all or any tissue 
samples removed. The cultural issues associated with storing your tissue should 
be discussed with your family/whānau as appropriate. There are a range of 
views held by Māori around these issues; some iwi disagree with storage of 
samples citing whakapapa and advise their people to consult before 
In addition, we would like to be able to store (freeze) your blood serum in either 
SCL, ESR, or Department of Microbiology and Immunology, University of Otago 
laboratory for testing with other SARS-CoV-19 antibody tests when these 
become available in New Zealand.  For you this part is optional.  You may 
consent to the main body of the study without consenting for this additional part.  
Your blood will not be used to test for anything else – it will only be tested for 
SARS-CoV-19 (COVID-19) antibodies.  No genetic tests will be performed and 
your blood serum will stay in New Zealand.  Your serum will be kept indefinitely. 
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participating in research where this occurs. However, it is acknowledged that 
individuals have the right to choose. 
 
WHO PAYS FOR THE STUDY? 
There will be no cost to you for participating in this study.   
 
WHAT IF SOMETHING GOES WRONG? 
If you are injured in this study, you are eligible to apply for compensation from ACC just as 
you would be if you were injured in an accident at work or at home. This does not mean that 
your claim will automatically be accepted. You will have to lodge a claim with ACC, which 
may take some time to assess. If your claim is accepted, you will receive funding to assist in 
your recovery. 
 
If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study won’t affect your cover. 
 
WHAT ARE MY RIGHTS? 
This study is voluntary – that means you do not have to be involved – it is up to you.  Not 
being involved will not have a negative impact on your care at your GPs or in the hospital. It 
will also not have a negative impact on your employment.   
 
You have the right to access information that is collected about you for this study. 
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
If you change your mind about the study and don’t want to be involved, don’t have the blood 
test.   
 
If, after you have had the blood test taken, and you don’t want it to be tested for SARS-CoV-
2 (COVID-19) antibodies, please contact Dr Upton by email: arlo.upton@sclabs.co.nz  
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, you can 
contact:  
 




If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
 
Phone:  0800 555 050 
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Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@advocacy.org.nz 
Website:  https://www.advocacy.org.nz/ 
 











You can also contact the health and disability ethics committee (HDEC) that approved this 
study on: 
 
 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
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Please tick to indicate you consent to the following  
 
I have read and I understand the Participant Information Sheet.     
I have been given sufficient time to consider whether or not to 
participate in this study. 
  
I have had the opportunity to use a legal representative, whanau/ 
family support or a friend to help me ask questions and understand 
the study. 
  
I am satisfied with the answers I have been given regarding the 
study and I have a copy of this consent form and information sheet. 
  
I understand that taking part in this study is voluntary (my choice) 
and that I may withdraw from the study at any time without this 
affecting my medical care or employment. 
  
I consent to the research staff collecting and processing my 
information, including information about my health. 
  
If I decide to withdraw from the study, I agree that the information 
collected about me up to the point when I withdraw may continue to 
be processed. 
  
I consent to my GP or current provider, if I have one, being 
informed about my participation in the study and to receive a copy 
of the antibody test results. 
Yes  No  
I consent to my antibody test results going onto the shared hospital-
based results system (Health Connect South). 
Yes  No  
I consent to Public Health South sharing my health information 




NA   
If I had diagnosed COVID-19 infection, I consent to either Dr Upton 
or Dr Ussher looking at my hospital records related to the COVID-




NA   
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant regulatory 
authority or their approved representative reviewing my relevant 
medical records for the sole purpose of checking the accuracy of 
the information recorded for the study. 
   
I understand that my participation in this study is confidential and 
that no material, which could identify me personally, will be used in 
any reports on this study. 
  
I understand the compensation provisions in case of injury during 
the study. 
  
Hard copy: Consent - adult
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7 
I know who to contact if I have any questions about the study in 
general. 
  
I understand my responsibilities as a study participant.   
I wish to receive a summary of the results from the study. Yes  No  
I wish to receive a report of my antibody test result. 
Email address: _________________________________ 
Yes  No  
I consent to the study team contacting me in the next two years for 
further consent for blood tests for COVID-19  
Yes  No  
I wish for my tissue (serum) to be disposed of at the end of the 
study with appropriate Karakia (only for those not consenting to 
storage for future specified research) 
Yes  No  
   
 







Declaration by whānau/family member (optional): 
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Optional Consent Form for the Use of Tissue (serum) for Future 
COVID-19 Research 
 
I agree for my tissue samples to be stored and used in future 
research but only on the same subject as the current research 
project : COVID-19 antibody testing 
Yes  No  
I give permission for my tissue samples to be stored indefinitely 
  
I want my identity to be kept with my tissue sample 
Yes  No  
I want my identity to be removed from my tissue samples and 
understand that in this case I will not be able to withdraw my consent 
in the future 
Yes  No  
I understand that I may withdraw from the study at any time  
  
If I decide to withdraw from the study, I agree that the information 
collected about me up to the point when I withdraw may continue to be 
used. 
  





Declaration by participant: 
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Participant Information Sheet for Parent / Legal Guardian  
Study title: Antibody tests for exposure to COVID-19 infection 
Locality: Southern Community Laboratories / Southern DHB 
Lead investigator: Arlo Upton, 021 0215 9863 
Ethics committee ref.: 20/NTB/101 
 
Your child is being invited to take part in a study on antibody testing for COVID-19 exposure.  
Whether or not your child takes part is your and their choice.  If you/they don’t want to take 
part, you/they don’t have to give a reason, and it won’t affect the care your child receives.  If 
you/they do want to take part now, but change your/their mind later, you/they can pull out of 
the study at any time.   
 
This Participant Information Sheet will help you decide if you’d like your child to take part.  It 
sets out why we are doing the study, what your child’s participation would involve, what the 
benefits and risks to your child might be, and what would happen after the study ends.  You 
do not have to decide today whether or not your child will participate in this study. Before you 
decide you may want to talk about the study with other people, such as family, whānau, 
friends, or healthcare providers.  Feel free to do this. 
 
If you agree for your child to take part in this study, you will be asked to sign the Consent Form 
on the last page of this document.  You will be given a copy of both the Participant Information 
Sheet and the Consent Form to keep. 
 
This document is eight pages long, including the Consent Form.  Please make sure you have 
read and understood all the pages. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
This study has three purposes: 
1. To assess the Abbott Architect SARS-CoV-19 IgG antibody test – to see how well it 
picks up people who we know have had COVID-19 infection, and if it is always negative 
in people who haven’t had COVID-19 infection 
2. To look for neutralising antibodies and cell mediated immune responses in people who 
have been diagnosed with COVID-19 infection or found to be antibody positive 
3. To estimate how many people had COVID-19 infection in the Southern District Health 
Board (SDHB) area who were not diagnosed by PCR testing 
 
Results from the first part of the study will help the laboratory understand how good this test 
is, and how reliable the results from the second part of the study are.  The results from the 
second part of the study will give the Public Health team, Ministry of Health, and SDHB a 
better understanding of the COVID-19 epidemic in the Southern region of NZ. 
 
Serology (antibody testing through a blood test) is the main way of seeing if well people have 
been exposed to an infection in the past.  With SARS-CoV-19 / COVID-19 the serology testing 
Hard copy: PIS - child
 
Lay study title: Antibodies to COVID-19 in Southern region of NZ  Page 2 of 8 
PIS/CF version no.:two  Dated:  12/05/2020 
  
results do not tell us if someone is immune or not.  It also doesn’t tell us / you whether there 
is a current infection. 
 
The study is being performed by Southern Community Laboratories (SCL), who are working 
with Public Health South, SDHB and Wellsouth. If you have further questions you can contact 
one of the study investigators.   
 
The study has been approved by the COVID-19 Emergency Health and Disability Ethics 
Committee. 
 
WHAT WILL MY PARTICIPATION IN THE STUDY INVOLVE? 
Your child has been asked to participate in the study because your child is one of the following: 
 Person known to have had COVID-19 infection 
 Person thought to have had COVID-19 infection but PCR test/s were negative 
 Person who had contact with someone with COVID-19 infection 
 
The study involves you filling out a questionnaire and your child having a blood test at the 
nearest collection centre.   
 
For those who have already had contact with Public Health South around COVID-19 it will 
also include some of your child’s health information being shared from Public Health South 
with the research team.  This information will be the same as outlined below in the following 
paragraph. If you do not consent, your child’s information will not be shared. 
 
For those who had diagnosed COVID-19 infection, it will include either Dr Upton or Dr Ussher 
looking at your child’s health records from the hospital to see how bad (severe) they illness 
was (were they admitted to hospital?; did they get oxygen therapy?; and did they have to go 
to the intensive care unit?). 
 
The following information about your child and your child’s health will be collected: 
 Age, gender, ethnicity, area your child lives in, and NZ deprivation score based on 
home address 
 Any symptoms of COVID-19 infection that your child may have had 
 If your child had COVID-19, how bad their infection was 
 Results of any COVID-19 PCR testing your child might have had 
 How your child was at risk for COVID-19 infection 
 
Your child’s blood will be collected (age-based amount for children) for the following: 
1. Testing for SARS-CoV-19 IgG antibodies by the Abbott Architect test 
2. If your blood is positive by the Abbott test, and/or if you had known COVID-19 infection, 
your blood will also be tested by another SARS-CoV-19 antibody test that has been 
developed by Dr Moreland at the University of Auckland, and in assays to measure 
virus neutralisation and other immune response to the virus at the University of Otago.  
This is only if there is enough serum left. 
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Your child’s blood will not be used to test for anything else – it will only be tested for SARS-
CoV-19 (COVID-19) antibodies. 
 
 
We may wish to contact you and your child in the next year for more blood collection for other 
COVID-related laboratory studies looking at immune system responses to infection.  Also, if 
there is another outbreak of COVID-19 infection in NZ in the future, we would like to be able 
to contact you and your child to ask whether you would consent to having more blood taken.  
All of this would have a new consent form, and as with this study, it is completely up to you 
and your child as to whether or not you want your child to be involved.  It is your choice, and 
not being involved will not have any impact on your child’s medical care with their GP/nurse 
or hospital. 
 
You will be asked whether you consent to your child’s GP or nurse getting the results of the 
test, and you will be able to get your child’s results from your GP or nurse.  If you are not sure 
of what the results mean, you will be able to discuss them with one of the study investigators 
(team). 
 
WHAT ARE THE POSSIBLE BENEFITS AND RISKS OF THIS STUDY? 
The study is low risk for your child. The risk of the study is having the blood test – which can 
be painful and cause bruising.  The people doing the blood test do them every day and are 
experienced professionals.  
 
The benefit to your child is to find out if you may have been exposed to COVID-19 infection. 
However, it is important to remember that the test is NOT an immunity test (i.e. a positive test 
does NOT mean that your child are immune to infection in the future). Also, a negative test is 
not evidence that your child is clear of COVID-19. 
 
CULTURAL STATEMENT REGARDING TISSUE COLLECTION AND STORAGE 
You may hold beliefs about a sacred and shared value of all or any tissue 
samples removed. The cultural issues associated with storing your tissue should 
be discussed with your family/whānau as appropriate. There are a range of 
views held by Māori around these issues; some iwi disagree with storage of 
In addition, we would like to be able to store (freeze) your child’s blood serum in 
either SCL, ESR, or Department of Microbiology and Immunology, University of 
Otago laboratory for testing with other SARS-CoV-19 antibody tests when these 
become available in New Zealand.  For you/your child this part is optional.  You 
may consent to the main body of the study without consenting for this additional 
part.  Your child’s blood will not be used to test for anything else – it will only be 
tested for SARS-CoV-19 (COVID-19) antibodies.  No genetic tests will be 
performed and your child’s blood serum will stay in New Zealand.  Your child’s 
serum will be kept indefinitely although your child will be asked to re-consent for 
this at aged 16 years, if there is still serum left-over in storage. 
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samples citing whakapapa and advise their people to consult before 
participating in research where this occurs. However, it is acknowledged that 
individuals have the right to choose.  
 
WHO PAYS FOR THE STUDY? 
There will be no cost to you or your child for participating in this study.   
 
WHAT IF SOMETHING GOES WRONG? 
If your child is injured in this study, they are eligible to apply for compensation from ACC 
just as they would be if you were injured in an accident at work or at home. This does not 
mean that their claim will automatically be accepted. You will have to lodge a claim with 
ACC, which may take some time to assess. If the claim is accepted, your child will receive 
funding to assist in their recovery. 
 
If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study won’t affect your child’s cover. 
 
WHAT ARE MY RIGHTS? 
This study is voluntary – that means your child does not have to be involved – it is up to you 
both.  Not being involved will not have a negative impact on your child’s care at your GPs or 
in the hospital.   
 
You have the right to access information that is collected about your child for this study. 
 
WHAT HAPPENS AFTER THE STUDY OR IF I CHANGE MY MIND? 
If you change your mind about the study and don’t want your child to be involved, don’t have 
the blood test.   
 
If, after your child has had the blood test taken, and you don’t want it to be tested for SARS-
CoV-2 (COVID-19) antibodies, please contact Dr Upton by email: arlo.upton@sclabs.co.nz  
 
WHO DO I CONTACT FOR MORE INFORMATION OR IF I HAVE CONCERNS? 
If you have any questions, concerns or complaints about the study at any stage, you can 
contact:  
 




If you want to talk to someone who isn’t involved with the study, you can contact an 
independent health and disability advocate on: 
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Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@advocacy.org.nz 
Website:  https://www.advocacy.org.nz/ 
 











You can also contact the health and disability ethics committee (HDEC) that approved this 
study on: 
 
 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
  
 
Lay study title: Antibodies to COVID-19 in Southern region of NZ  Page 6 of 8 




Please tick to indicate you consent to the following  
 
I have read and I understand the Participant Information Sheet.     
I have been given sufficient time to consider whether or not to 
consent to my child participating in this study. 
  
I have had the opportunity to use a legal representative, whanau/ 
family support or a friend to help me ask questions and understand 
the study. 
  
I am satisfied with the answers I have been given regarding the 
study and I have a copy of this consent form and information sheet. 
  
I understand that taking part in this study is voluntary (my choice) 
and that I may withdraw from the study at any time without this 
affecting my child’s medical care. 
  
I consent to the research staff collecting and processing my child’s 
information, including information about my child’s health. 
  
If I decide to withdraw from the study, I agree that the information 
collected about my child up to the point when I withdraw may 
continue to be processed. 
  
I consent to my child’s GP or current provider being informed about 
my child’s participation in the study and to receive a copy of the 
antibody test results. 
Yes  No  
I consent to my child’s antibody test results going onto the shared 
hospital-based results system (Health Connect South). 
Yes  No  
I consent to Public Health South sharing my child’s health 




NA   
If my child had diagnosed COVID-19 infection, I consent to either Dr 
Upton or Dr Ussher looking at my child’s hospital records related to 




NA   
I agree to an approved auditor appointed by the New Zealand 
Health and Disability Ethic Committees, or any relevant regulatory 
authority or their approved representative reviewing my child’s 
relevant medical records for the sole purpose of checking the 
accuracy of the information recorded for the study. 
  
I understand that my child’s participation in this study is confidential 
and that no material, which could identify them personally, will be 
used in any reports on this study. 
  
I understand the compensation provisions in case of injury during 
the study. 
  
Hard copy: Consent - child
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I know who to contact if I have any questions about the study in 
general. 
  
I understand my responsibilities as the parent / guardian of a study 
participant. 
  
I wish to receive a summary of the results from the study. Yes  No  
I wish to receive a report of my child’s antibody test result. 
Email address: _________________________________ 
Yes  No  
I consent to the study team contacting me in the next two years for 
further consent for blood tests for COVID-19  
Yes  No  
I wish for my tissue (serum) to be disposed of at the end of the 
study with appropriate Karakia (only for those not consenting to 
storage for future specified research) 
Yes  No  
 
 
Declaration by guardian: 
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Optional Consent Form for the Use of Tissue (serum) for Future 
COVID-19 Research 
 
I agree for my child’s tissue samples to be stored and used in 
future research but only on the same subject as the current 
research project : COVID-19 antibody testing 
Yes  No  
I give permission for my child’s tissue samples to be stored indefinitely 
  
I want my child’s identity to be kept with their tissue sample 
Yes  No  
I want my child’s identity to be removed from their tissue samples and 
understand that in this case I will not be able to withdraw my consent 
in the future 
Yes  No  
I understand that I may withdraw my child from the study at any time  
  
If I decide to withdraw from the study, I agree that the information 
collected about my child up to the point when I withdraw may continue 
to be used. 
  





Declaration by guardian: 
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PARTICPANT INFORMATION SHEET AND ASSENT FORM (AGED 7 – 11 YEARS) 
Study title Antibody tests for exposure to COVID-19 infection. 
Locality: SDHB/SCL Ethics committee ref.: 20/NTB/101  
Lead investigator: Dr Arlo Upton Contact phone number: 021 0215 9863 
 
Why am I being asked to be in the study? 
 
Because you live with or have been in contact with someone with the COVID-19 infection.  
 
Your mum, dad, or the person taking care of you and/or your study doctor will tell you more 
about being in this study.  Your study doctor is Dr. Upton, and her phone number is 021 0215 
9863.  You can call her any time you have any questions. 
 
What will happen if I agree to take part in this study? 
 
You will have one blood test by a small needle in your arm.  Also, your mum, dad, or the person 
caring for you will answer some questions about whether you have had a fever or cold in the last 
few months. 
 
Do I have to be in the study? 
NO:  You can choose if you want to be in this study or not.  Also, you can change your mind at 
any time even if you have started the study.  Even if your mum, dad or person taking care of you 
says YES, you can still say NO.  If you decide not to be in the study, no one will be angry with 
you.  All you have to do is tell your mum, dad, or person taking care of you or your doctor that 
you don’t want to be in the study any more.  
When a blood test is done, it may hurt or bleed a little bit where your blood is taken, leaving a 
small “black and blue” mark (bruise) on your skin. 
Talk with your mum, dad or person taking care of you or doctor about any changes you feel.  
They have more information and can answer your questions or will ask the doctor for you. 
Will being in this study help me? 
No – the study will help us know more about the COVID infection in New Zealand. 
 
 
Hard copy: Assent - 7-11 years
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What if there is a problem? 
If you are worried about anything to do with the study, please ask your doctor or nurse who will 
do their best to answer your questions. 
Name:  Arlo Upton 021 0215 9863  
Who do I contact for more information or if I have concerns? 
If you, mum or dad or the person taking care of you have any questions, concerns or complaints 
about the study at any stage, you can contact:  
 Arlo Upton 
 Clinical Microbiologist 
 021 0215 9863 
 Arlo.upton@sclabs.co.nz 
 
If you want to talk to someone who isn’t involved with the study, you can contact an independent 
health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@advocacy.org.nz 
 







Telephone: 474 0999 ext 58649 
Email: Wendi.Raumati@southerndhb.govt.nz 
 
You can also contact the health and disability ethics committee (HDEC) that approved this study 
on: 
Also, we would like to be able to store (freeze) your blood serum for testing with 
other SARS-CoV-19 tests when these become available in NZ.  For you this part is 
optional.  You may say YES to the main body of the study without saying YES for 
this part.  When you are 16 years old you will be asked about this again.  At that time 
you can also say YES or NO.  It is up to you. 
3  
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 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
4  
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PARTICPANT INFORMATION SHEET AND ASSENT FORM 
Study title Antibody tests for exposure to COVID-19 infection. 
Locality: SDHB/SCL Ethics committee ref.: 20/NTB/101  
Lead investigator: Dr Arlo Upton Contact phone number: 021 0215 9863 
 
Participant's Name: _______________________ Date of Birth:  ___________ 
 (Full Name in BLOCK CAPITALS)   (Month/Year) 
  
Please circle all you agree with: 
Have you read this form (or had it read to you)?     Yes/No 
Do you understand what this study is about?                  Yes/No 
Have you asked all the questions you want?         Yes/No 
Are you happy to take part in this research study?     Yes/No 
If any answers are “no” or you don’t want to take part, don’t sign your name! 
If you do want to take part in this study, please write your name and today’s date 
below.  You will be given a copy of this signed form. 
 
Participant’s Full Name: ___________________________________________ 
Participant’s Signature for Assent: ___________________________________  
Date: ______________________________ 
Statement of Person Obtaining Informed Assent 




Name of Person Conducting Assent Discussion (Print) 
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OPTIONAL ASSENT FORM FOR USE OF TISSUE (SERUM) FOR FUTURE COVID-19 
STUDIES 
 
Participant's Name: _______________________ Date of Birth:  ___________ 
 (Full Name in BLOCK CAPITALS)   (Month/Year) 
  
Please circle all you agree with: 
Have you read this form (or had it read to you)?     Yes/No 
Do you understand what this study is about?                  Yes/No 
Have you asked all the questions you want?         Yes/No 
Are you happy to take part in this research study?     Yes/No 
 
If any answers are “no” or you don’t want to take part, don’t sign your name! 
If you do want to take part in this study, please write your name and today’s date 
below.  You will be given a copy of this signed form. 
 
Participant’s Full Name: ___________________________________________ 
Participant’s Signature for Assent: ___________________________________  
Date: ______________________________ 
Statement of Person Obtaining Informed Assent 




Name of Person Conducting Assent Discussion (Print) 
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PARTICPANT INFORMATION SHEET AND ASSENT FORM (12 – 15 YEARS) 
Study title Antibody tests for exposure to COVID-19 infection. 
Locality: SDHB/SCL Ethics committee ref.: 20/NTB/101  
Lead investigator: Dr Arlo Upton Contact phone number: 021 0215 9863 
 
Why am I being asked to be in the study? 
 
Because you live with or have been in contact with someone with the COVID-19 infection.  This 
study is to look for an immune response to exposure to COVID-19 in you – sometimes people 
can have a COVID infection that doesn’t make them sick, but can show up on a blood test for 
antibodies (the body’s response to infection).  
 
Your mum, dad, or the person taking care of you and/or your study doctor will tell you more 
about being in this study.  Your study doctor is Dr. Upton, and her phone number is 021 0215 
9863.  You can call her any time you have any questions. 
 
What will happen if I agree to take part in this study? 
 
You will have one blood test by a small needle in your arm.  Also, your mum, dad, or the person 
caring for you will answer some questions about whether you have had a fever or cold in the last 
few months.  Your blood will be tested for antibodies to COVID-19.   
 
Do I have to be in the study? 
NO:  You can choose if you want to be in this study or not.  Also, you can change your mind at 
any time even if you have started the study.  Even if your mum, dad or person taking care of you 
says YES, you can still say NO.  If you decide not to be in the study, no one will be angry with 
you and it will not have an impact on your future medical care or school.  All you have to do is 
tell your mum, dad or person taking care of you or your doctor that you don’t want to be in the 
study any more.  
When a blood test is done, it may hurt or bleed a little bit where your blood is taken, leaving a 
small bruise on your skin. 
Talk with your mum, dad or person taking care of you or doctor about any changes you feel.  
They have more information and can answer your questions or will ask the doctor for you. 
Will being in this study help me? 
Hard copy: Assent - 12-15 years
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No – the study will help us know more about the COVID infection in New Zealand.  It will not 
be able to tell you if you are immune or not to COVID-19 infection.  It will also not tell you 
whether or not you have infection.  It only tells you if you have had exposure to the virus 
(SARS-CoV-2) in the past few months.   
 
What if there is a problem? 
If you are worried about anything to do with the study, please ask your doctor or nurse who will 
do their best to answer your questions. 
Name:  Arlo Upton 021 0215 9863  
Who do I contact for more information or if I have concerns? 
If you, mum or dad or the person taking care of you have any questions, concerns or complaints 
about the study at any stage, you can contact:  
 Arlo Upton 
 Clinical Microbiologist 
 021 0215 9863 
 Arlo.upton@sclabs.co.nz 
 
If you want to talk to someone who isn’t involved with the study, you can contact an independent 
health and disability advocate on: 
 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:  advocacy@advocacy.org.nz 
 







Telephone: 474 0999 ext 58649 
Also, we would like to be able to store (freeze) your blood serum for testing with 
other SARS-CoV-19 tests when these become available in NZ.  For you this part is 
optional.  You may say YES to the main body of the study without saying YES for 
this part.  When you are 16 years old you will be asked about this again.  At that time 
you can also say YES or NO.  It is up to you. 
3  
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You can also contact the health and disability ethics committee (HDEC) that approved this study 
on: 
 Phone:  0800 4 ETHICS 
 Email:  hdecs@moh.govt.nz 
4  
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PARTICPANT INFORMATION SHEET AND ASSENT FORM 
Study title Antibody tests for exposure to COVID-19 infection. 
Locality: SDHB/SCL Ethics committee ref.: 20/NTB/101  
Lead investigator: Dr Arlo Upton Contact phone number: 021 0215 9863 
 
Participant's Name: _______________________ Date of Birth:  ___________ 
 (Full Name in BLOCK CAPITALS)   (Month/Year) 
  
Please circle all you agree with: 
Have you read this form (or had it read to you)?     Yes/No 
Do you understand what this study is about?                  Yes/No 
Have you asked all the questions you want?         Yes/No 
Are you happy to take part in this research study?     Yes/No 
If any answers are “no” or you don’t want to take part, don’t sign your name! 
If you do want to take part in this study, please write your name and today’s date 
below.  You will be given a copy of this signed form. 
 
Participant’s Full Name: ___________________________________________ 
Participant’s Signature for Assent: ___________________________________  
Date: ______________________________ 
Statement of Person Obtaining Informed Assent 




Name of Person Conducting Assent Discussion (Print) 
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OPTIONAL ASSENT FORM FOR USE OF TISSUE (SERUM) FOR FUTURE COVID-19 
STUDIES 
 
Participant's Name: _______________________ Date of Birth:  ___________ 
 (Full Name in BLOCK CAPITALS)   (Month/Year) 
  
Please circle all you agree with: 
Have you read this form (or had it read to you)?     Yes/No 
Do you understand what this study is about?                  Yes/No 
Have you asked all the questions you want?         Yes/No 
Are you happy to take part in this research study?     Yes/No 
 
If any answers are “no” or you don’t want to take part, don’t sign your name! 
If you do want to take part in this study, please write your name and today’s date 
below.  You will be given a copy of this signed form. 
 
Participant’s Full Name: ___________________________________________ 
Participant’s Signature for Assent: ___________________________________  
Date: ______________________________ 
Statement of Person Obtaining Informed Assent 




Name of Person Conducting Assent Discussion (Print) 
 
    





Place lab barcode here:  
 
 
Study: Antibody tests for exposure to COVID-19 infection, ethics approval 20/NTB/101 
Gender (please circle)  Female Male  Other 
Your postcode _________________ 
GP name and practice ____________________________________________________ 
Ethnicity (please circle) NZ European 
    Maori 
    Samoan 
    Cook Island Maori 
    Tongan 
    Niuean 
    Chinese 
    Indian 
    Other 
COVID risk (please circle the one that best describes you) 
    A COVID-19 case 
    Household contact of case 
    Other contact of case 
    Front-line health worker 
    Tourism work 
    Queenstown resident 
 
Do you remember having any of the following symptoms in the two weeks before and during the 




 Runny nose or congestion 
 Sore/scratchy/tickly throat 
 Shortness of breath 
 Loss of smell 
 Loss of taste 
 Headache 











Thank you for agreeing to participate in the COVID-19 antibody study. 
We appreciate you taking the time be a part of this research.
This section will collect some personal details and develop an electronic form that will be part of the consent process.
Consent form
Please tick to indicate you consent to the following 
I have read and I understand the Participant Information Sheet.   
 
I have been given sufficient time to consider whether or not to participate in this study.  
I have had the opportunity to use a legal representative, whanau/ family support or a friend to help me ask questions
and understand the study. 
 
I am satisfied with the answers I have been given regarding the study and I have a copy of this consent form and
information sheet. 
 
I understand that taking part in this study is voluntary (my choice) and that I may withdraw from the study at any
time without this affecting my medical care or employment.  
I consent to the research staff collecting and processing my information, including information about my health.  
If I decide to withdraw from the study, I agree that the information collected about me up to the point when I
withdraw may continue to be processed.
I consent to my GP or current provider, if I have one, Yes
being informed about my participation in the study and No
to receive a copy of the antibody test results.
I consent to my antibody test results going onto the Yes
shared hospital-based results system (Health Connect No
South).
I consent to Public Health South sharing my health Yes
information related to COVID-19 with the study team. No
Not applicable
If I had diagnosed COVID-19 infection, I consent to Yes
either Dr Upton or Dr Ussher looking at my hospital No
records related to the COVID-19 infection (only). Not applicable
I agree to an approved auditor appointed by the New Zealand Health and Disability Ethic Committees, or any
relevant regulatory authority or their approved representative reviewing my relevant medical records for the sole
purpose of checking the accuracy of the information recorded for the study.
I understand that my participation in this study is confidential and that no material, which could identify me
personally, will be used in any reports on this study.
I understand the compensation provisions in case of injury during the study.
I know who to contact if I have any questions about the study in general.
I understand my responsibilities as a study participant.






I wish to receive a report of my antibody test Yes
results. No
I consent to the study team contacting me in the next Yes
two years for further consent for blood tests for No
COVID-19.
I wish for my tissue (serum) to be disposed of at the Yes
end of the study with appropriate Karakia (only for No












Telephone number or mobile phone number
__________________________________
Please confirm your e-mail address
__________________________________





Optional Consent Form for the Use of Tissue (serum) for Future COVID-19 Research
Yes No
I agree for my tissue samples to
be stored and used in future
research but only on the same
subject as the current research
project : COVID-19 antibody
testing
I give permission for my tissue
samples to be stored indefinitely
I want my identity to be kept
with my tissue sample
I want my identity to be
removed from my tissue
samples and understand that in
this case I will not be able to
withdraw my consent in the
future
I understand that I may
withdraw from the study at any
time
If I decide to withdraw from the
study, I agree that the
information collected about me
up to the point when I withdraw
may continue to be used.
I know who to contact if I have
any questions about the study in
general.
Optional Consent Form for the Use of Tissue (serum)
for Future COVID-19 Research





Thank you for your interest in our study: Antibody tests for exposure to COVID-19 infection, ethics approval
20/NTB/101.   You have been invited to enrol as you are considered to have had higher risk for COVID-19 infection in
Feb – May 2020 due to your work, where you live, or you having had contact with a person diagnosed with COVID-19
infection.  The study involves a blood test to look for antibodies to COVID-19.  There is an additional optional
component (the second consent) around whether or not you are happy to have your blood stored indefinitely for
future COVID-19 antibody testing.  You will be able to receive your blood test result.  It is important to note that it is
not an immunity test. 
INVESTIGATORS (indicate principal investigator by asterisk)
    Dr Arlo Upton*
Clinical Microbiologist
Southern Community Laboratories Dr James Usher
Associate Professor
Microbiology and Immunology 
  Dr Susan Jack
Lead Public Health Physician
Public Health South   
   
For participant information regarding the COVID-19 antibody study please click on the pdf file to download the
participant information sheet - to ensure that you are fully informed of what you are consenting for.
[Attachment: "SARS-CoV-2 sero-prevalence study PIS 120520.pdf"]
Are you agreeable to participate in this research? Yes
No





Thank you for agreeing to participate in the COVID-19 antibody study.   
We appreciate you taking the time be a part of this research.
This section will collect some personal details and develop an electronic form that will be part of the consent process.
Your gender is:- Male
Female
Other




General practitioner's name and practice
 
__________________________________________








Other (such as Dutch, Japanese, Tokelauan etc)
(mark all that apply)
If you chose "Other" in the Ethnicity question please





Do you associate with any of these high risk A COVID-19 case
categories for COVID-19. Are you:- A household contact of a COVID-19 case
Other contact of a COVID-19 case
A front-line healthcare worker
A tourism worker
A Queenstown resident
(mark all that apply)
Do you know if you have had  contact with anyone who Yes








Runny nose or congestion









Is there anything else you would like to comment on?
 
__________________________________________
Thank you for enrolling in the COVID-19 serology study. 
If you live in Dunedin, Clyde, Invercargill, Queenstown, Gore, or Oamaru, you can present to your local SCL laboratory
collection room for blood collection.  
If you are unable to attend these collection rooms, please email covid.serology@sclabs.co.nz , so that we can find an
alterative for you.





Thank you for your interest in our study: Antibody tests for exposure to COVID-19 infection, ethics approval
20/NTB/101.   You have been invited to enrol as you were diagnosed with COVID-19 infection.  The study involves a
blood test to look for antibodies to COVID-19.  There is an additional optional component (the second consent)
around whether or not you are happy to have your blood stored indefinitely for future COVID-19 antibody testing. 
You will be able to receive your blood test result.  It is important to note that it is not an immunity test. 
INVESTIGATORS (indicate principal investigator by asterisk)
    Dr Arlo Upton*
Clinical Microbiologist
Southern Community Laboratories Dr James Usher
Associate Professor
Microbiology and Immunology 
  Dr Susan Jack
Lead Public Health Physician
Public Health South   
   
For participant information regarding the COVID-19 antibody study please click on the pdf file to download the
participant information sheet - to ensure that you are fully informed of what you are consenting for.
[Attachment: "SARS-CoV-2 sero-prevalence study PIS 120520.pdf"]
Are you agreeable to participate in this research? Yes
No





Thank you for agreeing to participate in the COVID-19 antibody study.   
We appreciate you taking the time be a part of this research.
This section will collect some personal details and develop an electronic form that will be part of the consent process.
Your gender is:- Male
Female
Other








Other (such as Dutch, Japanese, Tokelauan etc)
(mark all that apply)
If you chose "Other" in the Ethnicity question please








Runny nose or congestion









Is there anything else you would like to comment on?
 
__________________________________________
Thank you for enrolling in the COVID-19 serology study. 
In order to complete the consenting process and having your blood taken, we need to make a booking for you.  It is a
little bit complicated as the extra bloods to look at a different kind of immunity (T cell immunity) have to get to the
laboratory relatively quickly - and so for non-Dunedin sites we need to ensure that blood collection corresponds with
when the laboratory couriers are leaving Queenstown, Gore, Invercargill, etc.  
To faciliate this, please email covid.serology@sclabs.co.nz , stating clearly that you were 'a case', and we will work
with you to organise your blood tests.
  Thank you.
Appendix C: Supplementary data file  
Filename: CraigieAlyson_supplementary_tables.xlsx 
The accompanying Excel spreadsheet contains the raw data for all assay results and the full 
PPV/NPV and concordance data results. The data is separated out into the different sample 
cohorts and includes participant demographics, PCR test results, disease severity, and self-
reported symptoms are also included where appropriate.  
• Table S1: Pre-pandemic/antenatal sera - raw results 
• Table S2: PCR-confirmed cases raw - results 
• Table S3: Higher-risk participants - raw results 
• Table S4: Probable cases - raw results 
• Table S5: PPV and NPV at various disease prevalence for SARS-CoV-2 serological 
assays 
• Table S6: OPA, PPA, NPA, Kappa statistic, and Pearson’s correlation coefficient for 
SARS-CoV-2 serological assays 
• Table S7: Antibody persistence study – raw results 
• Table S8: Pseudovirus neutralisation test – raw results 
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